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Abstracts 
The objective of this thesis was to use health administrative data to investigate two important 
adverse drug reactions (ADRs) related to renal function. The first study examined the risk of 
hyperkalemia associated with the antibiotic trimethoprim-sulfamethoxazole (TMP-SMX) and 
its interaction with beta-adrenergic receptor blockers (“beta blockers”). The second study 
evaluated the effect of impaired kidney function on the risk of hypoglycemia conferred by 
the anti-diabetic drug glyburide. 
  
The simultaneous use of beta adrenergic receptor blockers (β-blockers) and trimethoprim-
sulfamethoxazole (TMP-SMX) may confer a high risk of hyperkalemia. We conducted two 
nested case-control studies to examine the association between hospitalization for 
hyperkalemia and the use of TMP-SMX in older patients receiving β-blockers. We used 
linked health administrative records from Ontario, Canada to assemble a cohort of 299,749 β-
blockers users, aged 66 years or older and capture data regarding medication use and hospital 
admissions for hyperkalemia. Over the study period from 1994 to 2008, 189 patients in this 
cohort were hospitalized for hyperkalemia within 14 days of receiving a study antibiotic. 
Compared to amoxicillin, the use of TMP-SMX was associated with a substantially greater 
risk of hyperkalemia requiring hospital admission (adjusted odds ratio 5.1 [95% CI, 2.8 to 
9.4]). No such risk was identified with ciprofloxacin, norfloxacin, or nitrofurantoin. When 
dosing was considered, the association was greater at higher doses of TMP-SMX. When we 
repeated the primary analysis in a cohort of non-β-blocker users, the risk of hyperkalemia 
comparing TMP-SMX to amoxicillin was not significantly different from that found among 
β-blocker users. Although TMP-SMX is associated with an increased risk of hyperkalemia in 
older adults, our findings show no added risk when used in combination with β-blockers. 
 
Little evidence justifies the avoidance of glyburide in patients with impaired renal function. 
We aimed to determine if renal function modifies the risk of hypoglycemia among patients 
using glyburide. We conducted a nested case-control study using administrative records and 
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laboratory data from Ontario, Canada. We included outpatients 66 years of age and older 
with diabetes mellitus and prescriptions for glyburide, insulin or metformin. We ascertained 
hypoglycemic events using administrative records and we estimated glomerular filtration 
rates (eGFR) using serum creatinine concentrations. From a cohort of 19,620 patients, we 
identified 204 cases whose eGFR was ≥ 60 ml/min/1.73m2 (normal renal function) and 354 
cases whose eGFR was < 60 ml/min/1.73m2 (impaired renal function). Compared to 
metformin, glyburide associated with a greater risk of hypoglycemia in patients with both 
normal (adjusted OR 9.0, 95% CI 4.9 to 16.4) and impaired renal function (adjusted OR 6.0, 
95% CI 3.8 to 9.5). We observed a similar relationship when comparing insulin to 
metformin; the risk was greater in patients with normal renal function (adjusted OR 18.7, 
95% CI 10.5 to 33.5) compared to those with impaired renal function (adjusted OR 7.9, 95% 
CI 5.0 to 12.4). Tests of interaction showed that among glyburide users renal function did not 
significantly modify the risk of hypoglycemia, but among insulin users, impaired renal 
function associated with a lower risk. In this population-based study, impaired renal function 
did not augment the risk of hypoglycemia associated with glyburide use.  
 
In summary, these studies described important ADRs associated with commonly used 
prescription drugs and highlighted the kidney’s role, both as a target of the drug effect, as in 
the case of TMP-SMX, and as the cause of the drug accumulation, as in the case of 
glyburide. Both studies identified significant risks associated with the study drugs and 
reinforce the need for vigilance when monitoring patients prescribed these medications. 
Keywords 
Kidney, renal, pharmacoepidemiology, adverse drug events 
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Chapter 1  
1 Introduction 
 
1.1 Definitions 
The field of pharmacoepidemiology uses a variety of terms to describe the intentional and 
unintentional outcomes of medication use. Although the terms “side-effect”, “adverse 
drug event” and “adverse drug reaction” are often used interchangeably, their definitions 
differ in important ways. 1 “Side-effect” refers to an unintended outcome associated with 
medication use that may be beneficial, neutral, or harmful. “Adverse drug event” refers to 
any unintended, noxious outcome occurring during the course of medication use. 
“Adverse drug reaction” refers to an unintended, noxious outcome caused directly by 
medication use. Adverse drug reactions have multiple sub-categories based on the 
suspected underlying mechanisms. 
Because the studies conducted for this thesis were observational, a direct, causal link 
cannot be drawn between the study drugs and the outcomes of interest. Therefore, the 
most appropriate term to describe the outcomes of these studies is “adverse drug event” 
(ADE). 
1.2 The burden of adverse drug events 
ADEs pose a significant challenge to patients, health care providers and the healthcare 
system as a whole. A Dutch study found that ADEs caused 41,000 hospitalizations per 
year, 2 and a longitudinal German study found that 2.4% of all hospitalizations were 
caused by ADEs. 3 Once admitted to hospital, ADEs remain a significant concern. 
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Among British inpatients, 850,000 ADEs occur per year, 4 in the United States ADEs 
rank as the eighth leading cause of in-hospital death. 5 In addition, the increased duration 
of admission caused by ADEs has been estimated to cost the United Kingdom’s National 
Health Service over $900 million dollars annually. 6 In a Canadian study that examined 
medical errors occurring in hospitals, nearly one quarter were found to involve ADEs. 7 
Although these findings are troubling in their own right, the problem of ADEs is even 
more significant among elderly patients.    
1.3 ADEs and the elderly 
Of the 2.4% of hospital admissions attributed to ADEs in the study by Schneeweis, 
almost half (46.3%) of the patients were 70 years of age or older. 3 A study conducted by 
the Hospital Admissions Related to Medications (HARM) group found that compared to 
all unplanned hospitalizations, those related to ADEs were more likely to involve elderly 
patients. 8 In addition to being at higher risk for ADE-related hospitalization, elderly 
patients are also more likely to experience ADEs once admitted to hospital. Among 346 
elderly Dutch patients admitted for a mean of 6 days, 32% experienced an ADE. 9 A 
nearly identical finding was reported in a study of 377 patients admitted to a Veterans 
Affairs Medical Center. 10 Finally, elderly patients who experience an ADE are more 
likely to die or be left with significant disability. 11,12 Many factors predispose elderly 
patients to ADEs, including polypharmacy, malnutrition, cognitive impairment, age-
related changes in pharmacodynamics and pharmacokinetics, and co-existing chronic 
diseases. 13 In many studies, including a recently published tool for predicting ADEs in 
elderly patients, impaired renal function has been identified as a significant ADE risk 
factor. 8,14,15   
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1.4 The kidney’s role in ADEs 
Although the kidney can be a target of ADEs, as in the case of gentamycin-induced acute 
tubular necrosis, its primary role is that of a mediator. This mediation occurs via two 
mechanisms. First, in all patients, some drugs may disrupt specific renal functions. 
Examples include sodium retention induced by non-steroidal anti-inflammatory drugs, 16 
potassium wasting induced thaizide diuretics, 17 and the potassium retention caused by 
trimethoprim-sulfamethoxazole (TMP-SMX). 18 Second, in patients with impaired renal 
function, the therapeutic effects of some drugs can be augmented. This occurs because 
many drugs and their active metabolites are cleared from the bloodstream by the kidneys; 
such drugs will be cleared at a slower rate in patients with reduced kidney function, 
leading to their accumulation. Examples include the anti-metabolite drug methotrexate, 19 
the anti-inflammatory agent colchicine, 20 and the hypoglycemic drug glyburide. 21 In 
each case, toxicity occurs due to accumulation of the drug (or its active metabolites), 
which enhances its therapeutic effect.  
1.5 Clinically important kidney-mediated ADEs 
There are many consequences of kidney-mediated ADEs; however, some of the most 
dangerous are those that affect potassium and glucose homeostasis. Unfortunately, 
kidney-mediated derangements in serum concentrations of potassium and glucose can 
result from the use of commonly prescribed medications. 
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1.5.1 Potassium 
The concentration of potassium in the blood is normally maintained between 3.5 
and 5.5 millimoles per litre (mmol/L). “Hyperkalemia” refers to a state in which 
the potassium concentration exceeds 5.5 mmol/L. Mild hyperkalemia (5.6 to 6.9 
mmol/L) is often asymptomatic, but in severe cases (≥ 7.0 mmol/L), hyperkalemia 
can cause paralysis and fatal cardiac arrhythmias. The kidney is primarily 
responsible for maintaining potassium levels in a safe range, which it does by 
excreting excess dietary potassium in the urine. This process involves a number of 
hormones, cellular receptors and transmembrane channels. Of particular 
importance is the epithelial sodium channel (abbreviated as ENaC). By allowing 
the absorption of sodium from the distal tubules of the kidney, the ENaC 
establishes an electrochemical gradient that facilitates potassium excretion. 22 
Blockade of this channel causes impaired potassium excretion that may lead to 
hyperkalemia. In the treatment of high blood pressure, the ENaC can blocked by 
two anti-hypertensive medications designed specifically for that purpose 
(amiloride and triamterene); however, the ENaC can also be blocked 
inadvertently by medications prescribed for reasons unrelated to the channel’s 
function. Case reports, 23,24,25,26 and small cohort studies (summarized in Table 1-
1) have suggested that the fixed-dose combination antibiotic trimethoprim-
sulfamethoxazole (Septra®) is associated with hyperkalemia. 27,28  The 
trimethoprim component of this antibiotic is structurally similar to amiloride and 
is thought to be responsible for antagonism of the ENaC. 29  
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Although the kidney is responsible for the long-term management of serum 
potassium concentrations, short-acting mechanisms are also in place to deal with 
sudden increases in serum potassium. In particular, the sympathetic nervous 
system is responsible for approximately 40% of the initial compensatory response 
to increases in serum potassium. 30 Hyperkalemia stimulates the sympathetic 
nervous system to release epinephrine, which binds to beta-2 adrenergic receptors. 
This binding increases the activity of the Na-K-ATPase pump resulting in the 
movement of potassium from the extracellular fluid (including the blood stream) 
into the intracellular fluid. 31 This mechanism has important clinical implications 
because the beta-2 adrenergic receptor is blocked by a commonly prescribed class 
of drugs called “beta blockers”. 
1.5.2 Glucose 
Through a complex balance of hyper- and hypoglycemic hormones, serum 
glucose concentrations are maintained between approximately 3.9 mmol/L and 
7.0 mmol/L. In patients with type II diabetes mellitus (“diabetes”), the effects of 
the hypoglycemic hormone insulin are less potent; this results in elevated serum 
glucose concentrations. 32 To lower their glucose concentrations, patients with 
diabetes may use a number of ‘hypoglycemic’ medications that work through a 
variety of mechanisms. Medications such as metformin work by increasing 
insulin sensitivity and limiting hepatic glucose production. 33,34  Drugs such as 
glyburide work by increasing pancreatic insulin production. 35 Injectable forms of 
insulin supplement the body’s own supply of this hormone. These medications are 
all effective therapies for patients with diabetes, and all carry a risk of ADEs. One 
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of the most important ADEs associated with their use is severe hypoglycemia. If 
serum glucose concentrations fall below 3.1 mmol/L patients can experience heart 
palpitations, sweating, anxiety, and tremors. 36 Levels that fall below 2.8 mmol/L 
are associated with cognitive impairment, seizures, coma and the possibility of 
death. 36 Glyburide lies at the nexus of drug-induced hypoglycemia and kidney 
function.  
Glyburide is a potent member of the sulfonylurea family of hypoglycemic drugs. 
It is known to cause hypoglycemia, but its pharmacokinetic characteristics have 
implicated it in severe, prolonged cases of hypoglycemia in patients with impaired 
kidney function. 21 Glyburide is broken down by the liver into two metabolites, 
each of which retains some of the parent compound’s hypoglycemic activity. 37 
Because these active metabolites are cleared from the circulation by the kidney, 
there exists a potential for them to accumulate and cause severe hypoglycemia in 
patients whose kidney function is impaired (see table 1-2). 38  
1.6 The need for research 
ADEs among elderly patients is a significant cause of morbidity and mortality, and the 
kidney’s role in mediating these ADEs is under-recognized. To draw attention to two of 
the most important renally mediated ADEs we conducted two studies among elderly 
residents of Ontario. First, we examined the risk of hospital admission for hyperkalemia 
among elderly patients using both trimethoprim-sulfamethoxazole and beta blockers. 
Second, we examined the interaction between impaired renal function and glyburide use 
in the risk of severe hypoglycemia. 
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1.7 Tables 
Table 1-1 Trimethoprim-sulphamethoxazole and hyperkalemia: Literature 
summary. 
Author Title Date 
Study 
Type 
Description Finding 
Shishido, T 
39 
Case of 
trimethoprim-
induced 
hyperkalemia 
complicating 
ANCA-
associated 
vasculitis 
2012 
Case 
Report 
(Japan) 
76 year old 
man with 
hyperkalemia 
during 
prophylaxis 
against 
Pneumocysti
s jiroveci. 
Low transtubular 
potassium gradient and 
normal plasma renin 
activity and aldosterone 
concentrations 
suggested TMP-SMX 
produced hyperkalemia 
in a fashion similar to a 
potassium-sparring 
diuretic. 
Antoniou, T 
40 
Trimethoprim-
sulfamethoxazol
e induced 
hyperkalaemia 
in elderly 
patients 
receiving 
spironolactone: 
nested case-
control study. 
2011 
Administ
rative 
data 
(ON, 
Canada)
Nested 
case-
control 
17,859 
patients co-
prescribed 
spironolacton
e and short-
course 
antibiotics. 
Compared to amoxicillin, 
those prescribed TMP-
SMX had a adjusted 
odds ratio of admission 
to hospital with 
hyperkalemia of 12.4 
(95% CI 7.1 to 21.6). 
Lam, N 41 
Hospital 
admissions for 
hyperkalemia 
with 
trimethoprim-
sulfamethoxazol
2011 
Administ
rative 
data 
(ON, 
Canada)
Retrosp
393,039 
women 
prescribed 
an antibiotic 
for cystitis. 
The adjusted odds ratio 
for the risk of admission 
with hyperkalemia was 
3.33 (95% CI 1.32 to 
8.42) comparing TMP-
SMX to amoxicillin. 
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e: a cohort study 
using health 
care database 
codes for 
393,039 older 
women with 
urinary tract 
infections 
ective 
cohort 
Calderón-
Ortiz, R 42 
Life threatening 
hyperkalemia 
chronic kidney 
diseases 
patients treated 
with 
trimethoprim-
sulfamethoxazol
e: a case series. 
2011 
Case 
series 
(Puerto 
Rico) 
3 patients 
treated with 
standard-
dose TMP-
SMX. All had 
pre-existing 
chronic 
kidney 
disease. 
Refractory hyperkalemia 
developed after 4 days 
to therapy and in each 
case, hemodialysis was 
required to normalize 
the serum potassium. 
Antoniou, T 
43 
Trimethoprim-
sulfamethoxazol
e-induced 
hyperkalemia in 
patients 
receiving 
inhibitors of the 
renin-
angiotensin 
system: a 
population-
based study. 
2010 
Administ
rative 
data 
(ON, 
Canada)
Nested 
case-
control 
4148 
admissions 
for 
hyperkalemia 
among users 
of ACE 
inhibitors or 
ARBs. 
The adjusted odds ratio 
of hyperkalemia 
admission with the co-
administration of ACE or 
ARB and TMP-SMX was 
6.7 (95% CI 4.5 to 10.0) 
compared to co-
administration of ACE or 
ARB and amoxicillin. 
Mohan, S 
44 
Influence of 
concomitant 
prednisolone on 
trimethoprim-
associated 
hyperkalaemia. 
2009 
Non-
randomi
zed trial  
30 patients 
assigned to 
receive either 
TMP-SMX 
alone (n=12) 
or TMP-SMX 
Seven patients 
developed hyperkalemia 
and all were in the 
combined therapy 
group. This is an unclear 
relationship between 
9 
 
and 
prednisone 
(n=18) for 
the treatment 
of 
Pneumocysti
s jiroveci 
pneumonia. 
prednisone use and the 
hyperkalemic potential 
of TMP-SMX. 
Sanjay, S 
45 
Refractory 
hyperkalaemia 
due to 
trimethoprim, 
successfully 
treated with 
fludrocortisone. 
2007 
Case 
report 
(India) 
Elderly man 
treated with 
high-dose 
TMP-SMX. 
Severe and refractory 
hyperkalemia developed 
and was treated 
successfully with 
mineralocorticoid. 
Muto, S 46 
Effect of 
trimethoprim-
sulfamethoxazol
e on Na and K+ 
transport 
properties in the 
rabbit cortical 
collecting duct 
perfused in vitro. 
2006 
In vitro 
study of 
rabbit 
renal 
tubule 
cells 
The effect of 
TMP-SMX on 
the 
conductance 
of tubule cell 
apical and 
basolateral 
membranes 
was studied 
in vitro. 
TMP inhibited the 
amiloride-sensitive 
sodium channel on the 
apical membrane of 
rabbit cortical collecting 
duct cells. 
Mori, H47 
Hyponatremia 
and/or 
hyperkalemia in 
patients treated 
with the 
standard dose 
of trimethoprim-
sulfamethoxazol
e. 
2003 
Retrosp
ective 
cohort 
53 patients 
prescribed 
TMP-SMX 
for a variety 
of infections. 
The risk of hyperkalemia 
was higher among 
patients on higher doses 
of TMP and with more 
impaired renal function. 
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Margasser
y 48, S 
Life threatening 
hyperkalemia 
and acidosis 
secondary to 
trimethoprim-
sulfamethoxazol
e treatment. 
2001 
Case 
report 
(USA) 
77 year old 
man with 
moderate 
CKD, treated 
with TMP-
SMX for a 
urinary tract 
infection. 
Severe hyperkalemia 
and metabolic acidosis 
occurred with the use of 
TMP-SMX and resolved 
with its discontinuation. 
Koç, M 49 
Severe 
hyperkalemia in 
two renal 
transplant 
recipients 
treated with 
standard dose 
of trimethoprim-
sulfamethoxazol
e. 
2000 
Case 
series 
Two patients 
with 
functioning 
renal 
transplants 
treated with 
treatment 
doses of 
TMP-SMX. 
Both patients developed 
severe hyperkalemia 
that resolved with 
suspension of TMP-
SMX. 
Marinella, 
M 50 
Trimethoprim-
induced 
hyperkalemia: 
An analysis of 
reported cases. 
1999 
Review 
of case 
reports 
Nine case 
reports of 
TMP-SMX 
associated 
hyperkalemia
. 
Most patients were on a 
standard dose of TMP-
SMX. Mean age of 
patients was 78 years, 
mean duration of 
therapy with TMP-SMX 
was 10 days. Mean level 
of hyperkalemia was 7 
mml/L. 
Alappan, R 
51 
Trimethoprim-
sulfamethoxazol
e therapy in 
outpatients: is 
hyperkalemia a 
significant 
problem? 
1999 
Random
ized trial 
97 patients 
with various 
minor 
infections 
were 
randomized 
to TMP-SMX 
Mean potassium 
concentrations in the 
TMP-SMX group 
increased significantly 
from baseline to day 5. 
Mean potassium levels 
fell over the same time 
11 
 
(n=51) or 
other 
antibiotics 
(n=46). 
period in the control 
group. In the TMP-SMX, 
none of the serum 
potassium levels 
increased to clinically 
significant levels. Older 
patients taking TMP-
SMX had larger 
increases in potassium 
than did younger 
patients. 
Sheehan, 
M 52 
Hyperkalemic 
renal tubular 
acidosis induced 
by 
trimethoprim/sulf
amethoxazole in 
an AIDS patient. 
1998 
Case 
report 
(USA) 
A patient with 
HIV/AIDS 
contracted 
through 
blood 
transfusion 
(sickle cell 
anemia) 
being treated 
for 
Pneumocysti
s jiroveci 
pneumonia. 
The patient underwent 
two treatment courses 
with TMP-SMX and 
clinically significant 
hyperkalemia occurred 
both times. The first 
episode resolved when 
Amphotericin B was 
added and the second 
resolved when TMP-
SMX was discontinued. 
David, L 53 
Severe 
hyponatraemia 
and severe 
hyperkalaemia 
in an HIV 
positive patient 
who received 
high dose co-
trimoxazole. 
1998 
Case 
report 
(USA) 
A patient with 
HIV/AIDS 
being treated 
with TMP for 
Pneumocysti
s jiroveci 
pneumonia.  
Severe hyperkalemia 
developed after 5 days 
of treatment and 
resolved upon 
discontinuation of TMP. 
Marinella, 
M 26 
Trimethoprim-
sulfamethoxazol
1997 
Case 
report 
81 year-old 
man on an 
Hyperkalemia of 6.3 
mmol/L developed 4 
12 
 
e associated 
with 
hyperkalemia 
(USA) ACE inhibitor 
with an 
urinary tract 
infection 
treated with 
TMP-SMX. 
days into treatment with 
TMP-SMX. It resolved 
with discontinuation of 
the drug. 
Elisaf, M 54 
Severe 
hyperkalaemia 
after 
cotrimoxazole 
administration in 
a patient with 
hyporeninaemic 
hypoaldosteroni
sm. 
1997 
Case 
report 
(Greece) 
71 year-old 
man with 
mild CKD 
and mild 
hyporeninae
mic 
hypoaldoster
onism who 
received 
TMP-SMX 
for a urinary 
tract 
infection. 
Hyperkalemia of 7.8 
mmol/L developed 5 
days into treatment with 
TMP-SMX. This 
resolved with withdrawal 
of the drug. 
Lin, S 55 
Reversible 
voltage-
dependent distal 
renal tubular 
acidosis in a 
patient receiving 
standard doses 
of trimethoprim-
sulphamethoxaz
ole. 
1997 
Case 
report 
(Taiwan) 
61 year-old 
man 
receiving 
TMP-SMX 
for treatment 
of a urinary 
tract 
infection. 
Hyperkalemia and 
metabolic acidosis arose 
after 5 days of treatment 
with TMP-SMX and 
resolved within 2 weeks 
of its discontinuation. 
Perazella. 
M 56 
Comparison of 
oral agents for 
the treatment of 
Pneumocystis 
carinii 
pneumonia. 
1997 
Prospec
tive 
cohort 
Patients with 
HIV/AIDS 
and 
Pneumocysti
s jiroveci 
pneumonia. 
Hyperkalemia > 5.6 
mmol/L occurred in 
20.3% of TMP-SMX, 
10.3% of dapsone-
trimethoprim, and 3.5% 
of clindamycin-
13 
 
Treatment 
was with 
TMP-SMX, 
dapsone-
trimethoprim, 
or 
clindamycin-
primaquine. 
primaquine treated 
patients. 
Schreiber, 
M 57 
Antikaliuretic 
action of 
trimethoprim is 
minimized by 
raising urine pH. 
1996 
In vitro 
and 
Animal 
study 
(rats) 
Cell lines and 
the urine of 
animals was 
alkalinized in 
order to see 
if high pH 
had the 
same 
inhibitory 
effect on 
TMP as it 
does on 
amiloride. 
Higher concentrations of 
TMP were required to 
induce potassium 
retention as the culture 
medium or urine pH 
increased. This helped 
confirm that TMP acts in 
a similar way to 
amiloride. 
Reiser, I 58 
Reversal of 
trimethoprim-
induced 
antikalluresis. 
1996 
Animal 
study 
(dog) 
Intrarenal 
infusion of 
vehicle, 
amiloride, or 
TMP 
(0.2mg/kg/mi
n). Then 
infusion of 
furosemide 
or normal 
saline. 
Intrarenal TMP infusion 
caused potassium 
retention in the 
ipsilateral kidney. There 
was no effect on the 
contralateral kidney. 
Concomitant treatment 
with furosemide of 
saline infusion reversed 
the potassium retention. 
Administration of 
amiloride competed with 
the actions of TMP. This 
implicates blockade of 
the ENaC as the 
14 
 
mechanism by which 
TMP causes 
hyperkalemia. 
Bugge, J 24 
Severe 
hyperkalaemia 
induced by 
trimethoprim in 
combination 
with an 
angiotensin-
converting 
enzyme inhibitor 
in a patient with 
transplanted 
lungs. 
1996 
Case 
report 
(Norway) 
40 year old 
woman with 
lung 
transplant 
and TMP-
SMX 
treatment for 
Pneumocysti
s jiroveci 
pneumonia.   
Hyperkalemia of 6.8 
mmol/L occurred during 
use of TMP-SMX and 
ACE inhibitor together. 
This resolved with 
discontinuation of TMP-
SMX. 
Alappan, R 
28 
Hyperkalemia in 
hospitalized 
patients treated 
with 
trimethoprim-
sulfamethoxazol
e. 
1996 
Retrosp
ective 
cohort 
80 patients 
on standard 
dose TMP-
SMX and 25 
on other 
antibiotics 
were 
followed for 
development 
of 
hyperkalemia
. 
TMP-SMX was 
associated with a 
significant increase in 
serum potassium 
concentrations. 62.5% 
of patients had a 
potassium concentration 
over 5.0 mmol/L. 21.2% 
had a potassium over 
5.5 mmol/L. Those with 
pre-existing CKD were 
at higher risk for 
significant hyperkalemia. 
Witt, J 59 
Effect of 
standard-dose 
trimethoprim/sulf
amethoxazole 
on the serum 
potassium 
concentration in 
1996 
Retrosp
ective 
cohort 
33 inpatients 
on TMP-SMX 
and 20 
patients on 
cephradine 
or amoxicillin 
were 
There was a small 
increase (0.31 mmol/L) 
in the mean serum 
potassium concentration 
of the TMP-SMX group, 
but none in the control 
group. 
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elderly men. followed for 
changes in 
serum 
potassium. 
Perlmutter, 
E 25 
Case report: 
severe 
hyperkalemia in 
a geriatric 
patient receiving 
standard doses 
of trimethoprim-
sulfamethoxazol
e. 
1996 
Case 
report 
(USA) 
96 year-old 
woman with 
treated with 
TMP-SMX 
for a bladder 
infection and 
pneumonia. 
Hyperkalemia of 9.3 
mmol/L developed 1 
week into therapy. This 
normalized after 
withdrawal of TMP-
SMX. 
Eiam-Ong, 
S 60 
Studies on the 
mechanism of 
trimethoprim-
induced 
hyperkalemia. 
1996 
Animal 
study 
(rats) 
Rats given 
TMP either 
acutely or 
chronically. 
Acute infusion of TMP 
into rats produced no 
significant effect on 
serum potassium, 
creatinine or sodium 
concentrations. Chronic 
oral intake of TMP over 
14 days resulted in 
significantly higher 
serum potassium levels 
compared to control 
animals. In dissected 
segments of tubules, 
Na-K-ATPase activity 
was significantly 
reduced by TMP in the 
cortical and medullary 
collecting ducts. There 
was no significant 
decrease in the function 
of the H-ATPase or H-K-
ATPase. This pattern is 
consistent with the 
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effects of amiloride. 
Mihm, L 61 
Hyperkalemia 
associated with 
high-dose 
trimethoprim-
sulfamethoxazol
e in a patient 
with the 
acquired 
immunodeficien
cy syndrome. 
1995 
Case 
report 
(USA) 
25 year-old 
man with HIV 
and 
Pneumocysti
s jiroveci 
pneumonia 
was treated 
with high 
dose TMP-
SMX. 
Hyperkalemia of 6.9 
mmol/L occurred after 8 
days of treatment and 
after concomitant oral 
potassium 
supplementation for an 
initially low level of 3.0 
mmol/L. Hyperkalemia 
resolved with withdrawal 
of TMP-SMX. 
Marinella, 
M 62 
Reversible 
hyperkalemia 
associated with 
trimethoprim- 
sulfamethoxazol
e. 
1995 
Case 
report 
(USA) 
78 year-old 
man treated 
with high 
dose IV 
TMP-SMX 
for a severe 
soft-tissue 
infection. The 
patient had 
normal 
kidney 
function. 
Hyperkalemia of 6.2 
mmol/L occurred after 5 
days of therapy and 
resolved with 
discontinuation of TMP-
SMX. 
Noto, H 63 
Severe 
Hyponatremia 
and 
Hyperkalemia 
Induced by 
Trimethoprim-
Sulfamethoxazol
e in Patients 
with 
Pneumocystis 
carinii 
Pneumonia. 
1995 
Case 
series 
(Japan) 
Two adult 
men with 
hematologic 
malignancy 
who 
developed 
Pneumocysti
s jiroveci 
pneumonia 
after 
receiving 
chemotherap
Hyperkalemia 
developed in both 
patients during 
treatment with high dose 
TMP-SMX, but not 
during subsequent low-
dose prophylactic use. 
During the treatment 
phases, hyperkalemia 
resolved with withdrawal 
of TMP-SMX. 
17 
 
y. TMP-SMX 
was used to 
treat the 
pneumonia in 
both cases.   
Schlanger, 
L 64 
K(+)-sparing 
diuretic actions 
of trimethoprim: 
inhibition of Na+ 
channels in A6 
distal nephron 
cells. 
1994 
In vitro 
(A6 
mammal
ian 
cortical 
tubule 
cell line) 
A6 cells 
grown on 
permeable 
supports 
were 
exposed to 
TMP and the 
activity of the 
ENaC was 
assessed. 
Adding TMP to the 
basolateral side of the 
cells had no effect 
ENaC activity, but 
adding TMP to the 
apical side reduced 
ENaC activity 10-fold. 
Progressive dilution of 
the TMP concentration 
produced lower degrees 
of ENaC inhibition. 
Modest, G 
23 
Hyperkalemia in 
Elderly Patients 
Receiving 
Standard Doses 
of Trimethoprim-
Sulfamethoxazol
e 
1994 
Case 
report 
(USA) 
72 year-old 
woman with 
sarcoidosis 
treated for 
pneumonia 
with standard 
dose TMP-
SMX. 
Hyperkalemia of 6.0 
mmol/L developed 
during the 4 day course 
of treatment. The 
potassium returned to 
normal 24 hours after 
stopping TMP-SMX. 
Greenberg, 
S 27 
Hyperkalemia 
with high-dose 
trimethoprim-
sulfamethoxazol
e therapy. 
1993 
Case 
report 
(USA) 
A patient with 
HIV and 
Pneumocysti
s jiroveci 
pneumonia 
treated with 
TMP-SMX 
Hyperkalemia 
developed 5 days into 
therapy and resolved 
upon withdrawal of 
TMP-SMX. 
Greenberg, 
S 65 
Trimethoprim-
sulfamethoxazol
e induces 
1993 
Retrosp
ective 
cohort 
51 patients 
admitted with 
symptomatic 
For the 26 patients not 
treated with TMP-SMX, 
the mean serum 
18 
 
reversible 
hyperkalemia. 
HIV infection 
between 
1989 and 
1991. 
Twenty-five 
of them 
required 
treatment for 
at least 6 
days with 
high dose 
TMP-SMX 
for 
Pneumocysti
s jiroveci 
pneumonia. 
potassium remained 
unchanged over the 
course of their 
hospitalization. For the 
25 patients treated with 
TMP-SMX, the serum 
potassium underwent a 
mean increase of 1.1 
mmol/L (p < 0.0001). 
Seven patients had 
potassiums > 5.5 
mmol/L. Potassium 
levels returned to 
baseline after 
withdrawal of TMP-
SMX. 
Funai, N 66 
Hyperkalaemia 
with renal 
tubular 
dysfunction by 
sulfamethoxazol
e-trimethoprim 
for 
Pneumocystis 
carinii 
pneumonia in 
patients with 
lymphoid 
malignancy. 
1993 
Case 
series 
(Japan) 
2 patients 
with 
lymphoid 
malignancy 
who 
developed 
Pneumocysti
s jiroveci 
pneumonia 
and required 
treatment 
with high-
dose TMP-
SMX. 
Hyperkalemia 
developed during 
treatment with high dose 
TMP-SMX and also 
subsequently with 
standard dose TMP-
SMX. Hyperkalemia 
resolved with the drug’s 
withdrawal. 
Velázquez, 
H 29 
Renal 
mechanism of 
trimethoprim-
induced 
hyperkalemia. 
1993 
Human 
and 
Animal 
study 
(Spragu
e-
Human: 30 
consecutive 
patients 
being treated 
with TMP-
SMX. 
Despite normal adrenal 
and renal function, TMP-
SMX increased the 
mean serum potassium 
levels in the human 
subjects (0.6 mmol/L, 
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Dawley 
rats) 
Animal: 39 
male rats 
with TMP 
infused into 
the renal 
tubules. 
95%CI 0.29 – 0.95). 
50% of subjects had 
levels > 5.0 mmol/L. In 
the animals, TMP 
infusion reduced 
potassium excretion by 
40% and depolarized 
the lumen-negative 
transepithelial voltage 
by 66%. These findings 
are similar to those 
observed with amiloride. 
Choi, M 67 
Brief report: 
trimethoprim-
induced 
hyperkalemia in 
a patient with 
AIDS. 
1993 
Case 
report  
A patient with 
HIV/AIDS 
receiving 
high-dose 
TMP-SMX 
for 
Pneumocysti
s jiroveci 
pneumonia 
Hyperkalemia of 7.9 
mmol/L developed after 
9 days of treatment and 
a concurrently low 
urinary potassium 
concentration of 5 
mmol/L was noted. The 
adrenal function was 
normal and 
fludrocortisone failed to 
increase the urinary 
potassium. Both the 
hyperkalemia and 
hypokaluria resolved 
with withdrawal of TMP-
SMX. 
Medina, I 68 
Oral therapy for 
Pneumocystis 
carinii 
pneumonia in 
the acquired 
immunodeficien
cy syndrome. A 
controlled trial of 
1990 
Random
ized 
controlle
d trial 
60 patients 
with AIDS 
and 
Pneumocysti
s jiroveci 
pneumonia 
randomized 
to TMP-SMX 
Mild hyperkalemia 
occurred in 20% of the 
patients taking TMP-
SMX and 53% of the 
patients taking TMP-
dapsone. The peak 
potassium was 6.1 
mmol/L and occurred in 
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trimethoprim-
sulfamethoxazol
e versus 
trimethoprim-
dapsone. 
or TMP-
dapsone 
the TMP-dapsone 
group. 
Guy, R 69 
Mineralocorticoi
d deficiency in 
HIV infection. 
1989 
Case 
report 
(UK) 
An HIV-
infected 41 
year-old man 
admitted for 
treatment of 
Pneumocysti
s jiroveci 
pneumonia 
with TMP-
SMX. 
Unrecognized role of 
TMP-SMX and the 
electrolyte abnormalities 
were attributed to 
mineralocorticoid 
deficiency. 
Murphy, C 
70 
Re: 
Mineralocorticoi
d deficiency in 
HIV infection. 
1989 
Case 
report 
(UK) 
A 60 year-old 
HIV-infected 
man with 
Pneumocysti
s jiroveci 
pneumonia 
treated with 
high dose 
TMP-SMX. 
Hyperkalemia of 7.7 
mmol/L and 
hyponatremia developed 
9 days into treatment 
and resolved after 
cessation of TMP-SMX. 
Plasma renin activity 
and aldosterone 
concentrations were 
within expected limits 
and therefore ruled out 
as a cause of 
hyperkalemia in this 
patient. 
Kalin, M 71 
Hyporeninemic 
hypo- 
aldosteronism 
associated with 
acquired 
immune 
1987 
Case 
series 
4 patients 
with 
HIV/AIDS 
and 
hyperkalemia
. 
The hyperkalemia was 
attributed to 
hyporeninemic hypo- 
aldosteronism, but all 
four patients were taking 
TMP-SMX at the times 
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deficiency 
syndrome. 
of their electrolyte 
disturbances. 
Kaufman, 
A 72 
Renal salt 
wasting and 
metabolic 
acidosis with 
trimethoprim-
sulfamethoxazol
e therapy. 
1983 
Case 
report 
(USA) 
A patient 
undergoing 
chemotherap
y for 
leukemia 
with 
developed 
Pneumocysti
s jiroveci 
pneumonia 
and required 
treatment 
with TMP-
SMX. 
Hyperkalemia (7.0 
mmol/L) developed 6 
days into therapy, 
resolved with withdrawal 
of TMP-SMX and then 
recurred again after 
TMP-SMX was re-
introduced. The authors 
speculated that TMP-
SMX was involved, but 
the mechanism was no 
known. 
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Table 1-2 Glyburide and hypoglycemia and patients with CKD: Literature 
summary. 
Author Title Date 
Study 
Type 
Description Finding 
Holstein, A 
73 
Severe 
sulfonylurea-
induced 
hypoglycemia: a 
problem of 
uncritical 
prescription and 
deficiencies of 
diabetes care in 
geriatric 
patients. 
2010 
Prospec
tive 
populati
on-
based 
observat
ional 
study 
All cases of 
sulfonylurea-
associated 
hypoglycemi
a were 
registered 
from 2000 to 
2009. 
Glyburide accounted for 
a number of cases of 
hypoglycemia 
disproportionate to its 
use in the studied 
population. Renal 
dysfunction was found in 
73% of the cases of 
hypoglycemia. 
Holstein, A 
74 
Characteristics 
and time course 
of severe 
glimepiride- 
versus 
glibenclamide-
induced 
hypoglycaemia. 
2003 Survey 
400 German 
physicians 
were 
surveyed and 
asked about 
the 
characteristic
s of their 
patients who 
had had 
severe 
hypoglycemi
c episodes. 
11 of the 13 patients 
with severe, prolonged 
hypoglycemia 
associated with 
glibenclamide 
(glyburide) had impaired 
renal function. 
Holstein, A 
75 
Lower incidence 
of severe 
hypoglycaemia 
in patients with 
2001 
Prospec
tive 
populati
on-
44 cases of 
hypoglycemi
a requiring 
hospitalizatio
Despite equivalent 
exposure, glibenclamide 
(glyburide) was 
associated with 38 
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type 2 diabetes 
treated with 
glimepiride 
versus 
glibenclamide 
based 
observat
ional 
study 
n cases, compared to 6 
cases for glimepiride. 
62% of the 
hypoglycemic patients 
had renal insufficiency. 
Krepinsky, 
J 21 
Prolonged 
sulfonylurea-
induced 
hypoglycemia in 
diabetic patients 
with end-stage 
renal disease. 
2000 
Case-
control 
38 patients 
receiving 
hemodialysis
: 7 case 
patients and 
31 controls. 
Cases had 
prolonged 
episodes of 
hypoglycemi
a. 
All case patients were 
taking glyburide at the 
time of hypoglycemia. 
28 out of the 31 control 
patients were taking 
glyburide. Risk factors 
for hypoglycemia in 
dialysis patients taking 
glyburide included (1) 
poor oral intake, (2) 
previous hypoglycemia, 
(3) longer duration of 
diabetes, (4) history of 
stroke. 
Ben-Ami, H 
76 
Drug-induced 
hypoglycemic 
coma in 102 
diabetic 
patients. 
1999 
Case 
series 
(Israel) 
102 patients 
with 
hypoglycemi
c coma. 
All cases were 
associated with either 
insulin or glyburide use. 
Renal impairment was a 
significant risk factor for 
drug-induced 
hypoglycemia. 
Ben-Ami, H 
77 
Glibenclamide-
induced 
hypoglycemic 
coma in 51 older 
patients with 
type 2 diabetes 
mellitus 
 
1999 
Retrosp
ective 
cohort 
51 patients 
with 
glibenclamid
e (glyburide) 
induced 
hypoglycemi
a. 
Risk factors for 
glibenclamide-induced 
hypoglycemia included 
age > 60 years, renal 
dysfunction, 
malnutrition, infection, 
overdose, cirrhosis, 
other liver disease. 
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Sills, M 78 
Prolonged 
hypoglycemic 
crisis associated 
with glyburide. 
1997 
Case 
report 
(USA) 
79 year old 
patient with 
renal 
impairment 
and using 
glyburide. 
Hypolgycemia was 
refractory to medical 
management and 
persisted for 3 days. 
Renal dysfunction was 
thought to have played a 
role in the delayed 
clearance of glyburide. 
Sketris, I 79 
Hypoglycemic 
coma induced 
by inadvertent 
administration of 
glyburide. 
1984 
Case 
report 
(USA) 
79 year old 
woman with 
mild renal 
insufficiency 
given 5 mg of 
glyburide 
mistakenly. 
Hypoglycemic lasting 3 
days resolved with 
continuous IV dextrose 
infusion. 
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2.1 Introduction 
Adverse drug reactions among the elderly are common. It is estimated that 50 serious 
adverse drug reactions occur for every 1000 patient-years.1 Drug-induced hyperkalemia 
is of particular concern because of its association with commonly used medications and 
its significant potential for harm, including sudden death.2-5 Common cardiovascular 
agents such as angiotensin converting enzyme inhibitors, angiotensin receptor blockers, 
and potassium sparing diuretics all impart a risk of hyperkalemia.2;6-10 Many studies have 
suggested an augmented risk of hyperkalemia associated with simultaneous use of two or 
more of these agents.11-15 However, there may also be significant risks associated with 
other combinations of common, hyperkalemia-inducing medications such as beta 
adrenergic receptor blockers (β-blockers) and trimethoprim-sulfamethoxazole antibiotics 
(TMP-SMX).  
β-blocker prescriptions have steadily increased over the last ten years.16 Their role in 
hyperkalemia through inhibition of cellular adrenergic receptor dependent potassium 
translocation has been extensively studied.17-19 TMP-SMX is also in common use, 
representing 30% of all antibiotics prescribed for urinary tract infections.20;21 
Trimethoprim is structurally related to the potassium-sparing diuretic amiloride and has 
been shown to block sodium channels in the distal nephron thereby limiting the 
electrochemical gradient driving potassium elimination.22-27 
Given their popularity, β-blockers and TMP-SMX antibiotics are frequently co-
administered. We conducted a nested case-control study using health administrative data 
to explore the risk of hyperkalemia conferred by this combination of drugs. We 
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hypothesized that concurrent use of β-blockers and TMP-SMX would pose a 
substantially greater risk of hyperkalemia requiring hospital admission than would the 
use of TMP-SMX alone. 
2.2 Materials and Methods 
2.2.1 Design  
Using health administrative data from July 1, 1994 to March 31, 2008, we established 
two cohorts of outpatient residents of Ontario, age 66 years and older. One cohort 
included only those with evidence of continuous β-blocker use, and the other included 
only those without evidence of any β-blocker use. Within these cohorts, we conducted 
separate nested case-control studies comparing the risk of hyperkalemia posed by TMP-
SMX to that of amoxicillin. To assess interaction between β-blockers and TMP-SMX, we 
compared the estimates of risk from the two cohorts. We acquired and analyzed 
exposure, outcome and covariate data according to a predefined protocol. The study was 
approved by the institutional review board at Sunnybrook Health Sciences Centre, 
Toronto, Canada. The reporting of this study follows the STROBE statement 
guidelines.28 
2.2.2 Setting 
Ontario is the most populous Canadian province, with approximately 12 million residents 
in the year 2008, of whom 1.6 million were older than 65 years.29 All residents received 
universal access to hospital and physician services, and elderly residents received 
coverage for prescription medications. Coverage for medical services and medications 
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from a single provincial payer provided a comprehensive set of health administrative 
data.  
2.2.3 Sources of Data  
We identified prescription drug use using the Ontario Drug Benefits (ODB) database. 
The ODB program provides residents of Ontario 65 years of age or older with coverage 
for most prescription medications. We identified all hospitalizations attributed to 
hyperkalemia based on ninth and tenth editions of the International Classification of 
Disease (ICD-9 and ICD-10) codes recorded in the Canadian Institute for Health 
Information Discharge Abstract Database (CIHI-DAD).We obtained covariate 
information from multiple databases including the ODB database, CIHI-DAD and the 
Ontario Health Insurance Plan (OHIP) database. The OHIP database contains claims 
information on inpatient, outpatient and laboratory services rendered to residents of 
Ontario. We obtained demographic data from the Registered Persons Database (RPD) 
which contains demographic information on all Ontarians ever issued a health card. 
Census data from Statistics Canada was linked to postal codes and used to determine 
neighborhood income quintile.  These databases have been validated in previous 
epidemiologic studies.30-34 Data were complete except for 5% of income estimates which 
we imputed as the mean. 
2.2.4 Participants  
Cohorts: Drug coverage for each individual prescription in ODB is maximally 100 days’ 
duration; therefore, we established the cohort of continuous β-blocker users by including 
only those with repeated β-blocker prescriptions that were no more than 100 days apart. 
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We established a cohort of non-users by including only those without a β-blocker 
prescription in the ODB database.  
Cases: Within the cohorts we identified hospitalizations for hyperkalemia within 14 days 
after filling a prescription for one of the five study antibiotics: TMP-SMX, ciprofloxacin, 
norfloxacin, nitrofurantoin, or amoxicillin. These antibiotics are typically prescribed for 
urinary tract infections, which is one of the most common reasons for outpatient 
antibiotic therapy.35 We chose these antibiotics to help mitigate indication bias by 
restricting the range of possible infections underlying the prescriptions. We chose 
amoxicillin as the reference drug because it is one of the most commonly prescribed 
antibiotics and its use is not associated with hyperkalemia. We defined cases as 
hospitalizations attributed to hyperkalemia at the time of admission (ICD-9 or ICD-10 
diagnosis codes 276.7 and E87.5, respectively). The date of hospital admission served as 
the index date for all analyses. Among individuals with multiple episodes of 
hyperkalemia, we considered only the first hospitalization. 
Controls: For each case, we randomly selected up to four patients who had filled a 
prescription for a study antibiotic but who had not been hospitalized for hyperkalemia. 
Potential controls had the same index date as their corresponding case patient and were 
included only if a study antibiotic prescription was detected in the preceding 14 days. 
Controls were also matched to cases on age at the index date (± 1 year), sex, history of 
chronic kidney disease, and history of diabetes mellitus.  
In both cases and controls, we excluded patients with prescriptions for multiple study 
antibiotics or a single non-study antibiotic within the 14 days prior to the index date. We 
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also excluded those with evidence of end-stage renal disease or renal transplantation in 
the three years preceding the index date. All patients were at least 66 years of age at the 
time of analysis to ensure the availability of at least one year of drug use records 
preceding the index date.  
2.2.5 Statistical Methods 
We assessed differences between the baseline characteristics of case and control groups 
and those who received various types of antibiotics using standardized differences.36;37 
We examined odds ratios for hyperkalemia comparing five groups of patients prescribed 
different study antibiotics. We used conditional logistic regression to estimate the odds 
ratios and their 95% confidence intervals. We adjusted for characteristics that may have 
predisposed to hyperkalemia in the multivariable model using all available data in the 
three years preceding the index date, including the Charlson comorbidity score (0, 1, 
≥2),38;39 the number of distinct prescriptions in the preceding year (≤5, 6-10, 11-15, 16-
20, 21-25, ≥ 26),40 socioeconomic status (quintiles 1-2, quintiles 3-5), congestive heart 
failure, coronary artery disease, and previous episodes of hyperkalemia. We adjusted for 
medications used within the 120 day interval prior to the index date that may have 
influenced serum potassium concentrations: non-potassium sparing diuretics, potassium-
sparing diuretics,7;8 potassium supplements, non-steroidal anti-inflammatory drugs, 
angiotensin converting enzyme inhibitors,9 and angiotensin receptor blockers.6 We 
assessed for a statistical interaction by comparing the odds ratios from the two cohorts 
using the technique of Altman and Bland; the odds ratio from the first cohort reflected the 
risk of hyperkalemia among users of both β-blockers and TMP-SMX, and the odds ratio 
from the second cohort reflected the same risk among users of TMP-SMX alone.41 Two-
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tailed p values of less than 0.05 were interpreted as statistically significant. We conducted 
all analyses using SAS 9.1.3 software (SAS Institute, Carey, NC). 
2.2.6 Additional Analyses 
Severity of hospital admissions: For case patients, we determined the median duration of 
the hospital admission, whether there was an intensive care unit admission, and whether 
the patient died during the hospital admission.  
Dose response: To identify a dose-response relationship, we repeated the primary 
analysis with the TMP-SMX exposure stratified into single strength (400mg/80mg) and 
double strength (800mg/160mg) dose categories. We expected a higher risk of 
hyperkalemia with a larger dose of TMP-SMX.  
Time from antibiotic prescription: We altered the time from antibiotic prescription and 
index date first to 7 days and then 21 days rather than 14 days as used in the primary 
analysis.  
β-1 receptor selectivity: We repeated the primary analysis and test for interaction 
differentiating between β-1-selective and non-selective β-blockers. Given the role of the 
β-2 adrenergic receptor in translocation of potassium, we expected to find a stronger 
relationship with hyperkalemia when TMP-SMX was used in the setting of non-selective 
β-blockers.17;42;43  
Serum potassium testing: For the purposes of billing, the performing of serum potassium 
tests but not the test results are recorded in Ontario administrative databases. We 
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examined the number of outpatient serum potassium tests performed between the dates of 
antibiotic prescription and the index date.  
Absolute risk of hyperkalemia: To obtain a crude estimate of the absolute risk of hospital 
admission for hyperkalemia we ascertained the number of cohort patients who received at 
least one TMP-SMX prescription and the number of those who required admission for 
hyperkalemia within the following 21 days.  
Absolute risk of death: To obtain a crude estimate of the absolute risk of death we 
ascertained the number of cohort patients who received at least one TMP-SMX 
prescription and the number of those who died within the following 21 days. 
2.3 Results 
2.3.1 Primary Analysis  
During the 14 year accrual period we identified a cohort of 299,749 β-blocker users. Of 
these, 31,186 filled at least one prescription for TMP-SMX and 195 were admitted to 
hospital for hyperkalemia. We excluded six cases who could not be matched to a control. 
The final sample comprised 189 cases of hyperkalemia and 641 controls.  
Characteristics according to hyperkalemia and antibiotic use are shown in table 2-1 and 
table 2-2, respectively. Cases had slightly lower incomes and greater comorbidity (table 
2-1). The distribution of baseline characteristics was relatively consistent across the five 
types of antibiotics (table 2-2). As shown in table 2-3, among patients receiving β-
blockers, those receiving concomitant TMP-SMX were five times more likely to be 
hospitalized for hyperkalemia than patients using amoxicillin (adjusted odds ratio [OR] 
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5.1, 95% CI 2.8 to 9.4). No significant associations were observed between the other 
study antibiotics and admissions for hyperkalemia.  
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Table 2-1 Characteristics of beta blocker users admitted to hospital with 
hyperkalemia and matched controls.* 
 Cases Controls N = 189 N = 641 
Demographic and medical characteristics 
Age, years 80 (73-84) 80 (74-84) 
Age groups   
65-74  56 (29.6) 189 (29.5) 
75-84 88 (46.6) 305 (47.6) 
≥ 85 45 (23.8) 147 (22.9) 
Male sex 66 (34.9) 219 (34.2) 
Income quintile 
1 to 2 (lower) 100 (52.9) 286 (44.6) † 
3 to 5 (higher) 89 (47.1) 355 (55.4) † 
Charlson Score  
0 30 (15.9) 224 (34.9) 
1 26 (13.8) 115 (17.9) † 
≥ 2 133 (70.4) 302 (47.1) † 
No. of prescription drugs in previous year  
≤ 5 < 6  17 (2.7)  
6 to 10 13 (6.9) 156 (24.3) † 
11 to 15 58 (30.7) 191 (29.8) 
16 to 20 59 (31.2) 171 (26.7) † 
21 to 25 31 (16.4) 59 (9.2) † 
≥ 26 25 (13.2) 47 (7.3) † 
Congestive heart failure 113 (59.8) 273 (42.6) † 
Coronary artery disease 138 (73.0) 393 (61.3) † 
Diabetes 81 (42.9) 245 (38.2) 
Chronic kidney disease 99 (52.4) 316 (49.3) 
Prior hospitalisation for hyperkalemia 16 (8.5) 13 (2.0) † 
Medication use in preceding 120 days 
Non-potassium sparing diuretics 124 (65.6) 319 (49.8) † 
Potassium sparing diuretics 52 (27.5) 72 (11.2) † 
Potassium supplements < 6  8 (1.2) † 
NSAIDs 69 (36.5) 231 (36.0) 
ACE / ARB 133 (70.4) 343 (53.5) † 
* Data presented as number (percent) with the exception of age, which is presented as median (interquartile range). In 
accordance with Ontario privacy law, patient values less than 6 are not reported. NSAID, non-steroidal anti-
inflammatory drug; ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker. 
† Indicates a standardised difference between case patients and controls greater than 10%. Standardised differences are 
less sensitive to sample size than tradition hypothesis tests. They provide a measure of the difference between groups 
divided by the pooled standard deviation.36;37 
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Table 2-2 Characteristics of beta blocker users by antibiotic use.* 
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N = 223 N = 210 N = 109 N = 108 N = 180 
Demographics and medical characteristics 
Age   80 (74-86) 80 (73-84) 81 (76-85) 81 (75-86) 78 (71-82) 
Age group  
65-74 63 (28.3) 68 (32.4) 25 (22.9) 24 (22.2) 65 (36.1) 
75-84 98 (43.9) 99 (47.1) 52 (47.7) 52 (48.1) 92 (51.1) 
≥ 85 62 (27.8) 43 (20.5) 32 (29.4) 32 (29.6) 23 (12.8) 
Male  77 (34.5) 83 (39.5) 35 (32.1) 20 (18.5) 70 (38.9) 
Income Quintile  
1 to 2 109 (48.9) 106 (50.5) 47 (43.1) 45 (41.7) 79 (43.9) 
3 to 5 114 (51.1) 104 (49.5) 62 (56.9) 63 (58.3) 101 (56.1) 
Charlson Score 
0 59 (26.5) 52 (24.8) 41 (37.6) 35 (32.4) 67 (37.2) 
1 40 (17.9) 35 (16.7) 19 (17.4) 13 (12.0) 34 (18.9) 
≥ 2 124 (55.6) 123 (58.6) 49 (45.0) 60 (55.6) 79 (43.9) 
Congestive heart failure  112 (50.2) 102 (48.6) 53 (48.6) 45 (41.7) 74 (41.1) 
Coronary artery disease  146 (65.5) 145 (69.0) 67 (61.5) 61 (56.5) 112 (62.2) 
Diabetes in past 3 years  93 (41.7) 78 (37.1) 41 (37.6) 43 (39.8) 71 (39.4) 
Prior hospitalisation for hyperkalemia 11 (4.9) < 6  < 6  < 6   < 6  
Chronic kidney disease  122 (54.7) 101 (48.1) 49 (45.0) 64 (59.3) 79 (43.9) 
No. of prescription drugs in previous year  
≤ 5 < 6  < 6  7 (6.4) < 6  < 6  
6 to 10 32 (14.3) 36 (17.1) 26 (23.9) 17 (15.7) 58 (32.2) 
11 to 15 80 (35.9) 61 (29.0) 33 (30.3) 29 (26.9) 46 (25.6) 
16 to 20 65 (29.1) 65 (31.0) 24 (22.0) 32 (29.6) 44 (24.4) 
21 to 25 24 (10.8) 25 (11.9) 11 (10.1) 13 (12.0) 17 (9.4) 
≥ 26 20 (9.0) 18 (8.6) 8 (7.3) 14 (13.0) 12 (6.7) 
Medication use in preceding 120 days  
Non-potassium sparing diuretics 127 (57.0) 122 (58.1) 51 (46.8) 58 (53.7) 85 (47.2) 
Potassium sparing diuretics 32 (14.3) 41 (19.5) 18 (16.5) 15 (13.9) 18 (10.0) 
Potassium supplements < 6  < 6  0 < 6  < 6  
NSAIDs 83 (37.2) 83 (39.5) 38 (34.9) 21 (19.4) 75 (41.7) 
ACE / ARB 146 (65.5) 128 (61.0) 46 (42.2) 58 (53.7) 98 (54.4) 
* Data presented as number (percent) with the exception of age, which is presented as median (interquartile range). In 
accordance with Ontario privacy law, patient values less than 6 are not reported. NSAID, non-steroidal anti-
inflammatory drug; ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker. 
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The cohort of non-β-blocker users had a distribution of baseline characteristics similar to 
that of the β-blocker cohort (tables available upon request). Among non-β-blocker users 
we identified 1349 cases patients and 5378 controls (table 2-4). The OR for hyperkalemia 
requiring hospital admission comparing TMP-SMX to amoxicillin was 5.8 (95% CI 4.7 
to 7.3). This was not significantly different from the risk associated with TMP-SMX use 
among β-blocker users (p value for interaction 0.65). This indicated the risk of 
hyperkalemia was attributable to TMP-SMX alone, rather than its combination with β-
blockers. 
Table 2-3 Association between hospitalization for hyperkalemia and antibiotic use 
among beta blocker users.* 
Variable 
Cases Controls Odds Ratio (95% CI) 
N = 189 N = 641 Unadjusted Adjusted 
TMP-SMX 98 (51.9) 125 (19.5) 5.9 (3.4 – 10.2) 5.1 (2.8 – 9.4) 
Ciprofloxacin 51 (27.0) 159 (24.8) 2.3 (1.3 – 4.1) 1.8 (0.9 – 3.3) 
Norfloxacin 8 (4.2) 101 (15.8) 0.7 (0.3 – 1.5) 0.5 (0.1 – 1.2) 
Nitrofurantoin 12 (6.3) 96 (15.0) 0.9 (0.4 – 2.0) 0.7 (0.3 – 1.7) 
Amoxicillin † 20 (10.6) 160 (25.0) 1.0 1.0 
 
* CI, confidence interval, TMP-SMX, trimethoprim-sulfamethoxazole 
† Amoxicillin users served as the reference group 
 
 
 
Table 2-4 Association between hospitalization for hyperkalemia and antibiotic use 
among non-beta blocker users.* 
Variable 
Cases Controls Odds Ratio (95% CI) 
N = 1349 N = 5378 Unadjusted Adjusted 
TMP-SMX 670 (49.7) 1064 (19.8) 6.3 (5.2 – 7.7) 5.8 (4.7 – 7.3) 
Amoxicillin † 163 (12.1) 1603 (29.8) 1.0 1.0 
 
* CI, confidence interval, TMP-SMX, trimethoprim-sulfamethoxazole 
† Amoxicillin users served as the reference group 
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2.3.2 Additional Analyses  
Severity of hospital admissions: For the 189 hospitalizations for hyperkalemia within the 
β-blocker cohort, the median length of stay was 7 days (interquartile range 4 to 13 days); 
17 patients (9%) were admitted to intensive care units, and 26 died during their hospital 
stay (14%). 
Dose-response: There was graded association with hospital admissions for hyperkalemia 
when TMP-SMX use was stratified by dose. For single-strength tablets the adjusted OR 
was 3.4 (95% CI 1.6 to 7.4) compared to 6.6 (95% CI 3.5 to 12.6) for double-strength 
tablets. 
Time from antibiotic prescription: When we altered the time from antibiotic prescription 
to index date, the risk of hospital admission for hyperkalemia with TMP-SMX compared 
to amoxicillin was unchanged (7 days OR 5.5, 95% CI 2.3 to 13.0; 21 days OR 5.9, 95% 
CI 3.3 to 10.4). 
β-blocker selectivity: The prevalence of non-selective β-blocker usage (7.3%) was 
insufficient for meaningful analysis. 
Serum potassium testing: Between the date of antibiotic prescription and index date, 26 
(14%) of case patients and 33 (5%) of controls had an outpatient serum potassium 
measurement. There was no difference in the proportion of patients tested across the five 
types of antibiotic users (between 6 to 7% for all five types). 
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Absolute risk of hyperkalemia: Within the β-blocker cohort, for every 1000 TMP-SMX 
prescriptions there were 6.9 (95% CI, 6.0 to 7.9) hospital admissions attributed to 
hyperkalemia within the subsequent 21 days. In comparison, there were 2.9 (95% CI, 2.4 
to 3.4) admissions for every 1000 amoxicillin prescriptions. 
Absolute risk of death: Within the β-blocker cohort, for every 1000 TMP-SMX 
prescriptions there were 26.2 (95% CI, 24.5 to 28.0) deaths within the subsequent 21 
days. In comparison, there were 15.7 (95% CI, 14.6 to 16.9) deaths for every 1000 
amoxicillin prescriptions.  
2.4 Discussion 
2.4.1 Main Finding 
Based on their pharmacodynamic interaction, we hypothesized that concomitant β-
blocker and TMP-SMX use would be associated with an excess risk of hyperkalemia. 
While we did observe a significant risk of hyperkalemia among elderly users of TMP-
SMX, concomitant β-blocker use did not augment this risk.  
2.4.2 Interpretation 
The role of β-blockers in hyperkalemia among elderly ambulatory patients may not be as 
great as originally anticipated. Historic evidence for this role comes largely from 
experimental studies, where β-blocker administration has been associated with transient 
rises in serum potassium concentrations in the local circulation of heavily exercising 
limbs, in anuric dialysis patients, or subsequent to potassium-chloride infusion.18;42-47 In 
some clinical studies of hyperkalemic events, the causal role of β-blockers has been 
assumed without the presence of a referent group,2;48 and in other studies their role has 
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been examined only in high-risk patient populations.49-51 Conversely, in more rigorously 
conducted clinical studies, β-blockers were not associated with hyperkalemia.6;52;53 Our 
study does not refute the physiologic effects of β-blockers, but does suggest their 
contribution to hyperkalemia in ambulatory patients may be relatively minor. An 
important caveat is the high prevalence of β-1-selective agent use in our cohort. This 
distribution of β-blocker selectivity reflects the usage of these drugs in Ontario and does 
not threaten the external validity of our study; however, extension of our findings to a 
specific population of non-selective β-blocker users would not be appropriate. 
Furthermore, in detecting modest effects, tests of statistical interaction are of limited 
power and failure to show significant effect measure modification does not rule out a 
biological interaction.  
Although the absolute rate of hospital admissions with a primary diagnosis of 
hyperkalemia was small, this finding must be interpreted judiciously. Our definition of 
hyperkalemia was very strict. We did not count events that did not prompt hospital 
admission, emergency room visits without hospital admission, hospital admissions 
attributed to another primary reason, or more severe events resulting in prehospital death. 
It is of concern that in absolute terms, the risk of death within 21 days of antibiotic use 
appeared higher in TMP-SMX users compared to those who took amoxicillin. 
Nonetheless, with all antibiotics there is a potential for adverse events that must be 
balanced against their benefits. We recognize the importance of TMP-SMX in the 
modern antibiotic armamentarium and do not suggest curtailing its use. Rather, it is likely 
that some cases of severe morbidity associated with TMP-SMX may be prevented 
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through simple measures such as serum potassium testing. In this analysis, only a small 
proportion of patients had such testing in the days following TMP-SMX prescription. 
2.4.3 Strengths and Limitations 
Our study has a number of strengths. The interaction between β-blockers and TMP-SMX 
has not been previously examined in a population-based study. Although the results can 
be generalized only to the elderly, our study was free of the screening biases that arise in 
the setting of clinical trials and restrictive cohorts. Ontario’s universal health care system 
allowed us to draw upon the records of approximately 1.4 million people over the age of 
66 years. The large sample afforded a unique opportunity to examine a relatively rare yet 
serious adverse drug event. Furthermore, emigration out of the Ontario Health Insurance 
plan is less than one percent per year, making it a very stable dataset (2001 Canadian 
Census).  
The most important limitation of our study is the non-random allocation of the study 
antibiotics. Therefore, residual confounding is certainly a possibility in driving the 
findings. Information on risk factors such as dietary potassium intake, non-prescription 
medication use, and medication compliance is not recorded within the administrative 
databases. Confounding by indication could also have occurred because severe infections 
can predispose to hyperkalemia through sepsis and resultant kidney injury. TMP-SMX is 
active against common and virulent organisms such as Staphylococcus aureus and 
methicillin-resistant Staphylococcus aureus, so it is possible that patients treated with 
TMP-SMX had particularly severe infections compared to patients using other types of 
antibiotics.54-56 We attempted to avoid this problem by restricting our case definition to 
patients admitted with a primary diagnosis of hyperkalemia, rather than hyperkalemia 
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occurring secondary to sepsis or acute kidney injury. Furthermore, while we cannot know 
the impact of potential confounders, the magnitude of the risk estimate observed in the 
primary analysis provides reassurance of a true biological effect. It is difficult to conceive 
of an unmeasured confounder that is predictive of hyperkalemia and differentially present 
among the various antibiotic types to the extent that it accounts for all of the excess risk 
we observed. 
We relied upon administrative databases and diagnostic codes to define the study 
outcome. Although our definition of hyperkalemia has not been validated, we believe it 
to be reliable for two of reasons. A similar definition of hyponatremia was shown to have 
a specificity greater than 99%.57 Also, electrolyte disturbances as a whole are accurately 
recorded in the CIHI-DAD with a sensitivity of 80% and a specificity greater than 95%.32 
Misclassification of exposure and outcome variables can occur when using health 
administrative data. However, the occurrence of coding errors between cases, controls 
and the β-blocker and non β-blocker cohorts was unlikely to have occurred at differential 
rates.  
Finally, knowledge of the hyperkalemic effects of β-blockers and TMP-SMX may have 
caused some physicians to more frequently measure serum potassium levels in patients 
who were using these drugs. However, there was no difference in rates of outpatient 
potassium measurement between antibiotic types. As well, serum electrolyte 
measurement is a routine component of emergency department assessment, making 
differential case ascertainment between exposure groups less likely.  
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2.5 Conclusions 
Our study shows a significant, biologically plausible, dose-dependent risk of 
hyperkalemia among elderly users of TMP-SMX. Physicians should be cognizant of this 
risk and consider measurement of serum potassium in older patients treated with this 
antibiotic. 
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3.1 Introduction 
Strict glycemic control is a tenet of diabetes mellitus management because it is associated 
with improved micro- and macrovascular outcomes.1-8 Diabetes is the primary etiology in 
one quarter of patients with chronic kidney disease (CKD) and about half of those with 
end-stage renal disease (ESRD).9;10 Among patients with established diabetic 
nephropathy, disease progression can be slowed by controlling blood glucose to near-
normal levels.1;4;7;11 However, this rigorous control is achieved at the expense of an 
increased rate of hypoglycemic events.1;7  
The risk of hypoglycemia is a particular concern among patients with impaired renal 
function.12 In these patients, the counter-regulatory response to hypoglycemia may be 
limited by impaired renal gluconeogenesis or poor glycogen reserves caused by uremia-
induced anorexia.13-15 In addition, the clearance of some commonly prescribed diabetes 
therapies depends on renal function. This is the case for glyburide, the active metabolites 
of which are slowly eliminated in the setting of impaired renal function.16-20 Based 
largely on glyburide’s pharmacokinetic data, national treatment guidelines have 
recommended avoiding its use once the estimated glomerular filtration rate (eGFR) falls 
below 60 ml/min/1.73m2.21 However, the body of evidence supporting this 
recommendation is weak and contradictory,22;23 and the limited clinical data on 
glyburide’s hypoglycemic potential has arisen from descriptive studies and small 
observational studies.24-26 Glyburide remains an effective diabetes therapy that has been 
used in a trial demonstrating the benefits of strict glycemic control.1 Unfortunately, this 
trial is of little use in understanding glyburide’s side-effect profile because, like many 
trials, it did not include patients with CKD.27 Without a clear understanding of the risk 
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glyburide poses to patients with impaired renal function we cannot adequately assess the 
appropriateness of its use in this population.  
To quantify this risk in a large population-based analysis, we conducted two nested case-
control studies using outpatient laboratory data that we linked to Ontario’s health 
administrative data. We designed each study to assess drug-specific hypoglycemia risks 
in patients with impaired and normal kidney function. We hypothesized that the risk of 
severe hypoglycemic events in patients using glyburide would be greater in those with 
impaired kidney function compared to those with normal kidney function. 
3.2 Materials and Methods 
3.2.1 Design 
We used health administrative databases in Ontario, Canada to establish a nest cohort of 
patients older than 65 years with diabetes. Within this cohort we conducted two case-
control studies to assess the risk of hypoglycemia associated with the use of glyburide or 
insulin as compared to the reference drug, metformin. Two studies were done to explore 
the interaction between renal function and these diabetes therapies in terms of their 
hypoglycemic risks; patients with eGFR values above 60 mL/min/1.73m2 were included 
in the first study, and patients with an eGFR value below this level were included in the 
second study. To assess interaction we compared adjusted odds ratios derived from the 
two studies. We collected and analyzed all exposure, outcome and covariate data 
according to a predefined protocol. The study was approved by the institutional review 
board at Sunnybrook Health Sciences Centre, Toronto, Canada and its design and 
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reporting follow the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) statement guidelines.28 
3.2.2 Setting 
We acquired data from January 1, 1997 to March 31, 2008 using the linked health 
administrative data of Ontario, Canada. Ontario has approximately 12 million residents, 
1.6 million of whom are 65 years of age or older.29 All Ontario residents receive 
universal access to physician and hospital services through the Ontario Health Insurance 
Plan (OHIP). Ontario residents older than 65 years also receive universal formulary 
coverage for prescription medications through the Ontario Drug Benefits (ODB) 
program. Ontario’s single health insurance payer and the yearly emigration rate of less 
than one percent provide a set of health administrative data that is both comprehensive 
and stable.30  
3.2.3 Sources of Data 
We ascertained dispensed prescription medications using the ODB database, which has a 
basic error rate less than one percent.31 We collected data regarding inpatient and 
outpatient hospital visits from the Canadian Institute for Health Information Discharge 
Abstract Database (CIHI-DAD) and the National Ambulatory Care Reporting System 
(NACRS) database. These databases contain detailed diagnostic information coded using 
the ninth and tenth revisions of the International Classification of Disease (ICD-9 and 
ICD-10). The coding accuracy of these databases has been assessed for many 
diagnoses.32;33 We determined kidney function using serum creatinine values obtained 
from the Gamma-Dynacare laboratory database. Gamma-Dynacare laboratories provide 
ambulatory blood work in South-Western Ontario and have maintained a database of test 
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results since 2002. We collected demographic information and vital statistics from the 
Registered Persons Database (RPD) and we estimated neighborhood income levels using 
Statistics Canada census data.34 We also collected diagnostic information and physician 
service claims data from the Ontario Health Insurance Plan (OHIP) database. 
3.2.4 Participants  
Cohorts: In order to estimate GFR for all participants, we restricted cohort entry to those 
with at least one serum creatinine measurement. These measurements were available 
beginning January 1, 2002. Outcome ascertainment began on this date and continued to 
March 31, 2008, the last date for which complete data were available. To ensure all 
cohort members had at least one full year of medication use data, we restricted entry to 
those aged 66 years and older as of March 31, 2008. Finally, to exclude diet-controlled 
diabetes, we included only patients with at least one prescription for a diabetes therapy. 
Cases and Controls: We studied patients separately in groups determined by renal 
function (“normal” or “impaired”, defined by their most recent eGFR). In each of the two 
studies we defined cases as cohort members who presented to an emergency room or 
hospital with an admission diagnosis of hypoglycemia. We identified these events by 
detecting hypoglycemia diagnosis codes in either the CIHI-DAD or NACRS databases 
(ICD-9 codes 250.8, 251.0, 251.1, 251.2, or 962.3; ICD-10 codes E10.63, E11.63, 
E13.63, E14.63, E15, E16.0, E16.1, or E16.2). For patients with multiple hypoglycemic 
events during the study period, only the first event was counted. The date of the 
hypoglycemic event served as the index date. For each case, we randomly selected up to 
four cohort patients who at the time of the index date had no evidence of a hypoglycemic 
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event during the study period. These controls were matched to cases on age at the index 
date (±1 year) and sex.  
Exposure Status: For all patients, we searched the ODB database in the 120 day interval 
immediately preceding the index date to identify prescriptions for diabetes therapies. The 
ODB formulary provided coverage for the following diabetes therapies: acarbose, 
gliclazide, glyburide, glimepiride, chlorpropamide, tolbutamide, metformin, pioglitazone, 
rosiglitazone, nateglinide, repaglinide, and multiple formulations of insulin. To simplify 
interpretation, we excluded patients with prescriptions for more than one type of diabetes 
therapy in the 120 days prior to the index date. Patients with a prescription for metformin 
served as the reference group for comparison with each of the other drugs. Patients with 
prescriptions for different insulin formulations were all deemed to be taking insulin. 
Renal Function: Using the abbreviated Modification of Diet in Renal Disease (MDRD) 
formula,35 we used the most recent serum creatinine value prior to the index date to 
calculate each patient’s eGFR. For the primary analysis, patients with an eGFR less than 
60 mL/min/1.73m2 were considered to have impaired kidney function while those with an 
eGFR greater than or equal to 60 mL/min/1.73m2 were considered to have normal renal 
function. All serum creatinine measurements during the study period were calibrated for 
use in the MDRD formula.  
Potential Confounders: Point estimates of risk were adjusted for multiple baseline 
characteristics, confounding diagnoses and medication exposures. 
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3.2.5 Statistical methods 
We used standardized differences to compare baseline characteristics between case and 
control groups, and groups receiving different diabetes therapies. This metric describes 
differences between group means relative to the pooled standard deviation, and is deemed 
significant if greater than 10%.36;37 We conducted the primary analysis separately for 
each of the two studies. Using conditional logistic regression, we estimated odds ratios 
and 95% confidence intervals describing the risk of hypoglycemia for glyburide and 
insulin compared to metformin. We forced four variables well-associated with 
hypoglycemia into the regression models (Charlson score, hospital discharge within 30 
days prior to index date, infection within 21 days prior to index date, and liver disease). 
We included other variables based on their performance in bivariate testing. Those 
having an association with hypoglycemia with a two-sided p value less than or equal to 
0.2 were included in the regression model. We used a two-tailed Type I error rate of less 
than 0.05 as the threshold for statistical significance. We conducted all analyses with 
SAS 9.1.3 software (SAS Institute, Carey, NC). 
To assess interaction between specific diabetes therapies and renal function, we 
compared the drug-specific adjusted odds ratios that were determined separately for the 
impaired and normal kidney function groups using the technique of Altman and Bland.38 
Altered definition of impaired renal function: To explore the effect of altering the 
definition of impaired renal function, we repeated the primary analysis using eGFR cutoff 
values of 45 and 30 mL/min/1.73m2.  
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3.3 Results 
3.3.1 Participants 
Over the accrual period we identified 19,620 patients aged 66 years and older with one or 
more serum creatinine levels who had at least one prescription for a diabetes therapy. 
Within this cohort, 364 patients with impaired kidney function experienced a 
hypoglycemic event after use of a single drug. We identified 207 such cases among those 
with normal kidney function. Matching was relatively complete with only 13 cases 
excluded for lack of a matched control (ten from the impaired kidney function group and 
three from the normal kidney function group). Although we recorded exposure data on all 
diabetes therapies in the province-wide drug formulary, only metformin, glyburide and 
insulin provided enough data for meaningful analysis.  
Patient characteristics according to hypoglycemic events and diabetes therapy are shown 
in table 3-1 and table 3-2. Cases and controls within both renal function groups were 
similar with respect to age and socioeconomic status; however case patients were more 
likely than controls to have significant comorbidities, and were more likely to have 
higher stage CKD. Table 3-2 shows a similar pattern, with patients prescribed glyburide 
or insulin more likely to have markers of poor health than those receiving metformin. 
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Table 3-1 Baseline characteristics for cases and matched controls 
 
NORMAL 
RENAL FUNCTION 
IMPAIRED 
RENAL FUNCTION 
Control Case Control Case 
N=802 N=204 N=1,290 N=354 
Demographics      
Age at Index Date 
66-74 326 (40.6) 84 (41.2) 417 (32.3) 112 (31.6) 
75-84 371 (46.3) 93 (45.6) 616 (47.8) 174 (49.2) 
≥ 85 105 (13.1) 27 (13.2) 257 (19.9) 68 (19.2) 
Female 397 (49.5) 102 (50.0) 660 (51.2) 183 (51.7) 
Income Quintile  
 ≤ 2 368 (45.9) 89 (43.6) 555 (43.0) 167 (47.2) 
 ≥ 3 432 (53.9) 115 (56.4) 729 (56.5) 187 (52.8) 
Co-morbidity† 
No. of distinct prescriptions in last year 10 (7-14) 13 (10-19) ‡ 13 (9-17) 15 (11-21)‡ 
Charlson Score 
  ≤ 1 349 (43.5) 56 (27.5) ‡ 452 (35.0) 79 (22.3) ‡ 
  2 103 (12.8) 48 (23.5) ‡ 192 (14.9) 53 (15.0) 
  ≥ 3 157 (19.6) 76 (37.3) ‡ 430 (33.3) 188 (53.1) ‡ 
       Missing§ 193 (24.1) 24 (11.8) ‡ 216 (16.7) 34 (9.6) ‡ 
Hospital discharge within 30 days 21 (2.6) 33 (16.2) ‡ 62 (4.8) 43 (12.1) ‡ 
Infection within 30 days 63 (7.9) 30 (14.7) ‡ 113 (8.8) 62 (17.5) ‡ 
Liver disease 35 (4.4) 16 (7.8) ‡ 56 (4.3) 23 (6.5) ‡ 
Alcoholism 9 (1.1) 6 (2.9) ‡ 13 (1.0) 6 (1.7) 
Coronary artery disease 253 (31.5) 94 (46.1) ‡ 637 (49.4) 211 (59.6) ‡ 
Congestive heart failure 148 (18.5) 65 (31.9) ‡ 478 (37.1) 177 (50.0) ‡ 
Cerebrovascular disease 163 (20.3) 66 (32.4) ‡ 320 (24.8) 101 (28.5) 
Number of primary care visits 1 (0-3) 2 (0-3) ‡ 1 (0-3) 1 (0-3) 
Number of internist visits 1 (0-4) 4 (1-8) ‡ 2 (0-7) 6 (2-10) ‡ 
Previous hypoglycemic event 10 (1.2) 20 (9.8) ‡ 58 (4.5) 38 (10.7) ‡ 
Kidney Function 
Serum creatinine, mg/dL 0.9 (0.7-1.0) 0.9 (0.7-1.0) 1.4 (1.2-1.7) 1.6 (1.3-2.0) ‡  
eGFR mL/min/1.73 m2 76 (68-87) 74 (67-87) 46 (35-53) 40 (28-50) ‡ 
Most recent eGFR category 
Normal: ≥ 90 mL/min/1.73m2 171 (21.3) 39 (19.1) -- -- 
Normal: 60 to 89  mL/min/1.73m2 631 (78.7) 165 (80.9) -- -- 
CKD III: 30 to 59 mL/min/1.73m2 -- -- 1,081 (83.8) 247 (69.8) ‡ 
CKD IV: 15 to 29 mL/min/1.73m2 -- -- 168 (13.0) 83 (23.4) ‡ 
CKD V: < 15 mL/min/1.73m2 -- -- 41 (3.2) 24 (6.8) ‡ 
Hypoglycemic Medications 
β – Blockers 249 (31.0) 69 (33.8) 564 (43.7) 168 (47.5) 
ACE Inhibitors 433 (54.0) 118 (57.8) 740 (57.4) 209 (59.0) 
Hyperglycemic Medications 
Corticosteroids 34 (4.2) 15 (7.4) ‡ 72 (5.6) 37 (10.5) ‡ 
Thiazide diuretics 194 (24.2) 38 (18.6) ‡ 346 (26.8) 78 (22.0) ‡ 
Atypical antipsychotics 39 (4.9) 14 (6.9) 56 (4.3) 23 (6.5) ‡ 
Diabetes Therapy Use 
Glyburide 140 (17.5) 53 (26.0) 335 (26.0) 109 (30.8) 
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Metformin 545 (68.0) 27 (13.2) 551 (42.7) 29 (8.2) 
Insulin 117 (14.6) 124 (60.8) 404 (31.3) 216 (61.0) 
 
Note: Data presented as number (percent) or as median (interquartile range). In accordance with Ontario privacy law, 
patient values less than 6 are not reported. In accordance with Ontario privacy law, patient values less than 6 are not 
reported. Conversion factors for units: serum creatinine in mg/dL to mol/L, ×88.4 
† Comorbidity data was obtained for the 5 years prior to the index date unless otherwise specified. 
‡ Indicates a standardized difference between cases and controls greater than 10%. Standardized differences are less 
sensitive to sample size than tradition hypothesis testing. They express the difference between the means of two 
populations as a proportion of the pooled standard deviation.36;37 
§ Charlson scores were based on previous hospitalizations, and are only missing where patients did not have a 
previous hospitalization. 
Abbreviations: eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; ACE, angiotensin 
converting enzyme. 
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Table 3-2 Baseline characteristics according to diabetes therapy used 
  
NORMAL 
RENAL FUNCTION 
IMPAIRED 
 RENAL FUNCTION 
 Metformin Glyburide Insulin Metformin Glyburide Insulin 
N=572 N=193 N=241 N=580 N=444 N=620 
Demographics 
Age at Index Date 
     66-74 244 (42.7) 57 (29.5)‡ 109 (45.2) 179 (30.9) 111 (25.0)‡ 239 (38.5)§ 
     75-84 259 (45.3) 95 (49.2) 110 (45.6) 282 (48.6) 220 (49.5) 288 (46.5) 
     85+ 69 (12.1) 41 (21.2) ‡ 22 (9.1) 119 (20.5) 113 (25.5) ‡ 93 (15.0) § 
Female 278 (48.6) 95 (49.2) 126 (52.3) 309 (53.3) 216 (48.6) 318 (51.3) 
Income Quintile  
     ≤ 2 253 (44.2) 102 (52.8) ‡ 102 (42.3) 246 (42.4) 203 (45.7) 273 (44.0) 
     ≥ 3 319 (55.8) 89 (46.1) ‡ 139 (57.7) 330 (56.9) 240 (54.1) 346 (55.8) 
Co-morbidity† 
No. of distinct drugs in last year 10 (7-14) 10 (8-14) 13 (9-17)§ 11 (8-15) 13 (9-17) ‡ 16 (12-20) § 
Charlson Score 
     ≤ 1 270 (47.2) 69 (35.8) ‡ 66 (27.4) § 259 (44.7) 127 (28.6) ‡ 145 (23.4) § 
     2 61 (10.7) 35 (18.1) ‡ 55 (22.8) § 83 (14.3) 65 (14.6) 97 (15.6) 
     ≥ 3 96 (16.8) 47 (24.4) ‡ 90 (37.3) § 125 (21.6) 172 (38.7) ‡ 321 (51.8) § 
    Missing§§ 145 (25.3) 42 (21.8) 30 (12.4) § 113 (19.5) 80 (18.0) 57 (9.2) § 
Hospital discharge within 30 
days 17 (3.0) 15 (7.8)
 ‡ 22 (9.1) § 25 (4.3) 23 (5.2) 57 (9.2) § 
Infection within 30 days 45 (7.9) 17 (8.8) 31 (12.9) § 51 (8.8) 47 (10.6) 77 (12.4) § 
Liver disease  26 (4.5) 7 (3.6) 18 (7.5) § 25 (4.3) 13 (2.9) 41 (6.6) § 
Alcoholism 6 (1.0) < 6 7 (2.9) § 6 (1.0) 7 (1.6) 6 (1.0)  
Coronary artery disease 162 (28.3) 74 (38.3) ‡ 111 (46.1) § 217 (37.4) 245 (55.2) ‡ 386 (62.3)§ 
Congestive heart failure 99 (17.3) 39 (20.2) 75 (31.1) § 155 (26.7) 196 (44.1) ‡ 304 (49.0) § 
Cerebrovascular disease 116 (20.3) 49 (25.4) ‡ 64 (26.6) § 128 (22.1) 109 (24.5) 184 (29.7) § 
Number of primary care visits 1 (0-3) 1 (0-3) 2 (0-3) § 1 (0-3) 1 (0-3) 1 (0-3) 
Number of internist visits 1 (0-4) 1 (0-2) ‡ 4 (1-8) § 1 (0-4) 3 (0-6) ‡ 7 (2-12) § 
Previous hypoglycemic event < 6 < 6 24 (10.0) § 11 (1.9) 19 (4.3) ‡ 66 (10.6) § 
Kidney Function 
Serum creatinine, mg/dL 0.9 (0.8-1.0) 0.8 (0.7-1.0) 0.8 (0.7-0.9) 1.3 (1.1-1.5) 1.4 (1.2-1.9) ‡ 1.6 (1.3-2.0) § 
eGFR mL/min/1.73 m2 76 (68-88) 77 (69-87) 75 (66-87) 49 (41-55) 44 (32-53) ‡ 39 (29-49) § 
Most recent eGFR category 
Normal: ≥ 90 mL/min/1.73m2 124 (21.7) 35 (18.1) 51 (21.2) -- -- -- 
Normal: 60 - 89  mL/min/1.73m2 448 (78.3) 158 (81.9) 190 (78.8) -- -- -- 
CKD III: 30 - 59 mL/min/1.73m2 -- -- --  532 (91.7) 349 (78.6) ‡ 447 (72.1) § 
CKD IV: 15 - 29 mL/min/1.73m2 -- -- -- 44 (7.6) 74 (16.7) ‡ 133 (21.5) § 
CKD V: < 15 mL/min/1.73m2 -- -- -- < 6 21 (4.7) ‡ 40 (6.5) § 
Hypoglycemic Medications 
β – Blockers 179 (31.3) 56 (29.0) 83 (34.4) 232 (40.0) 205 (46.2) ‡ 295 (47.6) § 
ACE Inhibitors 303 (53.0) 101 (52.3) 147 (61.0) § 337 (58.1) 256 (57.7) 356 (57.4) 
Hyperglycemic Medications 
Corticosteroids 27 (4.7) 12 (6.2) 10 (4.1) 31 (5.3) 20 (4.5) 58 (9.4) § 
Thiazide diuretics 140 (24.5) 44 (22.8) 48 (19.9) § 190 (32.8) 98 (22.1) ‡ 136 (21.9) § 
Atypical antipsychotics 29 (5.1) 8 (4.1) 16 (6.6) 23 (4.0) 21 (4.7) 35 (5.6) 
 
Note: Data presented as number (percent) or as median (interquartile range). In accordance with Ontario privacy law, patient 
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values less than 6 are not reported. In accordance with Ontario privacy law, patient values less than 6 are not reported. 
Conversion factors for units: serum creatinine in mg/dL to mol/L, ×88.4 
† Comorbidity data was obtained for the 5 years prior to the index date unless otherwise specified. 
‡ Indicates a standardized difference between glyburide and metformin users greater than 10%. 
§ Indicates a standardized difference between insulin and metformin users greater than 10%. Standardized differences are less 
sensitive to sample size than tradition hypothesis testing. They express the difference between the means of two populations as a 
proportion of the pooled standard deviation.36;37 
§§ Charlson scores were based on previous hospitalizations, and are only missing where patients did not have a previous 
hospitalization. 
Abbreviations: eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; ACE, angiotensin converting enzyme. 
 
 
3.3.2 Primary Analysis 
Table 3-3 displays the results of the primary analysis. In patients with normal kidney 
function, we found the risk of a severe hypoglycemic event to be 18 fold higher 
comparing insulin to metformin (adjusted odds ratio [OR] 18.7, 95% CI 10.5 to 33.5), 
and nine fold higher comparing glyburide to metformin (adjusted OR 9.0, 95% CI 4.9 to 
16.4). Unexpectedly, we found that the analogous risks among patients with impaired 
kidney function were lower for both insulin (adjusted OR 7.9, 95% CI 5.0 to 12.4) and 
glyburide (adjusted OR 6.0, 95% CI 3.8 to 9.5). 
We found that renal function did not significantly modify glyburide’s hypoglycemic risk 
(p for interaction 0.15). However, we did find that insulin’s hypoglycemic risk was 
significantly attenuated in the setting of impaired renal function (p for interaction < 
0.001).  
3.3.3 Additional analysis: Altered definition of impaired renal 
function 
Table 3-4 displays the risks of hypoglycemia that associate with glyburide and insulin 
when the primary analysis was repeated with stricter definitions of impaired kidney 
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function. For both glyburide and insulin users, we found that the risk of hypoglycemia 
attenuates as kidney function decreases.  
Table 3-3 Association between diabetes therapy and hypoglycemia 
 
Normal Kidney Function 
 
 Cases Controls 
Odds Ratio (95% CI) 
N = 204 N = 802 Unadjusted Adjusted* 
Insulin 124 (60.8) 117 (14.6) 22.5  (13.4 - 37.8) 18.7  (10.5 - 33.5) 
Glyburide 53 (26.0) 140 (17.5) 8.1  (4.7 - 13.9) 9.0  (4.9 - 16.4) 
Metformin† 27 (13.2) 545 (68.0) 1.0 1.0 
 
Impaired Kidney Function 
 
 Cases Controls Odds Ratio (95% CI) 
N = 354 N = 1290 Unadjusted Adjusted* 
Insulin 216 (61.0) 404 (31.3) 10.5  (6.9 - 16.1) 7.9  (5.0 - 12.4) 
Glyburide 109 (30.8) 335 (26.0) 6.4   (4.1 - 10.0) 6.0  (3.8 - 9.5) 
Metformin† 29 (8.2) 551 (42.7) 1.0 1.0 
 
* Adjusted for previous hypoglycemic events, Charlson comorbidity index (1, 2, or ≥ 3), recent 
hospitalization, chronic liver disease, alcoholism, coronary artery disease, congestive heart failure, 
number of distinct medications used in the previous year (≤ 5, 6-10, 11-15, 16-20, 21-26, or ≥ 26), 
number of internist visits in the previous five years (≤ 5, 6-14, or ≥ 15), concurrent use of 
corticosteroids, thiazide diuretics, or atypical antipsychotics. 
† Metformin users served as the reference group. 
Abbreviations: CI, confidence interval. 
 
 
 
 
Table 3-4 Association between diabetes therapy and hypoglycemia using two 
different definitions of impaired renal function 
 eGFR (ml/min/1.73m2) 
Odds Ratio (95% CI) 
Unadjusted Adjusted* 
Insulin 
< 45 11.6 (6.0 - 22.5) 8.9 (4.3 - 17.8) 
< 30 3.4 (1.3 - 9.1) 3.2 (1.1 - 9.5) 
Glyburide 
< 45 7.7 (3.8 - 15.3) 7.5 (3.7 - 15.3) 
< 30 3.8 (1.4 - 10.5) 4.7 (1.5 - 14.1) 
 
* Adjusted for previous hypoglycemic events, Charlson comorbidity index (1, 2, or ≥ 3), recent 
hospitalization, chronic liver disease, alcoholism, coronary artery disease, congestive heart 
failure, number of distinct medications used in the previous year (≤ 5, 6-10, 11-15, 16-20, 21-26, 
or ≥ 26), number of internist visits in the previous five years (≤ 5, 6-14, or ≥ 15), concurrent use 
of corticosteroids, thiazide diuretics, or atypical antipsychotics. 
Note: In all comparisons, metformin users served as the reference groups. Abbreviations: CI, 
confidence interval; eGFR, estimated glomerular filtration rate. 
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3.4 Discussion 
3.4.1 Main Findings 
The risk of hypoglycemia among elderly patients with diabetes is significantly greater for 
those using insulin or glyburide as compared to metformin. We expected to find an 
augmented risk among glyburide users with impaired renal function, but no such 
relationship was observed. Instead, for both glyburide users and insulin users, our data 
showed less risk when the eGFR was below 60 ml/min/1.73m2.  
3.4.2 Interpretation 
It is not surprising that glyburide and insulin conferred higher risks of hypoglycemia than 
metformin. These findings are congruent with those of previous studies.24;39-43 Less 
expected was the lack of interaction found between impaired renal function and glyburide 
use. This contradicts the predictions of existing pharmacokinetic data; however, relying 
on the delayed clearance of glyburide’s weakly active metabolites to explain 
hypoglycemic events in these patients discounts the nuanced relationship between renal 
function and serum glucose concentration. 
The impaired kidney plays a complex and dynamic role in serum glucose control. 
Reductions in drug clearance, gluconeogenesis, and insulin metabolism can predispose 
patients with CKD to hypoglycemia,12 but a number of mitigating factors must also be 
considered. Clinically significant reductions in renal insulin metabolism are uncommon 
until the GFR falls below 20 ml/min/1.73m2.44 CKD is associated with peripheral insulin 
resistance,45-47 even at the earliest stages,48 and derangements in parathyroid hormone 
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concentrations may impair pancreatic insulin secretion.49 Moen and colleagues recently 
described the cumulative effect of these hypo- and hyperglycemic factors, showing that 
CKD is a risk factor for hypoglycemia even among patients without diabetes.12 The 
protective effect of impaired renal function that we observed may be the result of the 
interplay between these hypo- and hyperglycemic features of CKD. Alternatively, there 
may be other, immeasurable factors at play. Our study cannot address the effects of these 
individual mechanisms, nor can we exclude the effects of unknown or unmeasured 
confounders. However, our findings do suggest that renally cleared drugs such as 
glyburide play a role in hypoglycemia among patients with moderate CKD that is less 
significant than previously thought. 
3.4.3 Strengths and Limitations 
Our study has a number of strengths. This is the first study to examine drug-specific risks 
for hypoglycemia in the context of renal function. We assessed renal function directly 
using serum creatinine concentrations. Our results are most applicable to patients over the 
age of 65 years, the largest growing segment of the diabetes population.50 We had 
adequate power to assess this uncommon but serious adverse drug reaction and our 
administrative data were derived from reliable, broadly inclusive datasets.   
Our study’s most important limitation is the non-random allocation of diabetes therapies. 
Physicians chose to prescribe drugs for specific reasons. It is possible that patients who 
were perceived to be at higher risk for hypoglycemia received metformin in lieu of 
glyburide or insulin, or were more closely monitored. Similarly, if physicians were more 
concerned with the risk of lactic acidosis than hypoglycemia, this “confounding by 
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contraindication” may account for the proportionately lower use of metformin we 
observed among patients with impaired renal function (table 3-1). 
The ascertainment of outcome, exposure and covariate data was limited by our reliance 
on health administrative records.  By including only cases of hypoglycemia severe 
enough to prompt admission or emergency room treatment, we optimized the validity of 
our outcome definition but undoubtedly missed mild cases and extremely severe cases 
that resulted in pre-hospital death. In ascertaining drug use, the ODB database is known 
to be accurate but filling a prescription is not equivalent to taking a medication, nor to 
taking it properly. Although we took care to adjust our results for important predictors of 
hypoglycemia, the administrative records do not include data on confounding variables 
such as diet, exercise, innate insulin resistance, or the individual’s targeted and achieved 
level of glucose control.  
A selection bias pertinent to the issue of glycemic control could also have affected our 
findings. It is likely that diabetes was the etiologic factor for many of our patients’ 
impaired renal function; therefore, this group may have had relatively poor glycemic 
control which could be protective against hypoglycemia.   
Our definition of impaired renal function was strong in that it did not rely on 
administrative codes, but we recognize that eGFR is not a static value. It is conceivable 
that some patients with an eGFR less than 60 ml/min/1.73m2 prior to the index date had 
only a transient fall in eGFR, and that factors such as infection could contribute to both a 
reduced eGFR and dysglycemia. However, previous studies in Ontario have shown most 
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initial single low values of eGFR using outpatient serum creatinine results have proven 
persistent with subsequent testing.51 
Finally, we had hoped to compare the hypoglycemic risks of other diabetes therapies but 
found that only metformin, glyburide and insulin were in common enough use for 
meaningful analysis.  
3.5 Conclusions 
In conclusion, our findings do not justify the use of glyburide in patients with impaired 
renal function. Rather, our study supports previous research that has found an increased 
risk of hypoglycemia among patients with CKD. Our findings support a multi-factorial 
model of hypoglycemia in patients with impaired renal function and deemphasize the role 
played by renally cleared diabetes therapies. 
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4 Chapter Four: Discussion 
 
4.1 Drug-induced impairment of renal function: 
hyperkalemia and trimethoprim-sulfamethoxazole. 
The results presented in chapter two highlight the small but significant risk of 
hyperkalemia among elderly patients using trimethoprim-sulfamethoxazole (TMP-SMX). 
This finding is biologically plausible and was dose-dependent. No interaction with 
concomitant beta blocker use was identified, likely due to ß-1-selectivity of modern beta 
blockers; however, our study successfully showed the real-world manifestations of 
trimethoprim-sulfamethoxazole’s inhibition of the ENaC. Our findings were consistent 
with those of Perazella et al and Alappan et al but extend the observations made within 
these highly selected cohorts to a general population of ambulatory, elderly residents of 
Ontario.1,2 In an additional analysis we observed a low rate of serum potassium testing 
among patients using TMP-SMX; changes in this practice may help patients avoid the 
potentially serious ramifications and TMP-SMX-induced hyperkalemia. 
4.2 Drug accumulation in patients with impaired renal 
function: hypoglycemia and glyburide 
Although the results of the study presented in chapter three did not support the widely 
held belief that impaired kidney function augments glyburide’s hypoglycemic risk, it did 
highlight the significant risk of hypoglycemia conferred by both glyburide and insulin 
among the elderly residents of Ontario. Our failure to observe the expected interaction 
between renal function and glyburide use was likely the result of both study and 
biological factors. Although we adjusted for a variety of proven hypoglycemia risk 
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factors, some variables that may have influenced this outcome were not recorded in the 
databases, such as glucose testing frequency, diet, exercise, and intensity of glycemic 
control. Furthermore, the influence of indication bias also may have played a role in the 
lack of interaction we found. Biologic factors are also likely to have contributed to our 
findings. The potency of glyburide’s active metabolites may have been over-estimated 
and the complex and dynamic relationship between renal impairment, insulin metabolism 
and peripheral insulin resistance may have rendered the role of glyburide’s active 
metabolites relatively minor. Despite observing results contrary to our hypothesis, our 
study’s findings are useful in that they support a complex model of drug-induced 
hypoglycemia, which should prompt physicians to consider multiple factors when 
assessing a patient’s risk for hypoglycemia. 
4.3 The role of observational research in shaping clinical 
practice 
The studies presented in chapters two and three were both observational in design. 
Although observational studies have long been employed in epidemiologic research, their 
influence on patient management is often viewed with suspicion. 3,4,5 A significant part of 
this suspicion probably arises from the discordance between the findings of a number of 
prominent randomized control trials and their corresponding observational studies. This 
discordance has been seen with vitamin supplementation for the primary or secondary 
prevention of cardiovascular disease, 6,7,8 suppression of ventricular premature beats after 
myocardial infarction,9 and perhaps most famously, the administration of estrogen for the 
prevention of cardiovascular disease in postmenopausal women.10 In some cases, harm 
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was done based on the findings of observational work and this has understandably 
heightened the suspicion with which some clinicians view observational findings.11,12,13 
Observational studies have a number of challenges that can adversely affect the accuracy 
of their findings. The most important of these is the nonrandom allocation of exposures. 
Non-random exposure allocation introduces a bias in pharmacoepidemiologic studies 
commonly referred to as an “indication bias”.14 The assumption underlying this bias is 
that outside of a randomized trial, patients are exposed to drugs for particular reasons. 
The variables underlying these reasons may predispose patients to the study's outcome of 
interest and in addition, these variables may not be readily measurable. For example, 
glyburide is a potent antidiabetic medication with a well-known reputation for causing 
hypoglycemia. Knowing this, physicians may have prescribed glyburide only to their 
more responsible patients: those who were relatively healthy, who checked their blood 
sugars regularly and who carefully followed dietary recommendations. If this were the 
case, these characteristics may have contributed to the relatively low rates of 
hypoglycemia we observed. If these variables are not measurable, the possibility for 
mathematical adjustment is lost.  
A related challenge encountered with observational research is that of residual 
confounding. Despite attempts to balance the effects of variables through study design or 
analysis, it is not possible to do so completely. Some important variables may not be 
measured accurately, some may not be measured at all, and others may not yet be known. 
As with indication bias, randomization is the solution to this problem. Appropriately 
conducted randomization will result in treatment and control groups that are balanced 
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with respect to both known, and unknown variables; this cannot be achieved in 
observation studies. 
The immunity of a randomized trial to indication bias and residual confounding make it 
the gold standard for establishing causality. However, randomized trials have a number of 
important limitations. In studies where the exposure is thought to be harmful, 
randomizing patients is unethical. Also, the cost of conducting a trial large enough to 
identify rare outcomes such as adverse drug events would likely be prohibitive 
(especially considering the pharmaceutical industry’s lack of interest in adverse drug 
events research). Finally, results arising from the highly regulated environment of a 
clinical trial may not readily generalize to real-world clinical practice. Vulnerable patient 
populations such as the elderly and those with CKD are often excluded,15 16,17 
medications are administered according to strict protocols, and follow-up is assiduous.  
Each of these limitations is pertinent to renal pharmacoepidemiology: exposures are 
harmful, outcomes are rare and generalizability is paramount. So despite the limitations 
of observational research, studies such as the ones presented in chapters two and three 
remain important, although imperfect, tools in the investigation of ADEs.  
4.4 Strengths and limitations of the thesis 
In addition to the strengths and limitations of observation studies in general, our studies’ 
use of Ontario’s health administrative databases introduced another layer of strengths and 
limitations. Administrative data afforded us the statistical power to detect rare outcomes 
such as adverse drug events and it gave us the ability to generalize our findings to broad 
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groups of Ontario residents. The use of administrative data also introduced some 
limitations additional to those already discussed in the individual chapters. 
4.4.1 Ontario’s Health Administrative Databases 
Ontario had a population of approximately 13 million in the year 2008, of which 1.8 
million were older than 65 years. All residents of Ontario receive universal access to 
hospital and physician services, and those over 65 years old receive coverage for 
prescription medications. Coverage for medical services and medications from a single 
provincial payer provides a comprehensive set of health administrative data, proven to be 
effective and reliable in previous pharmacoepidemiologic studies.18,19,20 
The data is housed at the Institute for Clinical Evaluative Sciences (ICES) in Toronto, 
Ontario. ICES retains a number of primary and derived databases; our studies used the 
following resources: 
Ontario Drug Benefits (ODB) Database: The ODB formulary includes a wide range of 
routine outpatient medications. We use this database to determine exposure to oral beta 
blockers and to other drugs that will be used as covariates in our regression models. This 
database is highly reliable with a basic error rate under 1% (~0.7%, 95% CI 0.5% to 
0.9%).21 
Canadian Institute of Health Information (CIHI) Discharge Abstract Database (DAD): 
Demographic, diagnostic and procedural variables for each admission to an acute care 
hospital in Ontario are collected in the CIHI-DAD. Coding of primary and secondary 
diagnoses and inpatient procedures uses the 9th version of the Canadian Modified 
International Classification of Disease system (ICD-9 CA) prior to 2002 and the 10th 
version (ICD-10 CA) for all diagnoses after 2002.  
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Ontario Health Insurance Plan (OHIP) Claims History Database: In all, 95% of 
physicians in Ontario submit billing claims using fee and diagnosis codes outlined in the 
OHIP Schedule of Benefits. These codes capture information on inpatient, outpatient, and 
laboratory services rendered to Ontario residents. In addition, OHIP includes information 
on the nature of the service and diagnostic information. In chart re-abstraction studies, 
agreement between abstracted OHIP fee codes compared to the actual code recorded on 
the chart for the “most responsible” diagnosis was over 90% while percent agreement for 
procedural codes was over 88%.21 
Registered Persons Database (RPDB): The RPDB captures information regarding 
Ontarians’ sex, date of birth, postal code and vital status. Relative to the CIHI-DAD in-
hospital death flag, the RPDB has a sensitivity of 94% and a positive predictive value of 
100%.22 
4.4.2 Strengths of health administrative data 
4.4.2.1 Strengths of Administrative Data in General 
Large sample sizes 
Health administrative databases are typically large and provide a high level of statistical 
power, allowing researchers to examine important but rare outcomes such as adverse 
drug reactions.23  
Long follow-up time 
The maximum duration of follow-up is usually longer with administrative databases 
compared to clinical trails.23 This affords another advantage in detecting adverse drug 
events that may not manifest during a short follow-up time. 
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High generalizability 
Entry into administrative databases typically has few limitations. Drug use and follow-up 
are not dictated by study protocols. As such, the results of studies conducted with 
administrative data do not incur much selection bias and better reflect “real- world” 
clinical practice.24 
Objectivity of data acquisition 
Because administrative data is not collected with a hypothesis in mind, systematic 
misclassification of variables cannot result from the influence of the investigator. In 
addition, the recording of variables is not subject to recall bias and patient non-response 
cannot limit the completeness of the database. 
Practicality of use 
Studies conducted with administrative data can be completed relatively quickly and at 
relatively low cost. This is particularly important for adverse drug events studies because 
it minimizes the time between the first suspicion of an adverse drug event and the 
acquisition of data sufficient to take preventative action. 
4.4.2.2 Strengths of Ontario’s Administrative Data 
Large sample size 
Ontario is Canada’s most populous province with more than 13 million people enrolled in 
the provincial health insurance plan.25  
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High generalizability 
Even within the context of administrative databases, Ontario’s includes very little 
selection bias because health care coverage is universal. Compared to the Veterans 
Administration (VA) database, which predominantly includes older men, Ontario 
provides a more realistic representation of age and sex variables. Compared to the 
databases of large Health Management Organizations (HMO) such as Kaiser Permanente, 
Ontario provides a more representative sample of socio-economic status because 
membership does not have to be purchased. 
Low churn rate 
In administrative data, “churn” refers to the enrolled population’s turnover rate. Ontario’s 
population is relatively stable with an annual emigration rate out of OHIP of 
approximately 1%.26 This compares favorably with HMO churn rates of 20 – 30% per 
year.27 
Extensive inter-database linkage 
In Ontario, there is excellent linkage of data between multiple sectors of health care 
(physician services, hospital records, medications, vital statistics). This allows a wide 
range of variables to be ascertained, which is important for building well-adjusted 
multivariable models. 
Proven validity 
The error rate in the Ontario Drug Benefits (ODB) database is less than 1%,21 20 and 
demographic information is accurately recorded in the RPDB (see table 4-1). The 
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administrative data definitions of many medical conditions and procedures have also 
been evaluated and found to be accurate (see table 4-1). 
4.4.3 Limitations of health administrative data 
4.4.3.1 Limitations of Administrative Data in General 
Incomplete coverage of variables  
In general, administrative data is limited by its primary purpose. Because it is collected to 
guide remuneration and resource allocation, some important variables may not be 
available. For example, dietary information would have been useful in both the 
hyperkalemia and hypoglycemia studies, but with little administrative utility, this 
information was not recorded.  
Incomplete validation of diagnostic codes 
Although some administrative data definitions have been validated, this is not the case for 
the majority. In general, data relating to physician and institutional remuneration is 
considered accurate because of the financial incentives involved and the specific 
mechanisms in place to submit and encode data. On the other hand, diagnoses that must 
be gleaned from the general medical record and converted to ICD-9 or ICD-10 codes are 
considered less reliable. This is particularly so for conditions with slow, insidious 
onsets.28 For example, table 4-1 shows the low sensitivity and high specificity for the 
administrative diagnosis of acute kidney injury. This pattern of operating characteristics 
is also seen with diagnoses such as hyponatremia.29,30 Low sensitivity diagnoses can 
affect studies by reducing cohort sizes and lowering event rates.  
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Table 4-1 Demographic variables and medical conditions for which administrative 
definitions have been validated 
Variable 
Sensitivity, 
% 
Specificity, 
% 
Positive 
Predictive 
Value, % 
Negative 
Predictive 
Value, % 
Reference 
Specific Administrative Database Algorithm  
Ontario 
Sex 98.5 99.5 99.6 97.8 Quinn22 
Death 90.2 97.8 94.4 96.1 Quinn22 
Outpatient 
Dialysis 
100.0  96.0  Quinn22 
Renal 
Transplantation 
81.8 100.0 100.0 99.1 Quinn22 
Coronary 
Artery Disease 
83.0 - 92.0 - Juurlink31 
Myocardial 
Infarction 
89.0 - 87.0 - Juurlink31 
Heart Failure 79.0 - 85.0 - Juurlink31 
Diabetes 
Mellitus Type 
II 
57.0 - 80.0 - Juurlink31 
Ischemic 
Stroke 
81.0 - 87.0 - Juurlink31 
94 
 
Hypertension 73.0 - 87.0 - Tu 32 
AKI 61.6 95.6 17.3 99.4 Hwang33 
Alberta 
Chronic kidney 
disease 
20.5 96.9 57.4 85.5 Ronksley 34 
End-stage renal 
disease 
(dialysis use) 
63.1 - 84.8 - James 35 
Primary 
sclerosising 
cholangitis 
81.9 90.7 41.0 - Molodecky 36 
ICD-9 
Cirrhosis 50.2 - 44.0 - Nehra 37 
Pancreatitis - - 46.0 99.0 Yadav 38 
Venous 
Thrombo-
embolism 
- - 26.0 - Spencer 39 
Epilepsy 98.8 69.6 84.9 97.1 Jetté40 
Ventricular 
arrhythmia 
77.0 94.0 - - McDonald  41 
Atrial 
fibrillation 
79.0 - 89.0 - Jensen 42 
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Myocardial 
infarction 
80.9 87.7 - - Pladevall 43 
Chronic 
obstructive 
pulmonary 
disease 
- - 50.4 - Lacasse 44 
Hepatocellular 
carcinoma 
91.7 98.7 88.0 - Goldberg 45 
End-stage liver 
disease 
- - 85.2 - Goldberg 46 
Ischemic 
Stroke 
- - 96.0 - Roumie 47 
ICD-10 
Epilepsy - - 98.6 94.0 Jetté40 
Pneumonia 89.2 62.0 71.4 84.4 Skull 48 
Hyponatremia 30.0 - 99.0 - Shea 29 
Syncope 62.7 99.9 95.0 99.5 Ruwald 49 
Misclassification of variables 
Misclassification of variables in administrative data is often considered to be non-
differential because the acquisition of administrative data is free of recall bias and is 
independent of the goals of individual research projects. However, there are three 
important features of misclassification to be considered. First, non-differential 
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misclassification biases results towards the null hypothesis, which can lead to type II 
errors in studies that were otherwise adequately designed and well powered. Second, non-
differential misclassification of covariates can lead to sub-optimal control of confounding 
variables. Third, differential misclassification can still occur in administrative data. For 
example, if a specific ADE is well known to a treating physician, then patients using that 
drug may be more likely to undergo specific testing for that reaction; in this way the 
exposure has increased the likelihood of diagnosing the outcome. 
4.4.3.2 Limitations of Ontario’s Administrative Data 
Information gaps: physical exam variables 
The databases of some large Health Management Organizations (HMOs) record physical 
exam characteristics such as height, weight and blood pressure during clinical encounters. 
This information could be useful in some research studies, but it’s not recorded in 
Ontario’s administrative data. 
Information gaps: medication use 
Despite the accuracy of the ODB database, it has three important shortcomings. First, 
with some exceptions, ODB only provides prescription drug coverage for residents over 
the age of 65 years. This is the main limitation to the generalizability of 
pharmacoepidemiologic studies conducted with Ontario’s administrative data. Second, 
although the ODB formulary includes a wide range of medications, its coverage is 
certainly not complete. Furthermore, ODB formulary changes can result in gaps in the 
data available for drugs that drop off the formulary. Third, there are special settings and 
patient populations in which drug coverage is not provided by ODB. Medications 
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administered to hospital inpatients are paid for by the hospital’s universal budget and are 
not recorded in the ODB database. Patients receiving chronic peritoneal dialysis or 
hemodialysis have dialysis-related medications such as vitamins, phosphate binders, 
activated vitamin D analogues and erythropoiesis-stimulating agents paid for by the 
Ontario Renal Network. Data for drugs administered in these settings, or to these patients 
is not available. 
Information gaps: physician services 
Although 95% of Ontario’s physicians submit claims to the Provincial health insurance 
provider (OHIP), the remainder are remunerated through an alternative-funding plan. For 
the patients cared for by these physicians, administrative diagnoses that depend on OHIP 
claims data cannot be made. 
4.5 Future Directions 
The critical role played by the kidneys in the development of adverse drug events makes 
this area fertile ground for administrative database research. In the upcoming years I will 
execute projects in three broad categories of renal adverse drug events: ADEs that result 
in acute kidney injury (AKI), ADEs associated with decreased drug clearance in patients 
with CKD, and ADEs associated with altered drug clearance in patients on hemodialysis. 
 
ADEs and AKI 
There are a number of potential ADEs supported by biologic mechanisms or case-report 
data. These ADEs require more thorough investigation to determine their validity, scope 
and impact. Examples of subjects in this area include the potential association between 
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cholesterol-lowering fibric acid derivatives and acute kidney injury, the weight-loss drug 
orlistat and acute kidney injury, and the anti-retroviral tenofovir and acute kidney injury.  
ADEs and CKD 
The clearance of many drugs and their metabolites relies heavily on renal function. When 
renal function is impaired, many drugs need to be prescribed at lower doses to 
compensate for the slower rate of clearance. Although information on “renal-adjusted” 
drug dosing is readily available, I suspect that many patients with CKD inappropriately 
receive full strength doses. I will examine this problem and its ramifications among 
patients with CKD by investigating three drugs and their full-dose ADEs. Potential 
subject areas include the associations between H2-receptor blockers and delirium, 
gabapentin and falls (as measured by traumatic orthopedic injuries), and quinine and 
cardiac arrhythmias. 
ADEs and Hemodialysis 
The efficiency with which hemodialysis removes drugs from a patient’s circulation varies 
according to the drug’s degree of protein binding, its volume of distribution and its 
lipophilicity. In some cases, these characteristics vary between drugs within the same 
therapeutic class. This sets the stage for studies designed to determine the effect of a 
drug’s dialyzability on its effectiveness in patients receiving chronic hemodialysis. For 
example, beta blockers are a class of medications known to decrease the risk of further 
heart damage among patients who have already had a heart attack or experienced heart 
failure. However, some beta blockers are readily removed from the circulation by 
hemodialysis while others are not. I plan to define a cohort of patients on chronic 
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hemodialysis who are receiving a beta blocker for the secondary prevention of 
cardiovascular disease. These patients will be divided into an exposed group (those 
taking a poorly dialyzed beta blocker) and an unexposed group (those taking a highly 
dialyzed beta blocker). The risk of subsequent cardiovascular disease will be compared 
between the two groups. Similar studies may also be conducted with angiotensin-
converting enzyme inhibitors and HMG-CoA reductase inhibitors.  
4.6 Conclusion 
Cognizance of kidney-related ADEs is an important part of safe prescribing practice. 
Medications may affect the function of normal kidneys, as in the case of trimethoprim-
sulfamethoxazole, or they may interact in complex ways with impaired renal function, as 
is the case with glyburide. Kidney-related ADEs provide a number of research avenues 
related to acute kidney injury, drug metabolism and clearance, and the effects of 
hemodialysis. 
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Short Description of 
Research Question 
Examine whether exposure to TMP-SMX leads to higher risk of hyperkalemia in a 
group of individuals taking other drugs (NSAIDS, Beta-blockers, K sparing diuretics, 
K supplements). The drug to be examined first is beta-blockers, and is presented in 
detail below. A near identical approach will be used for other drugs. ACE / ARBs 
were examined in a previous project.  
Physiologic Rationale 
Trimethoprim inhibits K+ secretion by the principle cells of the late distal tubule and 
cortical collecting duct. The mechanism of inhibition is similar to that of amiloride and 
triamterene (i.e. inhibition of the sodium channel in the apical membrane of the cell).  
 
Minute-to-minute levels of plasma potassium are controlled by intracellular 
to extracellular exchange by the sodium-potassium pump controlled by insulin and beta2 
receptors. (Beta receptors are linked to calcium-gated potassium channels, and their 
activation allows potassium to enter the cell directly. Beta2 agonists decrease potassium 
levels. A beta blocker decreases sodium-potassium adenosine triphosphatase (ATPase) 
activity and increases potassium levels. Non-selective beta blockade is known to cause 
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elevated potassium levels via this mechanism. Though treatment with beta blockers rarely 
causes hyperkalemia by itself, it contributes to the elevation in plasma potassium levels seen 
with other conditions or medications (such as TMP-SMX). 
 
Beta-blockers, especially blockade of the beta-1 receptor at the macula densa also inhibits 
renin release, thus decreasing the release of aldosterone, causing hyperkalemia. 
 
 
From Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med. 
2000 Sep;109(4):307-14. Review.  (about 10 references for statements below provided in this 
paper) 
 
Beta blockers. Acute disposal of a potassium load is handled primarily by the cellular uptake of 
this cation, which can be impaired by some medications. Nonselective beta blockers have 
been associated with the development of hyperkalemia, which may rarely be severe.  
Hyperkalemia develops by means of two different mechanisms. First, beta blockers suppress 
catecholamine-stimulated renin release, thereby decreasing aldosterone synthesis. Second, 
and more importantly, nonselective beta blockers decrease cellular uptake of potassium. 
Normally, agonist binding to the beta
2
-adrenergic receptor stimulates the formation of cyclic 
AMP, which acts through protein kinase A to phosphorylate and activate the Na-K-ATPase 
pump, leading to the influx of potassium into cells. Competitive inhibition of the beta
2 
receptor 
by beta blockers decreases Na-K-ATPase function and reduces potassium uptake by cells. 
For example, three renal transplant recipients developed hyperkalemia (6.0 to 8.3 mEq/liter). 
This occurred within hours of treatment with intravenous labetalol, suggesting that impaired 
cellular uptake of potassium, rather than decreased aldosterone synthesis, was responsible. 
Nonselective beta blockers have caused or contributed to hyperkalemia in 4% to 17% of 
hospitalized patients studied (5 references for this last sentence). 
List of Datasets Used 
• ODB 
• NACRS 
• RPDB 
• DAD  
• OHIP 
• Gamma-Dynacare Main List Jan 2002 - Mar 2009 (serum creatinine data 
from Southwestern Ontario) [Data sharing agreement made October 25th, 
2004. The agreement was reviewed again as part of the development of this 
DCP.  To confirm, under this agreement we are able to use this dataset to 
‘assess the appropriateness of drug use and dosing in patients’]  
a) Design: Case Control design within a Nested Cohort 
 
Considerations: The ‘cohort nest’ in this study is comprised of patients who had a prescription filled for beta-
blockers. We appreciate that within the nested case-control design that we are considering only the risk of 
hyperkalemia with TMP-SMX compared to other antibiotics (in patients taking beta-blockers). We are not 
considering other risks / adverse events (that may be higher with other antibiotics). We are not considering 
the benefits TMP-SMX compared to other antibiotics (i.e. perhaps TMP-SMX reduces the risk of urosepsis, 
compared to nitrofurantoin, or the required duration of therapy is shorter with TMP-SMX). With this type of 
design, it is possible to obtain indirect estimates of absolute risk / incidence, although the main output is an 
odd’s ratio of TMP-SMX compared to other antibiotics (relative terms)). If TMP-SMX is found to be associated 
with hyperkalemia, we will be able to perform an additional test interaction between beta-blockers and TMP-
SMX using 2 nested cohorts – those with and without beta-blocker use (Altman D, Bland JM, Interaction 
revisited: the difference between two estimates. BMJ 2003). 
 
b) Defining the Nest Cohort 
Nest cohort Describe Nest: 
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• Elderly Ontarians continuously taking beta-blockers (patients are allowed to switch 
between beta-blockers) and also taking an antibiotic in the 14 days prior to index 
date  
• in a secondary analysis, 7 and 21 days are used instead of 14 days 
• In one of the tertiary analyses, there will be a nest of no evidence of beta-
blocker use, in order to examine for an interaction effect of beta-blockers with 
TMP-SMX. In this case the nest will simply be taking an antibiotic in the 14 days 
prior to index date. 
• Continuous use defined as: 
o Any prescription within 100 day windows starting on date of first 
prescription for the drug 
o Next 100 day window defined as last prescription date + 100 days 
o If no prescription within next 100 day window, end follow-up (follow-up 
date defined as 100 days following date of last script) 
o Determine if new or chronic use (parameter &dl_lookback): 
   New use: # days to look back to define new use: ____________ 
   Chronic use (look back = 0) 
 
Codes: 
• Drug Claims: – See attached Excel spreadsheet 
Exclusions 
(In order) 
• Invalid IKN 
• Missing age or sex 
• Age < 66 at time of cohort entry (parameter &age_restrict) 
• Death on same date as start of beta-blocker 
• In 30 days prior to index date: 
o Prescription for another antibiotic (other than study antibiotics)  
o Prescribed multiple study antibiotics  
• In 3 years prior to index data: 
o Evidence of kidney failure receiving dialysis (see Appendix)  
 
• In one of the tertiary analyses (described below), use the following exclusion. This 
will enable an assessment of the interaction effect of beta-blockers, using the 
technique described by Bland and Altman:   
o Any prescription for a beta-blocker in 120 days preceding index date 
c) Time Frame Definitions 
 
 
 
 
 
 
Accrual Start/End Dates Beginning of Accrual Period for nest (parameter = &start_date): July 1, 1994 
End of Accrual Period for nest (parameter = &end_accrual): March 31, 2008 
Max Follow-up Date End of follow-up Period (parameter &end_fup) : March 31, 2008 
Cohort entry Date at which entry into the nest begins (parameter = &reference_date): 
Observation Window 
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• First ODB Claim for beta-blocker after 66th birthday 
When does observation 
window terminate? 
From date of cohort entry to first of: 
• Hospital admission for hyperkalemia  
[If necessary, two tertiary analyses with other definitions of hyperkalemia 
will be considered (as defined in tertiary analysis section)] 
• Death 
• End of follow-up (March 31 2008) 
• Beta-blocker discontinuation (date assigned as 120 days after last 
prescription for beta-blocker) 
d) Variable Definitions 
Cases Individuals from the nest cohort who are admitted to hospital for hyperkalemia using the 
codes below: 
• Diagnosis and/or procedure codes for outcome condition.   
 
CIHI datasets parameters defined by: 
o ICD9 diagnosis codes: 276.7 
o ICD10 diagnosis codes: E87.5 
o CIHI-DAD Diagnosis Type: admitdx 
o CIHI-DAD source: 
   Inpatient 
   Same-day-surgery 
   All 
• Cases have taken a study antibiotic in the 14 days prior to index date (for 
secondary analysis, cases have taken an antibiotic of interest in the 7 or 21 days 
prior to index date) 
• Cases have not taken multiple study antibiotics in the 30 days prior to index date 
• Cases have not had a prescription for another non-study antibiotic in the 30 days 
prior to index date 
• In a tertiary analysis definition of hyperkalemia is expanded to include a hospital 
admission for hyperkalemia or first use of K binding resin (see tertiary analysis 
section) 
Eligible Controls Individuals from the nest cohort who are event free at index date 
• Case to Control Ratio:  Match 4 controls to each case 
• Matching criteria: 
  Age at index date (+/- 1 year) 
  Sex 
  Presence of Chronic Kidney Disease in 3 years prior to index date (as 
defined in the Appendix)  
[in a tertiary analysis restrict sample to those individuals with at least one 
serum creatinine value preceding index date who are in Gamma-
Dynacare Main List Jan 2002 - Mar 2009, matched on most recent eGFR 
value proceeding index date +/- 20 mL/min per 1.73 m2, instead of 
matching based on presence of chronic kidney disease as defined above 
using administrative database codes] 
  Diabetics (use of an oral hypoglycemic OR insulin OR diabetic test 
strips in 3 years prior to index date – see attached spreadsheet for list of 
diabetic medications)  
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• Controls have taken a study antibiotic in the 14 days prior to index date  
[in a secondary analysis, controls have taken an antibiotic of interest in the 7 or 21 
days prior to index date] 
• Controls have not taken multiple study antibiotics in the 30 days prior to index 
date 
• Cases have not had a prescription for another non-study antibiotic in the 30 days 
prior to index dates 
• When full number of matched controls cannot be obtained, the matching process 
is maintained, and any available controls are analyzed. 
• Cases without at least 1 matched control are excluded 
Index date Case: Date of the first hospitalization for hyperkalemia occurring after cohort entry [If 
necessary, a tertiary analysis will use an expanded definition of hyperkalemia (see tertiary 
analysis section)] 
Control: The same date as the index date for matched cases 
Main Exposure 
or Risk Factor 
Primary Analysis:  Users of antibiotic drug in the 14 days prior to index date: 
• Ciprofloxacin  
• Norfloxacin 
• Nitrofurantoin 
• Amoxicillin (referent group) 
• TMP-SMX 
 
See attached Excel spreadsheet for drug lists for exposure variables  
 
Secondary Analysis:  
1. Change lookback to 7 days prior to index date 
2. Change lookback to 21 days prior to index date 
 
Tertiary Analysis: 
1. Split TMP-SMX into two different types (low dose and high dose) and rerun 
analyses (see Excel spreadsheet for labels) 
2. Repeat the primary analysis restricting nested cohort to non-cardioselective beta-
blockers (where we expect risk of hyperkalemia to be greater; see attached Excel 
spreadsheet, label ‘BBL_NC’). 
3. Repeat the primary analysis restricting the nested cohort to cardioselective beta-
blockers (see attached Excel spreadsheet, label ‘BBL_CARD’) 
4. Repeat the primary analysis with a nested cohort where do not need to have beta-
blocker use to be in the nest, and there is no evidence of beta-blocker use in 120 
days preceding index date (i.e. see sections ‘nest cohort’ and ‘exclusions’ for 
description) (sensitivity analysis). Do not expect there to be a major increase in 
hyperkalemia with TMP-SMX use across all clinical situations [if see the 
magnitude of association is similar to beta-blocker analysis, than have to question 
whether it is the beta-blocker TMP-SMX combination per se, or whether the 
increase in hyperkalemia is all due to TMP-SMX alone; if see no association with 
hyperkalemia when conduct this analysis, then this really will strengthen the 
assertion that effect is due to TMP-SMX beta-blocker combination].  
5. Repeat the primary analysis, applying the following additional inclusion and 
matching criteria: additional inclusion criteria: at least one serum creatinine value 
in Gamma-Dynacare dataset preceding index date; AND matching criteria: use 
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the most recent eGFR value prior to index date to match cases and controls [+/- 
20 mL/min per 1.73 m2] 
If necessary (decide on running these remaining two tertiary analyses only after 
reviewing previous analyses):  
6. Repeat the primary analysis using a broader definition of hyperkalemia – 
‘hyperkalemia hospital admission as defined above, or first claim for a K+binding 
resins here [from Brogan’s drug list; subclnam=”POTASSIUM-REMOVING 
RESINS” This will increase number of events, increase statistical power  
7. Repeat the primary analysis using a broader definition of hyperkalemia – 
‘hyperkalemia hospital admission as defined above, or ED visit for hyperkalemia. 
As NACRS is only available as of the year 2000, restrict the accrual start date to 
January 1st, 2000.   
NACRS dataset parameters defined by: 
o ICD9 diagnosis codes: 276.7 
o ICD10 diagnosis codes: E87.5 
o CIHI-DAD Diagnosis Type: Main Diagnosis 
 Methodological Issues: TMP-SMX is frequently used for UTIs, but 
can also be used for other infections [ear, skin, sinuses, 
gastroenteritis (traveler’s diarrhea, shigellosis), pneumonia 
(Pneumocystis carinii)]. The comparator drugs may be used for UTI 
and also other types of infections. Although UTI is not associated 
with hyperkalemia per se, could someone argue the indication for 
the antibiotic used, and not the antibiotic per se, is reason for 
any observed association with hyperkalemia.   
 
Nicolle L, et al. Uncomplicated urinary tract infection in women. 
Current practice and the effect of antibiotic resistance on 
empiric treatment. Can Fam Physician. 2006 May;52:612-8. Review. 
Prescribing behaviour suggests that, over the past decade, primary 
care physicians have altered their approach to first-line therapy 
for uUTI: TMP/SMX prescriptions for uUTI have declined, while 
fluoroquinolone prescriptions have increased. Current options for 
first-line antimicrobial treatment of uncomplicated urinary tract 
infection include TMP/SMX, fluoroquinolone, and nitrofurantoin. 
Ampicillin or amoxicillin were once standard therapy for uUTI, but 
the resistance of E coli to ampicillin now approaches 50% in most 
regions of North America. 
 
At least 8 sets of uUTI treatment guidelines have been available 
in Canada for the last 5 years (summarized in Nicole paper above). 
Despite a consistent spectrum of causative organisms and treatment 
objectives, antimicrobial regimens for uUTI, including drug 
selection and duration of therapy, vary widely. Various guidelines 
make conflicting recommendations on alternatives to TMP/SMX. 
 
We are only considering 2 fluoroquinolones (ciprofloxacin and 
norfloxacin which are used in UTI treatment; we are not 
considering ofloxacin or levofloxacin (used for many indications 
besides UTI), or gatifloxacin (now off the market)).  
 
Clinically, for UTI in a woman, TMP / SMX effective in a 3 day 
course, fluroquinolones effective in a 3 day course, and 
nitrofurantoin as a 7 day course 
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Besides TMP SMX, amoxicillin and ciprofloxacin were the 
antibiotics with the largest number of prescriptions in the 
similar ACE / ARB analysis.  
Baseline 
Characteristics 
 
(see Table 1 for 
format for these 
variables, 
including the renal 
function variables) 
 
At index date: 
• Age (as median and in age categories, 65-74, 75-84, 85+, see Table 1a for 
format) 
• Sex  
• Year of index date (see Table 1a for format)  
• Socioeconomic status (income quintiles: Income based socio-economic status 
(calculated by FSA)) at time of index date (reported as income quintile 1 to 5). If 
missing, impute value of ‘3’ 
• Number of years using beta-blockers (median) (between cohort entry and index 
date) 
 
In 3 years prior to index date 
• Charlson score (based on 3 years of hospitalization data prior to index date, 
reported as 0, 1, 2+) 
• Congestive heart failure (see appendix for codes – DXTYPE: ALL) 
• Coronary artery disease including angina (see appendix for codes DXTYPE: ALL) 
• Diabetes mellitus (use of an oral hypoglycemic, insulin or diabetic test strips in 3 
years prior to index date – see attached spreadsheet for list of diabetic 
medications) 
• At least one hospitalization for hyperkalemia (DXTYPE: ALL) 
• Hyperkalemia:  
o At least one hospitalization for hyperkalemia (DXTYPE: ALL) or  
o Evidence of use of subclnam=”POTASSIUM-REMOVING RESINS” in 
1 year prior to index date 
• Chronic kidney disease (see appendix for algorithm) 
• Evidence of diagnosis related to the genitourinary system: 
o OHIP Dx category 10 or  
o hospital admission for Dx genitourinary system (DXTYPE: ALL, ICD-9 
580 – 625.9, ICD-10 N00-N99) or  
o hospital admission for Dx benign or malignant cancer of the prostate 
(DXTYPE: ALL, ICD-9 18.5, 222.2, 233.4, 236.5; ICD-10 C61, D075, 
D291, D400) 
• Evidence of diagnosis related to cystitis: 
o OHIP Dx 595 or 
o hospital admission for cystitis (DXTYPE: ALL, ICD-9 595.x, ICD-10 
N30)  
 
In 6 weeks prior to index date 
• Evidence of diagnosis related to the genitourinary system in 6 weeks preceding 
index date. (Recognize these codes have not been validated): 
o OHIP Dx category 10 or 
o hospital admission for Dx genitourinary system, (DXTYPE: ALL, ICD-9 
580 – 625.9, ICD-10 N00-N99) or  
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o hospital admission for Dx benign or malignant cancer of the prostate 
(DXTYPE: ALL, ICD-9 18.5, 222.2, 233.4, 236.5; ICD-10 C61, D075, 
D291, D400)  
• Evidence of at least one OHIP Dx coded related to cystitis in the 6 weeks 
preceding index date. (Recognize this code has not been validated): 
o OHIP Dx code 595 or  
o hospital admission for cystitis (DXTYPE: ALL, ICD-9 595.x, ICD-10 N30)  
 
In 1 year prior to index date 
• Number of distinct drugs used, median (IQR) 
• Number of distinct drugs used, category ≤ 2, 3, 4, 5, ≥ 6 (see Table 1a) 
 
Renal function tests available in Gamma-Dynacare dataset (expect large number 
of individuals will have these values missing) 
o Most recent serum creatinine prior to index date  
o Most recent estimated glomerular filtration rate (eGFR) prior to index date 
o Most recent estimated glomerular filtration rate category prior to index 
date (see Table) 
 
Use of drugs in the 120 days prior to index date 
• Non-potassium sparing diuretics 
• Potassium sparing diuretics 
• Potassium supplements 
• NSAIDs 
• ACE or ARB 
 
Outpatient Potassium Measurement 
• Report these results in Table 1a, Table 1b and Table 1c 
• Number of days between antibiotic prescription and index date, median (IQR) 
• At least one potassium measurement day after antibiotic prescription to day prior 
to index date (hospital admission for cases) 
• OHIP fee code L204 
• Do not count measurement done on the date of prescription 
• Do not count measurement done on the date of index date (hospital 
admission for cases) 
• At least one potassium measurement on index date (date of hospital admission for 
cases) 
• OHIP fee code L204 
 
Matching results (restricted to cases only) 
• proportion of cases with matching controls, categories: 4 matching controls, 3 
matching controls, 2 matching controls, 1 matching control, zero matching 
controls 
• reported as N (%) per category 
• we expect no zero matching controls 
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• Report results in Table 1a only 
 
See attached Drug Lists for dins of drugs listed above 
Characteristics  
of Hyperkalemic 
Events 
A sample output is presented in table 4. Present results by each type of antibiotic, and 
then all cases together.  
Variables: 
• Length of hospital admission, days  
o restrict to those who had hospital admission 
o reported as median (IQR) 
• Event resulted in death 
o Death in hospital or in the emergency department. Use CIHI, NACRS and 
enhanced RPDB. 
o reported as N (%)  
• Event required admission to Intensive Care Unit 
o Defined as any one of the OHIP codes listed in Appendix A. 
o reported as N (%) 
Absolute 
Incidence 
of Events 
 Nest 
• Elderly Ontarians continuously taking beta-blockers (patients are allowed to switch 
between beta-blockers)  
• Continuous use defined as: 
o Any prescription within 100 day windows starting on date of first 
prescription for the drug 
o Next 100 day window defined as last prescription date + 100 days 
o If no prescription within next 100 day window, end follow-up (follow-up 
date defined as 100 days following date of last script) 
o Determine if new or chronic use (parameter &dl_lookback): 
• Exclude patients 
• Invalid IKN 
• Missing age or sex 
• Age < 66 at time of cohort entry (parameter &age_restrict) 
• Death on same date as start of beta-blocker 
• Sample output present in Table 5. 
• Number of patients who had at least 1 TMP-SMX prescription during the 
time of continuous beta-blocker use 
• Number of patients who died within 21 days after date of first prescription 
for TMP-SMX during the time of continuous beta-blocker use 
• Number of patients who had a hospital admission for hyperkalemia (as 
defined above) within 21 days after date of first prescription for TMP-SMX 
during the time of continuous beta-blocker use 
• Number of patients who had at least 1 Amoxicillin prescription during the 
time of continuous beta-blocker use 
• Number of patients who died within 21 days after date of first prescription 
for Amoxicillin during the time of continuous beta-blocker use 
• Number of patients who had a hospital admission for hyperkalemia (as 
defined above) within 21 days after date of first prescription for Amoxicillin 
during the time of continuous beta-blocker use 
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Recognize unlike main analysis there may be co-administration of antibiotics in this 
analysis.  
e) Analysis Plan 
f) Descriptive Analysis: 
• Table 1a of N(%) or median (IQR) for study variables by cases and respective matched-controls (see 
Table below for sample output) 
• Table 1b of N(%) or median (IQR) for study variables by exposure and cases and respective 
matched-controls (see Table below for sample output) 
• Table 1c of N(%) or median (IQR) for study variables by exposure only (see Table below for sample 
output) 
g)  
h) Conditional Logistic Regression Analysis (Table 2 and 3): 
• Unadjusted model with only exposure variables included 
• Adjusted model with all exposure and covariates of interest included.   
Model adjusted for: 
o Charlson Score (0 referent, 1, 2+) 
o Income Quintile (1 - 2 vs. 3 – 5 (referent)) 
o Congestive heart failure in past 3 years (see appendix for codes) (0 no referent, 1) 
o Coronary artery disease in past 3 years (see appendix for codes) (0 no referent, 1) 
o Number of distinct drugs used in past 1 year  (<=5 (referent), 6 to 10, 11 to 15, 16 to 20, 21 
to 25, 26+ 
o At least one hospitalization for hyperkalemia in past 3 years or claim for potassium binding 
resin in past 1 year 
o Medication use in preceding 120 days (prior to index date):  
o Non-potassium sparing diuretics,  
o Potassium sparing diuretics,  
o Potassium supplements,  
o NSAIDs,  
o ACE or ARB 
 
(Do NOT adjust for the factors used in matching, as they are accounted for by the design: index 
date, age, sex, presence of chronic kidney disease in 3 years prior to index date, diabetes)  
i)  
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Tables: 
 
Table 1a: Baseline characteristics for Cases and Matched Controls for Primary 
Analysis 
Variable Control Case 
Standardized 
Difference 
  N= N=   
Age (Median (IQR)) Median (IQR) Median (IQR)  
65-74    
75-84    
85+    
Female N (%) N(%)  
Year of Index date *    
       1994 – 1995 N (%) N(%)  
       1996 – 1997 N (%) N(%)  
       1998 – 1999 N (%) N(%)  
       2000 – 2001 N (%) N(%)  
       2002 – 2003 N (%) N(%)  
       2004 – 2005 N (%) N(%)  
       2006 – 2007 N (%) N(%)  
       2008 N (%) N(%)  
Income Quintile     
1 to 2 N (%) N(%)  
3 to 5 N (%) N(%)  
Years using beta-blockers Median(IQR) Median (IQR)  
Charlson Score    
0 N (%) N(%)  
1 N (%) N(%)  
2+ N (%) N(%)  
Congestive heart failure in past 3 
years N (%) N(%)  
Coronary artery disease / angina in 
past 3 years N (%) N(%)  
Diabetes in past 3 years N (%) N(%)  
At least one hospitalization for 
hyperkalemia in past 3 years N (%) N(%)  
At least one hospitalization for 
hyperkalemia in past 3 years or 
claim for potassium removing resin 
in past 1 year N (%) N(%)  
Chronic kidney disease in past 3 
years N (%) N(%)  
Dx of disorder of genitourinary 
system in past 3 years N (%) N(%)  
Dx of cystitis in the past 3 years N (%) N(%)  
Dx of disorder of genitourinary 
system in past 6 weeks N (%) N(%)  
Dx of cystitis in the past 6 weeks N (%) N(%)  
No. of distinct prescription drugs in 
previous year Median (IQR) Median (IQR)  
117 
 
No. of distinct prescription drugs in 
previous year    
   ≤ 5    
   6 to 10    
  11 to 15    
  16 to 20    
  21 to 25    
  26+    
Most recent serum creatinine, 
umol/L ** Median (IQR) Median (IQR)  
Most recent eGFR mL/min/1.73 m2 
** Median (IQR) Median (IQR)  
Most recent eGFR category    
   = > 60 mL/min/1.73 m2 N (%) N(%)  
   30 to 50 mL/min/1.73 m2 N (%) N(%)  
   < 30 mL/min/1.73m2 N (%) N(%)  
    Missing ** N N  
Medication use in preceding 120 
days N (%) N(%)  
Non-potassium sparing 
diuretics N (%) N(%)  
Potassium sparing diuretics N (%) N(%)  
Potassium supplements N (%) N(%)  
NSAIDs N (%) N(%)  
ACE / ARB N (%) N(%)  
Number of days between antibiotic 
prescription and index date Median (IQR) Median (IQR)  
At least one potassium 
measurement day after antibiotic 
prescription to day prior to index 
date (hospital admission for cases) N (%) N(%)  
At least one potassium 
measurement on index date 
(hospital admission for cases) N (%) N(%)  
Matching results (number of controls matched per case)  
      4  N(%)  
      3  N(%)  
      2  N(%)  
      1  N(%)  
      0  ***  
* may only be looked at for internal purposes to look at distribution, not reported in final manuscript 
** expect a large number of individuals will have missing values 
*** given exclusion criteria, there should be no matching results of 0 
 
Table 1b: Baseline characteristics for Cases and Matched Controls for Primary Analysis by 
Antibiotic type 
 Controls Cases 
 Cipr
o 
N = 
Norfl
x 
N = 
Nitr
o 
N = 
Amo
x 
N = 
TM
P 
SM
Cipr
o 
N = 
Norfl
x 
N = 
Nitr
o 
N = 
Amo
x 
N = 
TM
P 
SM
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X 
N = 
X 
N = 
Age 
(Media
n 
(IQR))   
        
65-74           
75-84           
85+           
…           
… identical variables as that presented in Table 1a.  
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Table 1c: Baseline characteristics for Primary Analysis by Antibiotic Type  
(Cases and Controls together) 
 Cipro 
N = 
Norflx 
N = 
Nitro 
N = 
Amox 
N = 
TMP 
SMX 
N = 
Age (Median 
(IQR))   
   
65-74      
75-84      
85+      
…      
… identical variables as that presented in Table 1a.  
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Table 2: Conditional Logistic Regression Results for Primary Outcome (OR and 95% CI) 
Exposure Unadjusted Adjusted 
  OR SE LCL UCL OR SE LCL UCL 
Primary Analysis: Previous 14 days (Beta-blocker nest) 
Ciprofloxacin (reference) 1 -- -- -- 1  -- -- -- 
Norfloxacin                 
Nitrofurantoin                 
Amoxicillin                 
TMP-SMX                 
Secondary Analysis: Previous 7 days 
Ciprofloxacin (reference) 1 -- -- -- 1  -- -- -- 
Norfloxacin                 
Nitrofurantoin                 
Amoxicillin                 
TMP-SMX                 
Secondary Analysis: Previous 21 days 
Ciprofloxacin (reference) 1 -- -- -- 1  -- -- -- 
Norfloxacin                 
Nitrofurantoin                 
Amoxicillin                 
TMP-SMX                 
Tertiary Analysis: Previous 14 days 
Ciprofloxacin (reference) 1 -- -- -- 1  -- -- -- 
Norfloxacin                 
Nitrofurantoin                 
Amoxicillin                 
TMP-SMX type 1 
(800/160)                 
TMP-SMX Type 2 
(400/80)                 
Tertiary Analysis, Nest: Non-cardioselective beta-blockers * 
Ciprofloxacin (reference) 1 -- -- -- 1  -- -- -- 
Norfloxacin                 
Nitrofurantoin                 
Amoxicillin                 
TMP-SMX                 
Tertiary Analysis, Nest: Cardioselective beta-blockers * 
Ciprofloxacin (reference) 1 -- -- -- 1  -- -- -- 
Norfloxacin                 
Nitrofurantoin                 
Amoxicillin                 
TMP-SMX                 
Tertiary Analysis, No Nest * 
Ciprofloxacin (reference) 1 -- -- -- 1  -- -- -- 
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Norfloxacin                 
Nitrofurantoin                 
Amoxicillin                 
TMP-SMX                 
Tertiary Analysis, Gamma-Dynacare Inclusion and Matching * 
Ciprofloxacin (reference) 1 -- -- -- 1  -- -- -- 
Norfloxacin                 
Nitrofurantoin                 
Amoxicillin                 
TMP-SMX                 
Tertiary Analysis, Broader Definition of Hyperkalemia * 
Ciprofloxacin (reference) 1 -- -- -- 1  -- -- -- 
Norfloxacin                 
Nitrofurantoin                 
Amoxicillin                 
TMP-SMX                 
Tertiary Analysis, Definition of Hyperkalemia which includes ED visits* 
Ciprofloxacin (reference) 1 -- -- -- 1  -- -- -- 
Norfloxacin                 
Nitrofurantoin                 
Amoxicillin                 
TMP-SMX                 
 
* otherwise identical to primary analysis 
* in addition to reporting OR, LCL, UCL for unadjusted and adjusted, also report the standard 
error for unadjusted and adjusted estimates (each in a separate column) [update table above 
accordingly]. Report all values to at least 4 decimal points. Will be using the method described by 
Altman and Bland to compare the odd’s ratio for no nest (no beta-blocker) to primary analysis 
with beta-blocker nest.  
 
Interaction revisited: The difference between two estimates 
Douglas G Altman; J Martin Bland British Medical Journal; Jan 25, 2003; 326, 7382; 
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Table 3: Conditional Logistic Regression Results for Primary Outcome (OR and 95% CI) 
Primary Analysis (Previous 14 days, beta-blocker nest) 
Results of full model 
Exposure Unadjusted Adjusted 
  OR SE LCL UCL OR SE LCL UCL 
Antibiotic used 
Ciprofloxacin (reference) 1 -- -- -- 1  -- -- -- 
Norfloxacin                 
Nitrofurantoin                 
Amoxicillin                 
TMP-SMX                 
Charlson Score 
0 (reference) 1 -- -- -- 1  -- -- -- 
1                 
2+                 
Income Quintile 
1 (reference) 1 -- -- -- 1  -- -- -- 
2                 
3                 
4         
5                 
Congestive Heart Failure 
no (reference) 1 -- -- -- 1  -- -- -- 
Yes                 
Coronary artery disease / angina 
no (reference) 1 -- -- -- 1  -- -- -- 
Yes                 
Number of distinct drugs in past year 
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      ≤ 2 (reference) 1 -- -- -- 1  -- -- -- 
      3                 
      4                 
      5         
      ≥ 6                 
At least one hospitalization for hyperkalemia in past 3 years or claim for potassium binding resin 
in past year 
no (reference) 1 -- -- -- 1  -- -- -- 
yes                 
Non-potassium sparring diuretic use in preceding 120 days 
no (reference) 1 -- -- -- 1  -- -- -- 
yes                 
Potassium sparring diuretic use in preceding 120 days 
no (reference) 1 -- -- -- 1  -- -- -- 
yes                 
Potassium supplement use in preceding 120 days 
no (reference) 1 -- -- -- 1  -- -- -- 
yes                 
NSAID use in preceding 120 days 
no (reference) 1 -- -- -- 1  -- -- -- 
yes                 
ACE or ARB use in preceding 120 days 
no (reference) 1 -- -- -- 1  -- -- -- 
yes                 
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Table 4  Characteristics of Hyperkalemic Events 
 
 
Table 5  Absolute Incidence of Events 
 
 Number 
TMP-SMX 
Number of patients who had at least 1 TMP-SMX prescription during the 
time of continuous beta-blocker use 
 
Number of patients who died within 21 days after date of first 
prescription for TMP-SMX during the time of continuous beta-blocker 
use 
 
Number of patients who had a hospital admission for hyperkalemia 
within 21 days after date of first prescription for TMP-SMX during the 
time of continuous beta-blocker use 
 
Amoxicillin 
Number of patients who had at least 1 Amoxicillin prescription during the 
time of continuous beta-blocker use 
 
Number of patients who died within 21 days after date of first 
prescription for Amoxicillin during the time of continuous beta-blocker 
use 
 
Number of patients who had a hospital admission for hyperkalemia 
within 21 days after date of first prescription for Amoxicillin during the 
time of continuous beta-blocker use 
 
 
 
 
 
 
 
 
 
 
 
 
Table A5: Outcomes and Severity of Cases (CASES ONLY) 
 
Variable 
Ciprofl
oxacin 
Norfloxa
cin 
Nitrofura
ntoin 
Amoxicill
in TMP-SMX 
Total 
 
N= N= N= N= N= N= 
Duration of hospital visit (median, 
IQR) 
      
Death during hospital admission, n       
Intubation / ICU visit during hospital, 
stay, n 
      
125 
 
j) Checklist of Parameters 
 
Date Variables 
 *Start Date of Accrual  
 *End Date of Accrual 
 *End Date of Follow-up 
 *Reference Date (date at which entry into nest begins) 
Define Population 
 *Age restriction (minimum age included in cohort) 
 *Sex restriction (Male, Female, or both) 
 Any other inclusion/exclusion criteria 
Define Nest (project specific – more information than below may be required) 
 ICD9/ICD10 diagnosis or procedure codes for nest 
 Diagnosis Type  
 Source from DAD (inpatient, same day surgery or both) 
 OHIP diagnosis or fee codes for subgrouping condition 
 OHIP source (lab, nonlab or all) 
 ODB DIN list for any drugs used to define nest 
 *Lookback period from start of accrual to identify subgrouping condition 
Matching Cases to Controls 
 *Case:Control ratio defined 
 *Matching variables described (include calipers) 
Definition of Exposure Drugs 
 *Drug List includes all DINs for drugs to be investigated 
 *Exposure Drug Names (DCLASS names to ID exposure drugs in DIN list) 
Outcome Definition (project specific – more information than below may be required) 
 ICD9/ICD10 diagnosis or procedure codes for outcome condition 
 Diagnosis type (CIHI datasets) 
 Source from DAD (inpatient, same day surgery, or both) 
 OHIP diagnosis or fee codes for outcome condition 
 OHIP source (lab, nonlab or all) 
Definition of Variables for Statistical Adjustment 
 *All variables required for statistical adjustment defined 
 *Lookback periods for variables defined (e.g. history of AMI in past 5 years) 
Analyses 
 *List of all continuous covariates of interest (included in Table 1 and adjusted model) 
 *List of all dichotomous covariates of interest (included in Table 1 and adjusted model) 
 *List of all categorical covariates of interest (included in Table 1 and adjusted model) 
 *List of referent categories to be used in regression analysis for categorical variables 
* Denotes required field 
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Drugs in Excel spreadsheet below: 
 
1. TMP-SMX (with additional specification of low dose and high dose for tertiary analysis) 
2. Beta-adrenergic receptor antagonists (with additional specification of cardioselective and 
non-selective for tertiary analysis) 
3. Other variables for adjustment:  
a. Non-potassium sparing diuretics 
b. Potassium sparing diuretics  
c. Potassium supplements  
d. NSAIDs  
e. ACE & ARB lists 
4. Lists for additional analyses 
a. Beta- Non cardioselective beta-adrenergic receptor antagonists 
b. Cardioselective beta-adrenergic receptor antagonists 
c. Calcium Channel Blockers 
d. Statins 
5. Other oral antibiotics  
 
Drug List June 5
 
 
Drug list for SMBG test strips: 
SMBG Drug List Diabetes Drugs
 
 
Drug list for Potassium-removing resins: 
Druglist for 
K-removing Resins
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Appendix A:  
Variable/Conditio
n 
ICD9 Dxcode ICD10 Dxcode OHIP 
CONGESTIVE 
HEART FAILURE 
 
ALL DIAGNOSIS 
TYPES 
425 
428x 
518.4 
514 
997.1; 
 
CCP: 49.6, 49.61, 
49.62, 49.63, 49.64; 
ALL DIAGNOSIS TYPES 
I255, I42, I43, I50, J81;  
 
CCI prcodes 1HP53, 1HP55, 
1HZ53GRFR, 1HZ53LAFR, 
1HZ53SYFR; 
OHIP dxcode 
428 
Hyperkalemia For outcome, use 
admitdx, for history 
of hyperkalemia, use 
all diagnosis types: 
276.7: 
HYPERPOTASSEMIA 
 
For outcome, use admitdx, for 
history of hyperkalemia, use all 
diagnosis types: 
E87.5: Hyperkalaemia 
None 
CORONARY 
ARTERY DISEASE 
(including angina) 
ALL DIAGNOSIS 
TYPES 
ICD9- 410 to 414, 
429.2, 429.5, 429.6, 
429.7; 
 
CCP prcodes 48.1, 
48.11 to 48.19 
[inclusive], 48.0, 48.01 
to 48.09 [inclusive], 
48.2, 48.3 
 
 
ALL DIAGNOSIS TYPES 
 
CIHI ICD10 dxcodes I20 to I25;  
 
CCI prcodes 1IJ76, 1IJ50, 1IJ26, 
1IJ27, 1IJ54, 1IJ57; 
 
• OHIP 
feecodes 
R741, R742, 
R743, Z434, 
G298, E646, 
E651, E652, 
E654, G262; 
 
• ODB 
subclnam=‘C
ORONARY 
VASODILATO
RS’ 
Kidney Failure 
receiving dialysis 
CCP: 5195 
(hemodialysis), 6698 
(peritoneal dialysis),  
CCI: 1PZ21 (dialysis, urinary 
system) 
All the Renal 
Diagnosis 
Feecodes 
(OHIP) listed 
below. 
Chronic kidney 
disease 
1 physician or 1 hospital-based claim in three years (see list below, all 
diagnosis types) 
Which in the work by Ruth Hall had a SN of 22.9%, SP of 87.5% and PPV of 
44.4% against a reference standard of a eGFR < 60 mL/min per 1.73 m2  - 
removed fluid and electrolyte and transplant components of these codes.  
Intensive Care Unit 
Admission   
OHIP feecodes 
G400, G401, 
G405, G406, 
G557, G558, 
G559 
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Renal Disease Feecodes (OHIP): 
 
Hemodialysis 
R849 Dialysis - Heamodialysis - Initial & acute 
R850 Dialysis - Haemodialysis - insert of Scribner shunt 
G323 Dialysis - Haemodialysis - Acute, repeat (max 3) 
G325 Dialysis - Haemodialysis - Medical component(incl in unit fee) 
G326 Dialysis - Chronic, contin. haemodialysis or haemofiltration each 
G860 Chronic hemodialysis  hospital location 
G862 Hospital self care Chronic hemodialysis 
G863 Chronic hemodialysis IHF location 
G865 Chronic Home hemodialysis 
G866 Intermittent hemodailysis treatment centre 
Peritoneal dialysis 
G330 Peritoneal dialysis - Acute (up to 48 hrs) 
G331 Peritoneal dialysis - Repeat acute (up to 48 hrs) max. 3 
G332 Peritoneal dialysis - Chronic (up to 48 hrs) 
G861 Chronic peritoneal dialysis hospital location 
G864 Chronic Home peritoneal dialysis 
CRRT 
G082 Continuous venovenous haemodialfiltration 
G083 Continuous venovenous haemodialysis 
G085 Continuous venovenous haemofiltration 
G090 Veneovenous slow continuous ultrafiltration 
G091 Continuous arteriovenous haemodialysis 
G092 Continuous arteriovenous haemodiafiltration 
G093 Haemodiafiltration - Contin. Init & Acute (repeatx3) 
G094 Haemodiafiltration - Contin. Chronic 
G095 Slow Continuous Ultra Filtration - Initial & Acute (repeat) 
G096 Slow Continuous Ultra Filtration – Chronic 
G294 Arteriovenous slow continuous ultrafiltration init and acute 
G295 Continuous aterivenous haemofiltration initial and acute 
OTHER 
G333 Home/self-care dialysis 
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Chronic Kidney Disease Codes  
 
Description icd9 codes icd10ca 
OHIP 
code 
Renal related 
Hypertension 
403, 404.0,404.1, 
404.9,  
 I12.x, I13.x, I15.00 I15.01, 
I15.10, I15.11 403 
 405.0, 405.1, 405.9   
    
Nephritis 
582.0, 582.1, 582.2, 
582.8, 582.9, 583.0, 
N01.x, N03.x,  N05.x, N07.x, 
N14.x, N15.0  
 
583.1, 583.2, 583.4, 
583.8, 583.9,    
    
Acute Renal Disease 
580.0, 580.1, 580.4, 
580.8, 580.9 N00.x, N04.x, N08.x 584 
 
581.0, 581.1, 581.2, 
581.3, 581.8 N17.x 580, 581 
 
581.9, 584.6, 584.7, 
584.8, 584.9   
    
Renal Failure 585, 586.0 N18.x N19.x 585 
    
Renal Sclerosis 587 N26.x NA 
    
Disorders Resulting in 
Impaired Renal 
588.0, 588.1, 588.8, 
588.9 N25.x NA 
Function    
    
Other Disorders of Kidney, 
Ureter 
593.1, 593.2, 593.3, 
593.5, 593.6, 593.7, 
 N13.4, N13.5, N13.7, N28.0, 
N28.1, 593 
 593.8, 593.9  N28.80, N28.88  
    
Renal Colic & Urinary 
Symptoms 788 
N06.x, N23, N39.2, R30.x, R33, 
R34, R35.x, R36, R39.x 788 
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Appendix B Data Creation Plan: Glyburide and hypoglycemia in CKD  
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Hypoglycemia in Impaired Kidney Function  
Name and Number of 
Study 
Risk of hypoglycemia requiring ER visit or hospitalization in patients with low kidney 
function. 
 
This DCP is examining the relationship between various diabetic agents, low kidney 
function and risk of hypoglycemia.  
PI and P&B Contacts 
Amit Garg  
Tara Gomes  
Dan Hackam  
Arsh Jain  
David Juurlink  
Jeff Mahon, Endocrinologist, UWO  
Muhammad Mamdani  
Mike Paterson  
Matthew Weir  
PIA Approved? Yes (July 23, 2009) 
DCP update history 
Version 8: July 27, 2009 (MW) 
Version 7: July 22, 2009 (MW) – after teleconference with Tara (with comments from 
Dan, Mike, Jeff and Muhammad) 
Version 6: July 18, 2009 (AG) 
Version 5: July 17, 2009 (MW) 
Version 4: July 16, 2009 (AG) 
Version 3: July 16, 2009 (MW) 
Version 2: July 12, 2009 (AG) 
Version 1: July 10, 2009 (MW) – after conference call with Tara and Muhammad 
Version 0: June – July 2009 (broad comments from all, Lawson grant application) 
Short Description of 
Research Question 
To determine the risk of severe hypoglycemic events associated with specific oral 
hypoglycemic agents in people with low and normal kidney function.  
Physiologic Rationale 
Diabetes mellitus is the cause low kidney function in 25% of cases; therefore, oral 
hypoglycemic agents are commonly used in these patients. Some of these drugs are 
cleared by the kidneys, making the risk of severe hypoglycemic events higher in 
those with reduced kidney function. Despite the known risks, further information is 
needed in this area for a two main reasons: 
 
First, pharmacokinetic data regarding the mechanism of hypoglycemia in patients 
with low kidney function does not explain the different risks reported with some 
closely related agents (eg: glyburide and glimepiride). Real-world data will clarify the 
actual risks associated with these agents and provide a better context for existing 
mechanistic theories. 
 
Second, despite the known risks associated with some agents, patients with low 
kidney function continue to use them. This may result from an under-appreciation of 
the risks or the state of a patient’s kidney function. Either way, awareness must be 
drawn to this issue to improve the safety of patients with low kidney function. 
List of Datasets Used 
1. ODB 
2. NACRS 
3. RPDB 
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4. DAD  
5. OHIP 
6. Gamma-Dynacare Main List Jan 2002 - Mar 2009 (serum creatinine data 
from Southwestern Ontario) [Data sharing agreement made October 25th, 
2004. The agreement was reviewed again as part of the development of this 
DCP. To confirm, under this agreement we are able to use this dataset to 
‘assess the appropriateness of drug use and dosing in patients’] 
Study Design Nested case-control. See Appendix C, Figure 1. 
Methodology 
Considerations 
Considerations: We appreciate that within the nested case-control design that we are 
considering only the risk of hypoglycemia with glyburide (one type of OHA) compared 
to other OHA or insulin. We are then looking for an interaction by CKD status, using 
the formula of Altman D, Bland JM, Interaction revisited: the difference between two 
estimates. BMJ 2003, enclosed near end of DCP). We are not considering the 
benefits of one type of OHA compared to another (i.e. is metformin the only oral 
hypoglycemia associated with improved survival despite varying hypoglycemic risk 
with various OHA?). With this type of design, it may be possible to obtain indirect 
estimates of absolute risk / incidence, although the main output is an odd’s ratio of 
one OHA compared to another OHA or insulin (i.e. results expressed in relative 
terms). 
1. Defining the Nest Cohort 
Nest cohort 
Defining characteristics: 
2. Ontario resident registered in the RPDB 
3. At least one serum creatinine level recorded in the Gamma-Dynacare database, 
entering the cohort at the time of first serum creatinine measurement. 
4. Evidence of at least one prescription for either an oral hypoglycemic agent or 
insulin after time of first serum creatinine measurement (see Appendix D, “oral 
hypoglycemic agents” and “insulins”) 
• This definition has been included in attempts to limit the number of 
subjects included in the nest, for ease of programming. 
Exclusion 
Criteria 
The following features will result in exclusion from the nest cohort: 
1. Invalid IKN 
2. Missing date of birth 
3. Missing sex 
4. Age < 66 years on March 31st, 2008 (Date of birth after March 31st, 1942 as March 
31st, 2008 is last possible day of cohort entry, this would make the patient less than 
66 years of age at time of last possible day of cohort entry).  
• This definition has been included in attempts to limit the number of 
subjects included in the nest, for ease of programming. 
5. Time Frame Definitions 
Accrual Start/End Dates 
Beginning of Accrual Period for nest: January 1, 2002 (this is the earliest data 
point in the Gamma-Dynacare database) 
End of Accrual Period for nest: March 31, 2008 
Max Follow-up Date End of follow-up Period: March 31, 2008 
Nest Cohort Entry Date of first Gamma-Dynacare serum creatinine level 
Look Back Window 
Conditions: 5 years prior to Index Date; earliest potential date is Jan 1st, 1997 
Medications: 1 year prior to Index Date; earliest potential date is Jan 1st, 2001 
When does observation Termination occurs with any of the following events 
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window terminate? 1. Hypoglycemic event (admission or emergency department visit) 
2. Death  
3. End of follow-up (March 31 2008) 
6. Variable Definitions 
Cases 
 
Patients with a 
hypoglycemic 
event using either 
a single oral 
hypoglycemic 
agent or insulin 
ANALYSIS A (Low Kidney Function) - see Appendix C, figure 1 
Looking forward from the time of entry into the nest, cases will be individuals from the nest 
cohort who experience a hypoglycemic event (first event looking forward) as defined by 
the codes below:  
• Diagnosis codes for outcome condition. CIHI and NACRS datasets parameters 
defined by: 
o ICD9 dxcodes:  
o 250.8, 251.0, 251.1, 251.2, 962.3  
o ICD10 dxcodes:  
o E10.63, E11.63, E13.63, E14.63, E15, E16.0, E16.1, E16.2 
• CIHI-DAD Diagnosis Type: admitdx 
• CIHI-DAD source: 
   Inpatient 
   Same-day-surgery 
   All 
• NACRS Diagnosis Type: main diagnosis 
• Exclusion criteria for cases: 
o Age < 66 years of age at the time of hypoglycemic event [index date] (to allow 
for a one year medication look-back in ODB) 
o Medication characteristics prompting exclusion (see Table 1 below) 
• NO prescription for any type OHA or insulin in the 120 days prior to the 
date of the hypoglycemic event. (using 120 vs. 100 days to provide a 20 
day grace period to the routine 100 day requirement for script renewal; we 
are excluding non-diabetics who present with hypoglycemia) 
• A prescription for more than one type of oral hypoglycemic agent (OHA) in 
the 120 days prior to the date of the hypoglycemic event. (individuals with 
multiple prescriptions for the same type of oral hypoglycemic are eligible 
for study participation)  
• A prescription for both insulin and any type of OHA in the 120 days prior 
to the hypoglycemic event. 
(See Appendix D, “oral hypoglycemic agents” and “insulins”)   
 
Table 1. Medication related inclusion and exclusion criteria. 
Prescription (within 120 days 
before index date) 
Status 
Included Excluded 
Single OHA √  
Single insulin product √  
Multiple insulin products √  
OHA and Insulin  √ 
≥ 2 different OHAs  √ 
No OHA or Insulin  √ 
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o Other characteristics prompting exclusion 
• No available matching control. 
• Evidence of one or more dialysis codes in 5 years prior to the index date 
(see Appendix B) 
• Most recent eGFR prior to index date ≥ 60 mL/min per 1.73 m2  
 
ANALYSIS B (Normal Kidney Function) – see Appendix C, figure 1 
• Definitions are identical to those of Analysis A except that subjects whose most 
recent eGFR prior to the index date is < 60 ml/min per 1.73m2 are excluded and 
those whose most recent eGFR prior to the index date is ≥ 60 ml/min/1.73m2 are 
included. 
Eligible Controls 
ANALYSIS A (Low Kidney Function) - see Appendix C, figure 1 
Individuals from the nest cohort who are event-free at index date. 
• Case to Control Ratio:  Match 4 controls to each case 
• Matching criteria: 
  Age at index date (± 1 year) 
  Gender 
  Most recent eGFR prior to index date (± 20 mL/min per 1.73 m2) [may need to 
augment range (e.g. 25 mL/min) if matching on this characteristic is difficult, or 
alternatively to 15 mL/min if eGFR characteristic between cases and controls is 
not similar]. 
• Exclusion criteria for controls: 
o Age < 66 years of age at index date (to allow for a one year medication look-
back in ODB) 
o Medication characteristics prompting exclusion (see Table 1 above) 
• NO prescription for any type OHA or insulin in the 120 days prior to the 
date of the hypoglycemic event. (using 120 vs. 100 days to provide a 20 
day grace period; we are excluding non-diabetics who present with 
hypoglycemia) 
• A prescription for more than one type of oral hypoglycemic agent (OHA) 
in the 120 days prior to the date of the hypoglycemic event. (individuals 
with multiple prescriptions for the same type of oral hypoglycemic are 
eligible for study participation)  
• A prescription for both insulin and any type of OHA in the 120 days prior 
to the hypoglycemic event. 
(see Appendix D, “oral hypoglycemic agents” and “insulins”)  
 
o Other characteristics prompting exclusion 
• Evidence of one or more dialysis codes in 5 years prior to the index date 
(see Appendix B) 
• Most recent eGFR prior to index date ≥ 60 mL/min per 1.73 m2  
 
• When full number of matched controls cannot be obtained (i.e. 4 controls per 
case), the matching process is maintained, and any available controls are 
analyzed. 
 
ANALYSIS B (Normal Kidney Function) – see Appendix C, figure 1 
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• Definitions are identical to those of Analysis A except that subjects (cases and 
controls) whose most recent eGFR prior to the index date is < 60 ml/min per 
1.73m2 are excluded and those whose most recent eGFR prior to the index date 
is ≥ 60 ml/min/1.73m2 are included. 
 
Index date 
Case: Date of the first hypoglycemic event after cohort entry 
Control: The same date as the index date for matched cases 
Main Exposure 
or Risk Factor 
Exposure status for both Analysis A and Analysis B is determined by the specific 
medication the subject was using in the 120 days prior to the index date.  
• Acarbose (referent group) 
• Gliclazide 
• Glyburide 
• Glimepiride 
• Chlorpropamide 
• Tolbutamide 
• Metformin 
• Pioglitazone 
• Rosiglitazone 
• Nateglinide 
• Repaglinide 
• Insulin  
(see Appendix D, “oral hypoglycemic agents” and “insulins”) 
Baseline 
Characteristics 
 
(see Appendix A, 
Table A1 for 
formatting of 
these variables, 
including the renal 
function variables) 
• Age at index date 
o as median (IQR) and in age categories (see  Appendix A, Table A1) 
• Gender 
o reported as N (%) women 
• Income  
o reported as income quintiles: Income based socio-economic status 
(calculated by FSA)) at cohort entry date (reported as two groups: income 
quintiles ≤ 2 and quintiles ≥ 3; for multivariable analysis any missing data 
should be coded as 3) 
• Year of index date  
o reported as categories 2002-2003, 2004-2005, 2006-2007, and 2008 (see 
Appendix A, table A1). 
• Number of distinct drugs used in the year prior to the index date 
o reported as median (IQR) and as categories ≤ 5, 6-10, 11-15, 16-20, 21-
26, or ≥26 (referent = ≤5) 
• Charlson score based on 5 years of hospitalization data  
o reported as ≤ 1, 2, or ≥ 3; if there are no hospitalizations, code as ≤ 1 and 
not as ‘missing’ 
• Hospital discharge (CIHI-DAD) within 30 days prior to index date 
o reported as N (%) 
• Recent infection  
o defined by an anti-infective outpatient prescription within 21 days prior to 
index date. (see Appendix D,  “Anti-Infective Agents”). Reported as N 
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(%). 
• Liver disease in 5 year prior to index date  
o defined in Appendix B, reported as N (%). 
• Alcoholism in 5 year prior to index date  
o defined in Appendix B, reported as N (%). 
• Coronary artery disease within 5 years prior to index  
o defined in Appendix B, reported as N (%). 
• Congestive heart failure within 5 years prior to index  
o defined in Appendix B, reported as N (%). 
• Cerebrovascular disease within 5 years prior to index  
o defined in Appendix B, reported as N (%). 
• Number of primary care visits in 5 years prior to index date 
o defined in Appendix B, reported as median (IQR) and a N (%) per 
categories ≤ 15, 16-29, or ≥ 30 (referent = ≤ 6) . 
o if more than one code appears on a single day count as one encounter. 
• Number of internist visits in 5 years prior to index date  
o defined in Appendix B, reported as median (IQR) and as N (%) per 
categories ≤ 5, 6-14, or ≥ 15 (referent = ≤ 4). 
o if more than one code appears on a single day count as one encounter. 
• Previous hypoglycemic event in 5 years prior to index date 
o defined as in definition of cases, reported as N (%) 
• Matching results (restricted to cases only) 
o proportion of cases with matching controls, categories: 4 matching 
controls, 3 matching controls, 2 matching controls, 1 matching control, 
zero matching controls 
o reported as N (%) per category 
o we expect no zero matching controls 
• Number of serum creatinine measurements in Gamma-Dynacare database prior 
to index date 
o reported as median (IQR) 
• Time between index date and most recent serum creatinine prior to index date 
o measured in days and reported as median (IQR). 
• Most recent serum creatinine prior to index date 
o reported as median (IQR)  
• Most recent estimated glomerular filtration rate (eGFR) prior to index date  
o measured in ml/min/1.73m2 and reported as median (IQR) 
• Most recent estimated glomerular filtration rate category prior to index date 
o defined by most recent eGFR prior to index date 
! Normal: ≥ 90 ml/min/1.73m2 
! Borderline: 60 – 89 ml/min/1.73m2 
! CKD III: 30 – 59 ml/min/1.73m2 
! CKD IV: 15 – 29 ml/min/1.73m2 
! CKD V: < 15 ml/min/1.73m2 
o reported as N (%) per category 
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Other Variables 
for statistical 
adjustment 
Potential Confounding Medications 
Medications with hypoglycemic effects (within 120 days prior to index date):  
• β-blockers 
• ACE Inhibitors 
• MAOI drugs 
(see Appendix D, “Hypoglycemic Medications”) 
Medications with hyperglycemic effects (within 120 days prior to index date): 
• Corticosteroids 
• Thiazide diuretics 
• Niacin 
• Atypical anti-psychotics 
(see Appendix D, “Hyperglycemic Medications”) 
Case Outcomes and Severity Analysis 
Purpose This will be a descriptive analysis of the outcomes and severity of the hypoglycemic events that we collect. 
Nest As above, except this analysis will be restricted to cases only. 
Characterizing  
the Nature of 
Hypoglycemic 
Events 
A sample output is presented in Appendix A, table A5. 
Variables: (reported as N and median (IQR) as specified in table A5) 
• Event did not require hospital admission 
o Hypoglycemic event defined as it is in the ‘Cases’ section but restricted to 
NACRS database. Diagnosis type: Main diagnosis. 
o reported as N (%) 
• Event required hospital admission 
o Hypoglycemic event defined as it is in the ‘Cases’ section but restricted to 
CIHI-DAD. Diagnosis Type: admitdx. Source: Inpatient 
o reported as N (%) 
• Length of hospital admission, days  
o restrict to those who had hospital admission 
o reported as median (IQR) 
• Event resulted in death 
o Death during hospital admission or in the emergency department. Use 
CIHI, NACRS and enhanced RPDB. 
o reported as N (%)  
• Event required admission to Intensive Care Unit during the hospital admission 
o restrict to those who had hospital admission 
o Defined as any one of the OHIP codes listed in Appendix B. 
o reported as N (%) 
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7. Analysis Plan 
8. Descriptive Analysis: (see Appendix A for sample output tables) 
• Table A1. Table of N(%) or median (IQR) for study variables by cases and respective matched-
controls (see Appendix A, table A1). 
• Sample Table A2. Table of N(%) or median (IQR) for study variables by hypoglycemic agent 
used, inclusive of both cases and controls (see Appendix A, table A2) 
• Sample Table A3 and Table A4. Tables of N (%) or median (IQR) for study variables by 
hypoglycemic agent used, separated by cases (table A3) and controls (table A4).  
 
Absolute Event Rate: 
 
• Sample Table A4.1. Estimated absolute risk of hypoglycemia for each hypoglycemic agent. 
Within the nest cohort determine the number of patients with at least one prescription for each of 
the three diabetes therapies (metformin, glyburide and insulin). 
 
Outcome Severity Analysis: 
• Sample Table A5. Table of N or median (IQR) for severity of outcome parameters by 
hypoglycemic agent use, restricted to cases only (see Appendix A, table A5). 
 
Covariate Analysis (Bivariate): 
• Bivariate conditional logistic regression assessing risk of hypoglycemia conferred by each non-
matched covariate (see Table 2 below). Results will be used to guide final model construction. 
For sample output format, see Appendix A, table A6. 
 
Table 2. Covariate Analysis 
 Variable Modeling 
Outcome  Hypoglycemic event Yes/No 
Exposure 
Model 1 Income Quintiles (referent = lowest) If missing impute 3 
Model 2 Year of index date 4 categories, 2002-2003 (referent), 2004-2005, 2006-2007, and 2008 
Model 3 
Number of distinct drugs in year prior to index * 
Continuous 
Model 4 ≤ 5, 6-10, 11-15, 16-20, 21-26, or ≥ 26 (referent = ≤ 5) 
Model 5 Charlson score 1, 2, or ≥ 3 (referent = 1) 
Model 6 Hospital discharge, ≤ 30 days prior to index Yes/No 
Model 7 Recent infection Yes/No 
Model 8 Liver disease ≤ 5 yr prior to index Yes/No 
Model 9 Alcoholism ≤ 5 yr prior to index  
Model 10 Coronary artery disease ≤5 yr prior to index Yes/No 
Model 11 Congestive heart failure ≤ 5 yr prior to index Yes/No 
Model 12 Cerebrovascular disease ≤ 5 yr prior to index Yes/No 
Model 13  Number of primary care visits ≤ 5 yr prior to 
index * 
Continuous 
Model 14 ≤ 15, 16-29, or ≥ 30 (referent = ≤15)   
Model 15 Number of internist visits ≤ 5 years prior to 
index * 
Continuous 
Model 16 ≤ 5, 6-14, or ≥ 15 (referent = ≤ 5) 
Model 17 Hypoglycemic events ≤ 5 yr prior to index 0, 1, or ≥ 2 (referent = 0) 
Model 18 β-blocker prescription ≤ 120 days prior to index Yes/No 
Model 19 ACE-inhibitor prescription ≤ 120 days prior to index Yes/No 
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Model 20 MAOI prescription ≤ 120 days prior to index Yes/No 
Model 21 
Corticosteroid prescription ≤ 120 days prior to 
index Yes/No 
Model 22 Thiazide diuretic prescription ≤ 120 days prior to index Yes/No 
Model 23 Niacin prescription ≤ 120 days prior to index Yes/No 
Model 24 Atypical anti-psychotic prescription ≤ 120 days prior to index Yes/No 
* Two modeling options exist for each of these variables.  
 
Analysis A:  
• Risk of hypoglycemia among subjects with LOW kidney function (eGFR < 60 ml/min/1.73m2) 
comparing each of gliclazide, glyburide, glimepiride, metformin, pioglitazone and insulin to the 
referent drug, acarbose. 
• Unadjusted models (see Table 3 below). Sample output format for these unadjusted models is 
presented in Appendix A, table A7. 
 
• Adjusted models (see Table 4 below). Conditional logistic regression models for each 
hypoglycemic agent. Output formatting for adjusted models is presented in Appendix A, table 
A7.  
• Variables for adjustment in each model: 
o Forced into the models.. 
1. Charlson score (≤1, 2, or ≥ 3) 
2. Hospital discharge within 30 days prior to index date (no, yes) 
3. Recent infection (no, yes) 
4. Liver disease (no, yes) 
5. Alcoholism (no, yes) 
o Added to models if found to be predictive of outcome. This will be determined 
through the covariate analysis described in Table 2 (above). Any covariate with a p value 
< 0.2 will be included in the adjusted models.  
1. Income (1, 2, 3, 4, 5) 
2. Year of index date (2002-2003, 2004-2005, 2006-2007, or 2008) 
3. Number of distinct drugs used in year prior to index (see Table for input) 
4. Coronary artery disease within 5 years prior to index (yes, no) 
5. Congestive heart failure within 5 years prior to index (yes, no) 
6. Cerebrovascular disease within 5 years prior to index (yes, no) 
Table 3. Unadjusted conditional logistic models for Analysis A 
 Variable Modeling 
Unadjusted Model 
Exposure Hypoglycemic agent 
 
Acarbose (referent) 
Gliclazide 
Glyburide 
Glimepiride 
Chlorpropamide 
Tolbutamide 
Metformin 
Pioglitazone 
Rosiglitazone 
Nateglinide 
Repaglinide 
Insulin 
 
Outcome Hypoglycemic event Yes/No 
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7. Number of primary care visits within 5 years prior to index  (see Table for input) 
8. Number of internist visits within 5 years prior to index (see Table for input) 
9. Hypoglycemic events within 5 years prior to index (0, 1, or ≥ 2) 
10. β-blocker use in 120 days prior to index (yes, no) 
11. ACE-inhibitor use in 120 days prior to index (yes, no) 
12. MAOI use in 120 days prior to index (yes, no) 
13. Corticosteroid use in 120 days prior to index (yes, no) 
14. Thiazide use in 120 days prior to index (yes, no) 
15. Niacin use in 120 days prior to index (yes, no) 
16. Atypical anti-psychotic use in 120 days prior to index (yes, no) 
o NOT to be included in the model (these variables are accounted for through matching): 
1. Age 
2. Gender 
3. Index date 
4. GFR 
 
Table 4. Adjusted conditional logistic regression models for Analysis A 
Adjusted Model 
 Variable Modeling 
Outcome Hypoglycemic event Yes/No 
Exposure of interest Hypoglycemic agent 
 
Acarbose (referent) 
Gliclazide 
Glyburide 
Glimepiride 
Chlorpropamide 
Tolbutamide 
Metformin 
Pioglitazone 
Rosiglitazone 
Nateglinide 
Repaglinide 
Insulin 
 
Forced covariates 
(included in the model regardless 
of performance in covariate 
analysis) 
Charlson score 1, 2, ≥3 (referent = 1) 
Hospitalization within 30 days 
prior to index Yes, No (referent = no) 
Recent infection Yes, No (referent = no) 
Liver disease within 5 years prior 
to index Yes, No (referent = no) 
Alcoholism within 5 years prior to 
index Yes, No (referent = no) 
Potential covariates  
(included based on performance 
in covariate analysis, Table 2 
above) 
Income Quintiles (referent = lowest group) 
Year of index date 
4 categories,  
2002-2003 (referent), 2004-2005, 
2006-2007, or 2008 
Number of distinct drugs used in 
year prior to index To be determined * 
Coronary artery disease within 5 
years prior to index 
 
Yes, No (referent = no) 
Congestive heart failure within 5 
years prior to index 
 
Yes, No (referent = no) 
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Cerebrovascular disease within 5 
years prior to index 
 
Yes, No (referent = no) 
Number of primary care visits in 5 
years prior to index  To be determined * 
Number of internist visits in 5 
years prior to index  To be determined * 
Hypoglycemic events within 5 
years prior to index 0, 1, or ≥ 2 (referent = 0) 
β-blocker  use in 120 days prior 
to index 
 
Yes, No (referent = no) 
Ace inhibitor use in 120 days prior 
to index 
 
Yes, No (referent = no) 
MAOI use in 120 days prior to 
index 
 
Yes, No (referent = no) 
Corticosteroid use in 120 days 
prior to index 
 
Yes, No (referent = no) 
Thiazide diuretic use in 120 days 
prior to index 
 
Yes, No (referent = no) 
Niacin use in 120 days prior to 
index 
 
Yes, No (referent = no) 
Atypical anti-psychotic use in 120 
days prior to index 
 
Yes, No (referent = no) 
 
* determined by performance of modeling options in “Covariate Analysis” (table 2) 
• If neither ordinal nor continuous modeling is significantly associated with hypoglycemic events (p 
≥ 0.2), the covariate is NOT included in the adjusted models. 
• If both ordinal and continuous modeling is significantly associated with hypoglycemic events (p < 
0.2), the covariate will be included in the adjusted models as an ordinal variable. 
• If only the continuous modeling is significantly associated with hypoglycemic events (p < 0.2), 
the covariate will be included in the adjusted models as a continuous variable. 
• If only the ordinal modeling is significantly associated with hypoglycemic events (p < 0.2), the 
covariate will be included in the adjusted models as an ordinal variable.  
 
 
Table 4.1: Absolute incidence of hypoglycemia 
 
Total Cohort 
Total size of nest cohort N = 19,620 
Metformin  
No. of patients with at least on prescription for metformin N =  
No. of hypoglycemic events among patients using metformin N =  56 
Events per 10,000 patients  
Glyburide 
No. of patients with at least on prescription for glyburide N = 
No. of hypoglycemic events among patients using glyburide N = 162 
Events per 10,000 patients  
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Insulin 
No. of patients with at least on prescription for insulin N =  
No. of hypoglycemic events among patients using insulin N =  240 
Events per 10,000 patients  
Normal Kidney Function 
Total number of patients with normal kidney function N =  
Metformin 
No. of patients with at least on prescription for metformin N =  
No. of hypoglycemic events among patients using metformin N = 27 
Events per 10,000 patients  
Glyburide 
No. of patients with at least on prescription for glyburide N =  
No. of hypoglycemic events among patients using glyburide N = 53 
Events per 10,000 patients  
Insulin 
No. of patients with at least on prescription for insulin N =  
No. of hypoglycemic events among patients using insulin N = 124 
Events per 10,000 patients  
Low Kidney Function 
Total number of patients with low kidney function N =  
Metformin 
No. of patients with at least on prescription for metformin N =  
No. of hypoglycemic events among patients using metformin N = 29 
Events per 10,000 patients  
Glyburide 
No. of patients with at least on prescription for glyburide N =  
No. of hypoglycemic events among patients using glyburide N = 109 
Events per 10,000 patients  
Insulin 
No. of patients with at least on prescription for insulin N = 
No. of hypoglycemic events among patients using insulin N = 216 
Events per 10,000 patients  
 
* the sum of these numbers will not likely equal 19,620 because some patients will, at different times, have 
had prescriptions for more than one diabetic therapy. Therefore, I would expect their sum to exceed 
19,620. 
† these numbers are the total number of cases 
 
 
Analysis B:  
• Risk of hypoglycemia among subjects with NORMAL kidney function (eGFR ≥ 60) comparing 
each of gliclazide, glyburide, glimepiride, metformin, pioglitazone and insulin to the referent drug, 
acarbose.  
 
• Unadjusted models (see Table 5 below). Sample output format for these unadjusted models is 
presented in Appendix A, table A7.  
 
• Adjusted models (see Table 6 below). Conditional logistic regression models for each of the 
hypoglycemic agents. Sample output format for these adjusted models is presented in Appendix 
A, table A7. In this Table also present associations with other variables in final adjusted model. 
144 
 
 
 
Additional Analyses: 
 
• Using the same adjusted conditional logistic regression model from Analysis A, please re-run 
the analysis with the following changes: 
o Additional Analysis 1: Cases and controls restricted to subjects with eGFR ≤ 45 
ml/min/1.73m2 . Sample output table is presented in Appendix A, table A8. 
 
o Additional Analysis 2: Cases and controls restricted to subjects with eGFR ≤ 30 
ml/min/1.73m2 . Sample output table is presented in Appendix A, table A9. 
 
Table 5. Unadjusted conditional logistic models for Analysis B 
 Variable Modeling 
Unadjusted 
Table cells identical to those of Table 3  
Table 6.  Adjusted conditional logistic regression models for Analysis B 
 Variable Modeling 
Adjusted Model 
Table cells identical to those of Table 4 
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Appendix A 
Table A1. Baseline characteristics for Cases and Matched Controls 
Variable 
Control Case Standardized 
Difference N= N= 
Demographics 
Age at Index Date 
66-74 
Median 
(IQR) 
Median 
(IQR)  
75-84 
Median 
(IQR) 
Median 
(IQR)  
85+ 
Median 
(IQR) 
Median 
(IQR)  
Female N (%) N(%)  
Income Quintile  
≤ 2 N (%) N(%)  
≥ 3 N (%) N(%)  
Missing N (%) N(%)  
Year of Index date * 
       2002 – 2003 N (%) N(%)  
       2004 – 2005 N (%) N(%)  
       2006 – 2007 N (%) N(%)  
       2008 N (%) N(%)  
Co-morbidity 
No. of distinct drugs in year prior to index 
Median 
(IQR) 
Median 
(IQR)  
No. of distinct drugs in year prior, categories 
        ≤ 5 N (%) N (%)  
        6 - 10 N (%) N (%)  
        11 - 15 N (%) N (%)  
        16 - 20 N (%) N (%)  
        21 – 25 N (%) N (%)  
        ≥ 26 N (%) N (%)  
Charlson Score 
≤ 1 N (%) N(%)  
   2 N (%) N(%)  
≥ 3 N (%) N(%)  
Missing N (%) N(%)  
Hospital discharge within 30 days prior to index date N (%) N(%)  
Recent infection N (%) N(%)  
Liver disease within 5 years before index N (%) N(%)  
Alcoholism  within 5 years before index N (%) N(%)  
Coronary artery disease within 5 years before index N (%) N(%)  
Congestive heart failure within 5 years before index N (%) N (%)  
Cerebrovascular disease within 5 years before index N (%) N (%)  
Number of primary care visits within 5 years of index, 
median 
Median 
(IQR) 
Median 
(IQR)  
Number of primary care visits within 5 years of index, by category 
       ≤ 15 (referent) N (%) N(%)  
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       16 – 29 N (%) N(%)  
       ≥ 30 N (%) N(%)  
Number of internist visits within 5 years before index 
Median 
(IQR) 
Median 
(IQR)  
Number of internist visits within 5 years before index, by category 
      ≤ 5 N (%) N(%)  
      6 – 14  N (%) N(%)  
      ≥ 15 N (%) N(%)  
Number of hypoglycemic events within 5 years before index 
      0 N (%) N(%)  
      1 N (%) N(%)  
      ≥ 2 N (%) N(%)  
Matching results (number of controls matched per case)  
      4  N(%)  
      3  N(%)  
      2  N(%)  
      1  N(%)  
      0  **  
Kidney Function 
Number of serum creatinine measurements in 
database  
Median 
(IQR) 
Median 
(IQR)  
Time between index date and most recent serum 
creatinine, days  
Median 
(IQR) 
Median 
(IQR)  
Most recent serum creatinine, µmol/L 
Median 
(IQR) 
Median 
(IQR)  
Most recent eGFR mL/min/1.73 m2 
Median 
(IQR) 
Median 
(IQR)  
Most recent eGFR category 
     Normal: ≥ 90 mL/min/1.73m2 N (%) N(%)  
     Normal: 60 to 89  mL/min/1.73m2 N (%) N(%)  
     CKD III: 30 to 59 mL/min/1.73m2 N (%) N(%)  
     CKD IV: 15 to 29 mL/min/1.73m2 N (%) N(%)  
     CKD V: < 15 mL/min/1.73m2 N (%) N(%)  
Hypoglycemic Medications 
β – Blockers N (%) N(%)  
ACE Inhibitors N (%) N(%)  
MAOI N (%) N(%)  
Hyperglycemic Medications 
Corticosteroids N (%) N(%)  
Thiazide diuretics N (%) N(%)  
Niacin N (%) N(%)  
Atypical antipsychotics N (%) N(%)  
Oral Hypoglycemic Agent Use 
Acarbose (referent) N (%) N(%)  
Gliclazide N (%) N(%)  
Glyburide N (%) N(%)  
Glimepiride N (%) N(%)  
Chlorpropamide N (%) N(%)  
Tolbutamide N (%) N(%)  
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Metformin N (%) N(%)  
Pioglitazone N (%) N(%)  
Rosiglitazone N (%) N(%)  
Nateglinide N (%) N(%)  
Repaglinide N (%) N(%)  
Insulin N (%) N(%)  
* may only be looked at for internal purposes to look at distribution, not reported in final 
manuscript 
** given exclusion criteria, we do not expect to have any subjects in this category 
Table A2: Baseline characteristics for users of single oral hypoglycemic agents  
CASES & CONTROLS 
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N= N= N= N= N= N= N= N= N= N= N= N= 
Demographics 
Age [Median (IQR)] 
      66-74             
      75-84             
      85+             
Female [N (%)]             
Income Quintile [N (%)] 
      ≤ 2             
      ≥ 3             
      Missing             
Year of Index date [N (%)] * 
       2002 – 2003             
       2004 – 2005             
       2006 – 2007             
       2008             
Co-morbidity 
No. of distinct drugs in previous 
year [Median (IQR)] 
            
No. of distinct drugs in previous year, by category [N (%)] 
       ≤ 5             
       6 - 10             
       11 - 15             
       16 - 20             
       21 – 25             
       ≥ 26             
Charlson Score [N (%)] 
      ≤ 1             
      2             
      ≥ 3             
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     Missing             
Coronary artery disease within 5 
years before index [N (%)] 
            
Congestive heart failure within 5 
years before index [N (%)] 
            
Cerebrovascular disease within 5 
years before index [N (%)] 
            
Number of primary care visits within 
5 years of index [Median (IQR)] 
            
Number of primary care visits within 5 years of index, by category [N (%)] 
       ≤ 6 (referent)             
       7 - 13             
       ≥ 14             
Number of internist visits within 5 
years before index [Median (IQR)] 
            
Number of internist visits within 5 years before index, by category [N (%)] 
      ≤ 4             
      5 – 9             
      ≥ 10             
Number of hypoglycemic events with 5 years before index 
      0             
      1             
      ≥ 2             
Kidney Function 
Number of serum creatinine 
measurements in database [Median 
(IQR)] 
            
Time between index date and most 
recent serum creatinine, days 
[Median (IQR)]  
            
Most recent serum creatinine, 
µmol/L [Median (IQR)] 
            
Most recent eGFR mL/min/1.73 m2 
[Median (IQR)] 
            
Most recent eGFR category [N (%)] 
  Normal ≥ 90 mL/min/1.73m2             
  Normal ≥ 60 mL/min/1.73m2             
  CKD III 30-59 mL/min/1.73m2             
  CKD IV 15-29 mL/min/1.73m2             
  CKD V < 15 mL/min/1.73m2             
Hypoglycemic Medications 
β – Blockers [N (%)]             
ACE Inhibitors [N (%)]             
MAOI [N (%)]             
Hyperglycemic Medications 
Corticosteroids             
Thiazide diuretics             
Niacin             
Atypical antipsychotics             
* may only be looked at for internal purposes to look at distribution, not reported in final 
manuscript 
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Table A3: Baseline characteristics for users of single oral hypoglycemic agents  
CASES ONLY 
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N= N= N= N= N= N= N= N= N= N= N= N= 
Demographics 
Age [Median (IQR)] 
      …             
      Replicate variables in Table A2. 
 
 
Table A4: Baseline characteristics for users of single oral hypoglycemic agents  
CONTROLS ONLY 
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N= N= N= N= N= N= N= N= N= N= N= N= 
Demographics 
Age [Median (IQR)] 
      …             
      Replicate variables in Table A2. 
 
 
Table A5: Outcomes and Severity of Cases (CASES ONLY) 
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N= N= N= N= N= N= N= N= N= N= N= N= 
Event did not require admission, n             
Event was hospital admission, n             
Duration of hospital visit (median, 
IQR)*  
            
Death in ER or during hospital 
admission, n 
            
ICU visit during hospital stay, n *             
  * Restrict these analyses to only those patients who were admitted to hospital (no ER visits). 
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Table A6: Covariate analysis outcomes 
   OR LCL UCL 
Model Exposure Variable Modeling    
Model 1 
Income (quintiles) 
 
* for missing income 
data input 3  
(mid-point) 
1 lowest (referent) 1.000 -- -- 
2    
3    
4    
5 highest    
Model 2 Year of index date (4 categories) 
2002-2003 (referent) 1.000 -- -- 
2004-2005    
2006-2007    
2008    
Model 3 Number of distinct 
drugs in year prior to 
index  
Continuous (per drug)    
Model 4 
≤ 3 (referent) 1.000 -- -- 
4 – 7    
> 7    
Model 5 Charlson score 
0 1.000 -- -- 
1    
≥ 2    
Model 6 Hospital discharge in 30 days prior to index 
No (referent) 1.000 -- -- 
Yes    
Model 7 Recent infection 
No (referent) 1.000 -- -- 
Yes    
Model 8 Liver disease in 5 years prior to index 
No (referent) 1.000 -- -- 
Yes    
Model 9 Alcoholism in 5 years prior to index 
No (referent) 1.000 -- -- 
Yes    
Model 10 
Coronary artery 
disease in 5 years 
prior to index 
No (referent) 1.000 -- -- 
Yes    
Model 11 
Congestive heart 
failure in 5 years prior 
to index 
No (referent) 1.000 -- -- 
Yes    
Model 12 
Cerebrovascular 
disease in 5 years 
prior to index 
No (referent) 1.000 -- -- 
Yes    
Model 13 Number of primary 
care visits in 5 years 
prior to index  
Continuous (per visit)    
Model 14 
≤ 15 (referent) 1.000 -- -- 
16-29    
≥ 30    
Model 15 Number of internist 
visits in 5 years prior 
to index  
Continuous (per visit)    
Model 16 
≤ 5 (referent) 1.000 -- -- 
6-14    
≥ 15    
Model 17 
Hypoglycemic events 
in 5 years prior to 
index 
0 (referent) 1.000 -- -- 
1    
≥ 2    
Model 18 
β-blocker prescription 
in 120 days prior to 
index 
No (referent) 1.000 -- -- 
Yes    
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Model 19 
ACE-inhibitor 
prescription in 120 
days prior to index 
No (referent) 1.000 -- -- 
Yes    
Model 20 
MAOI prescription in 
120 days prior to 
index 
No (referent) 1.000 -- -- 
Yes    
Model 21 
Corticosteroid 
prescription in 120 
days prior to index 
No (referent) 1.000 -- -- 
Yes    
Model 22 
Thiazide diuretic 
prescription in 120 
days prior to index 
No (referent) 1.000 -- -- 
Yes    
Model 23 
Niacin prescription in 
120 days prior to 
index 
No (referent) 1.000 -- -- 
Yes    
Model 24 
Atypical anti-
psychotic prescription 
in 120 days prior to 
index 
No (referent) 1.000 -- -- 
Yes    
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Table A7: Conditional Logistic Regression Results for Primary Outcome (OR and 95% CI) * 
Exposure Unadjusted Adjusted 
  OR SE LCL UCL OR SE LCL UCL 
Analysis A (eGFR < 60 mL/min per 1.73 m2) 
Acarbose (referent) 1.0000 -- -- -- 1.0000 -- -- -- 
Gliclazide         
Glyburide         
Glimepiride         
Chlorpropamide         
Tolbutamide         
Metformin         
Pioglitazone         
Rosiglitazone         
Nateglinide         
Repaglinide         
Insulin         
Charlson score: 1 (referent) 1.0000 -- -- -- 1.0000 -- -- -- 
                          2         
                          ≥ 3         
Hospital discharge 30 days: no (referent) 1.0000 -- -- -- 1.0000 -- -- -- 
                                             yes         
Recent infection: no (referent) 1.0000 -- -- -- 1.0000 -- -- -- 
                           yes         
Liver disease: no (referent) 1.0000 -- -- -- 1.0000 -- -- -- 
                       yes         
Alcholism: no (referent) 1.0000 -- -- -- 1.0000 -- -- -- 
                 yes         
Describe other variables in adjusted model         
Secondary Analysis (eGFR ≥ 60 mL/min per 1.73 m2) 
Acarbose (referent) 1.0000 -- -- -- 1.0000 -- -- -- 
Gliclazide         
Glyburide         
Glimepiride         
Chlorpropamide         
Tolbutamide         
Metformin         
Pioglitazone         
Rosiglitazone         
Nateglinide         
Repaglinide         
Insulin         
Charlson score: 1 (referent) 1.0000 -- -- -- 1.0000 -- -- -- 
                          2         
                         ≥ 3         
Hospital discharge 30 days: no (referent) 1.0000 -- -- -- 1.0000 -- -- -- 
                                             yes         
Recent infection: no (referent) 1.0000 -- -- -- 1.0000 -- -- -- 
                           yes         
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Liver disease: no (referent) 1.0000 -- -- -- 1.0000 -- -- -- 
                       yes         
Alcholism: no (referent) 1.0000 -- -- -- 1.0000 -- -- -- 
                 yes         
Describe other variables in adjusted model         
* report results to 4 decimal points 
 
Table A8: Conditional Logistic Regression Results for Additional Analysis 1 (OR and 95% CI) * 
Exposure Unadjusted Adjusted 
  OR SE LCL UCL OR SE LCL UCL 
Primary Analysis (eGFR < 45 mL/min per 1.73 m2) 
Acarbose (referent) 1.0000 -- -- -- 1.0000 -- -- -- 
Gliclazide         
Glyburide         
Glimepiride         
Chlorpropamide         
Tolbutamide         
Metformin         
Pioglitazone         
Rosiglitazone         
Nateglinide         
Repaglinide         
Insulin         
Table A9: Conditional Logistic Regression Results for Additional Analysis 2 (OR and 95% CI) * 
Exposure Unadjusted Adjusted 
  OR SE LCL UCL OR SE LCL UCL 
Primary Analysis (eGFR < 30 mL/min per 1.73 m2) 
Acarbose (referent) 1.0000 -- -- -- 1.0000 -- -- -- 
Gliclazide         
Glyburide         
Glimepiride         
Chlorpropamide         
Tolbutamide         
Metformin         
Pioglitazone         
Rosiglitazone         
Nateglinide         
Repaglinide         
Insulin         
*Regression model for both Additional Analyses 1 and 2 should be the same as that for the Analysis A and B 
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Adjusted OR from model
CI for adjusted OR 0.46 0.98 0.71 1.08
log OR
CI for log OR -0.7765 -0.0202 -0.3425 0.0770
Width of CI for log OR
SE of log OR
Difference in log ORs
SE of the difference
CI for the difference
Test of interaction (z test)
Ratio of ORs (ROR)
CI for ROR
Comparison of the log ORs
-0.2726
0.2206
Table A8: Interaction
Drug: 
log Transformation of OR to normalize the distribution
Obtain the standard error for log OR 
Impaired Kidney Function
0.67
-0.4005
Describing the interaction
-0.7051 0.1598
0.4941 1.1733
0.7614
-1.2358
0.1929
Normal Kidney Function
0.88
-0.1278
0.7563 0.4195
0.1070
 
 
Double click on table to edit highlighted fields. Table and sample values derived from Interaction 
revisited: The difference between two estimates. Douglas G Altman; J Martin Bland British 
Medical Journal; Jan 25, 2003; 326, 7382. OR, odds ratio; CI, confidence interval; SE standard 
error; ROR, ratio of odds ratios.  
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Appendix B:  
 
Variable/Condition 
(Defined by the 
presence of any of the 
listed codes) 
ICD9 Dxcode ICD10 Dxcode Other 
Coronary Artery 
Disease 
(including angina) 
410 to 414, 429.2, 
429.5, 429.6, 429.7 
 
 
I20 to I25  
 
 
CCP prcodes 48.1, 
48.11 to 48.19 
[inclusive], 48.0, 48.01 to 
48.09 [inclusive], 48.2, 
48.3 
CCI prcodes 1IJ76, 
1IJ50, 1IJ26, 1IJ27, 
1IJ54, 1IJ57;  
OHIP feecodes R741, 
R742, R743, Z434, 
G298, E646, E651, 
E652, E654, G262 
ODB 
subclnam=‘CORONARY 
VASODILATORS’ 
Congestive Heart 
Failure 
425, 428, 518.4, 514, 
997.1 I255, I42, I43, I50, J81 
CCP prcodes: 49.6, 
49.61, 49.62, 49.63, 
49.64 
CCI prcodes 1HP53, 
1HP55, 1HZ53GRFR, 
1HZ53LAFR, 
1HZ53SYFR 
OHIP dxcode 428 
OHIP feecodes R701, 
R702, Z429 
Cerebral Vascular 
Disease 430 to 438, 362.3 
I60 to I69, G45 to G46, 
H34 
CCP prcodes 50.11, 
50.12, 51.28;  
CCI prcodes 1JE50, 
1JE57, 1JE87, 1JW50, 
1JX57, 1JW57, 1JW76;  
OHIP dxcodes 432, 
435, 436, 437;  
OHIP fee codes R792, 
N220, N223, J050, 
N104, N157, N120 
 
Liver Disease 
456.0, 456.1, 456.2, 
070.2, 070.3, 070.4, 
070.5, 070.6, 070.9, 
571, 572.2, 572.3, 
572.4, 572.8, 573, 
782.4, V02.60 to V02.69, 
275.0, 789.5, 789.1 
B16 to B19, I85, R17, 
R18, R160, R162, B942, 
Z2250, Z2251, Z2258, 
E8310, K70, K713, 
K714, K715, K717, 
K721, K729, K73 to K74, 
K753, K754, K758, 
K759, K76, K77 
571, 573, 070 
Alcohol Abuse 
303, 303.00, 303.01, 
303.02, 303.90, 303.91, 
303.92, 305.0 
E24.4, E51.2, F10, 
G31.2. G62.1, G72.1, 
I42.6, K29.2, K70, 
K86.0, T51.0, X45, X65, 
Y15, Y57.3 Z50.2 Z71.4, 
Z72.1 
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Kidney Failure 
receiving dialysis   
CCP prcodes: 5195 
(hemodialysis), 6698 
(peritoneal dialysis), 
CCI prcodes: 1PZ21 
(dialysis, urinary system) 
OHIP Feecodes: listed 
below. * 
Intensive Care Unit 
Admission   
OHIP feecodes G400, 
G401, G405, G406, 
G557, G558, G559 
Primary Care Visit   
OHIP feecodes A003, 
A004, A005, A006, 
A905, A901 
Internist Visit   
OHIP feecodes A131, 
A133, A134, A135, 
A136, A435,  
 
 
* Renal Disease OHIP feecodes: 
Hemodialysis 
R849 Dialysis - Heamodialysis - Initial & acute 
R850 Dialysis - Haemodialysis - insert of Scribner shunt 
G323 Dialysis - Haemodialysis - Acute, repeat (max 3) 
G325 Dialysis - Haemodialysis - Medical component(incl in unit fee) 
G326 Dialysis - Chronic, contin. haemodialysis or haemofiltration each 
G860 Chronic hemodialysis  hospital location 
G862 Hospital self care Chronic hemodialysis 
G863 Chronic hemodialysis IHF location 
G865 Chronic Home hemodialysis 
G866 Intermittent hemodailysis treatment centre 
Peritoneal dialysis 
G330 Peritoneal dialysis - Acute (up to 48 hrs) 
G331 Peritoneal dialysis - Repeat acute (up to 48 hrs) max. 3 
G332 Peritoneal dialysis - Chronic (up to 48 hrs) 
G861 Chronic peritoneal dialysis hospital location 
G864 Chronic Home peritoneal dialysis 
CRRT 
G082 Continuous venovenous haemodialfiltration 
G083 Continuous venovenous haemodialysis 
G085 Continuous venovenous haemofiltration 
G090 Veneovenous slow continuous ultrafiltration 
G091 Continuous arteriovenous haemodialysis 
G092 Continuous arteriovenous haemodiafiltration 
G093 Haemodiafiltration - Contin. Init & Acute (repeatx3) 
G094 Haemodiafiltration - Contin. Chronic 
G095 Slow Continuous Ultra Filtration - Initial & Acute (repeat) 
G096 Slow Continuous Ultra Filtration – Chronic 
G294 Arteriovenous slow continuous ultrafiltration init and acute 
G295 Continuous aterivenous haemofiltration initial and acute 
OTHER 
G333 Home/self-care dialysis 
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Appendix C: Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ontario
Cases
Controls
Nest
1. Case: hypoglycemic 
event, Control: no 
hypoglycemic event.
2. ≥ 1 serum creatinine 
value prior to index 
date.
3. Single OHA type or 
insulin Rx prior to 
index date.
4. At least one matching 
control per case
5. No evidence of 
dialysis.
Low Kidney Function
Normal Kidney Function
1. Registered in RPDB
2. ≥ 1 serum 
creatinine level in 
GDC database
3. Evidence of at least 
1 Rx for an OHA or 
insulin
4. Birth date earlier 
than March 31st, 
1942
Controls
Cases
Controls
Cases
Analysis B
Analysis A
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Appendix D. Drug Lists 
 
 
1. Oral hypoglycemic agents – exposure of interest 
 
Oral Hypoglycemic 
Agents
 
 
2. Insulins – exposure of interest 
 
Insulins
 
 
3. Ant- infective agents - used to define recent infection. Three worksheets covering anti-
viral, anti-fungal and anti-bacterial agents. 
 
Anti-Infective 
Agents
 
 
4. HYPOglycemic medications – potential confounders. Three worksheets covering β-
blockers, ACE inhibitors and MAOIs 
 
Hypoglycemic 
Medications
 
 
5. HYPERglycemic medications – potential confounders. Four worksheets covering 
corticosteroids, thiazide diuretics, niacin and atypical anti-psychotics. 
 
       
Hyperglycemic 
Medications
 
 
6. Coronary vasodilators – used to help define coronary artery disease 
 
Vasodilators
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Checklist of Parameters 
 
Date Variables 
 *Start Date of Accrual  
 *End Date of Accrual 
 *End Date of Follow-up 
 *Reference Date (date at which entry into nest begins) 
Define Population 
 *Age restriction (minimum age included in cohort) 
 *Sex restriction (Male, Female, or both) 
 Any other inclusion/exclusion criteria 
Define Nest (project specific – more information than below may be required) 
 ICD9/ICD10 diagnosis or procedure codes for nest 
 Diagnosis Type  
 Source from DAD (inpatient, same day surgery or both) 
 OHIP diagnosis or fee codes for subgrouping condition 
 OHIP source (lab, nonlab or all) 
 ODB DIN list for any drugs used to define nest 
 *Lookback period from start of accrual to identify subgrouping condition 
Matching Cases to Controls 
 *Case:Control ratio defined 
 *Matching variables described (include calipers) 
Definition of Exposure Drugs 
 *Drug List includes all DINs for drugs to be investigated 
 *Exposure Drug Names (DCLASS names to ID exposure drugs in DIN list) 
Outcome Definition (project specific – more information than below may be required) 
 ICD9/ICD10 diagnosis or procedure codes for outcome condition 
 Diagnosis type (CIHI datasets) 
 Source from DAD (inpatient, same day surgery, or both) 
 OHIP diagnosis or fee codes for outcome condition 
 OHIP source (lab, nonlab or all) 
Definition of Variables for Statistical Adjustment 
 *All variables required for statistical adjustment defined 
 *Lookback periods for variables defined (e.g. history of AMI in past 5 years) 
Analyses 
 *List of all continuous covariates of interest (included in Table 1 and adjusted model) 
 *List of all dichotomous covariates of interest (included in Table 1 and adjusted model) 
 *List of all categorical covariates of interest (included in Table 1 and adjusted model) 
 *List of referent categories to be used in regression analysis for categorical variables 
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Appendix C Chapter 2 License Agreement with the Clinical Journal of the 
American Society of Nephrology for use of “Beta-blockers, trimethoprim-
sulfamethoxazole and the risk of hyperkalemia requiring hospitalization in the 
elderly: a nested case-control study” 
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Appendix D Chapter 3 License Agreement with the Nephrology, Dialysis, 
Transplantation for use of “Impaired renal function modifies the risk of severe 
hypoglycaemia among users of insulin but not glyburide: a population-based nested 
case-control study” 
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